US9580680B2 - Canine probiotic bifidobacterium pseudolongum - Google Patents
Canine probiotic bifidobacterium pseudolongum Download PDFInfo
- Publication number
- US9580680B2 US9580680B2 US12/292,171 US29217108A US9580680B2 US 9580680 B2 US9580680 B2 US 9580680B2 US 29217108 A US29217108 A US 29217108A US 9580680 B2 US9580680 B2 US 9580680B2
- Authority
- US
- United States
- Prior art keywords
- strain
- composition
- composition according
- companion animal
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C12R1/01—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to the field of probiotic micro-organisms, more specifically canine probiotic lactic acid bacteria and methods of use.
- the defense mechanisms to protect the mammalian gastrointestinal (GI) tract from colonisation by pathogenic bacteria are highly complex.
- the GI tract of most mammals are colonised by native microflora, and invasive pathogenic micro-organisms. In a healthy individual, these competing microflora are in a state of equilibrium. Modification of the intestinal microflora equilibrium may lead to or prevent many GI disorders, both in humans, and other mammalian species, such as companion animals including cats, dogs and rabbits.
- companion animals including cats, dogs and rabbits.
- the well being of companion animals is closely related to their feeding and GI health, and maintenance of the intestinal microflora equilibrium in these animals may result in healthier pets.
- the number and composition of the intestinal microflora tend to be stable, although age and diet may modify it.
- Gastric acidity, bile, intestinal peristalsis and local immunity are factors thought to be important in the regulation of bacterial flora in the small intestine of human beings and various other mammals.
- pet GI disorders, including those found in canines and felines are linked to bacterial overgrowth and the production of enterotoxins by pathogenic bacteria. These factors disrupt the intestinal microflora equilibrium and can promote inflammation and aberrant immune responses.
- probiotics are considered to be preparations of bacteria, either viable or dead, their constituents such as proteins or carbohydrates, or purified fractions of bacterial ferments that promote mammalian health by preserving and promoting the natural microflora in the GI tract, and reinforcing the normal controls on aberrant immune responses. It is believed by some that probiotic bacteria are more effective when derived from the species, or a closely related species to the individual intended to be treated. Therefore, there is a need for probiotic strains derived from companion animals to be used for companion animals, that are different to those derived from humans.
- WO 01/90311 discloses probiotic micro-organisms isolated from fecal samples obtained from cats and dogs having probiotic activity. However, these bacteria were obtained from fecal samples, and may not form part of the natural intestinal microflora present in the upper portion of the GI tract.
- a strain of lactic acid bacteria of the species Bifidobacterium pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals.
- the lactic acid bacterial strain is a Bifidobacterium pseudolongum having a 16s-23s spacer region DNA sequence having at least 93% homology to SEQ. ID NO. 1.
- the lactic acid bacterial strain is Bifidobacterium pseudolongum AHC7 (NCIMB 41199).
- the present invention is directed towards providing uses of Bifidobacterium pseudolongum bacteria obtainable by isolation from resected and washed canine gastrointestinal tract for maintaining and improving pet health, and compositions comprising the lactic acid bacteria.
- FIG. 1 demonstrates the inhibition of the growth in vitro of Salmonella typhimurium by the Bifidobacterium pseudolongum bacteria of the present invention according to methodology set out in example 2.
- FIG. 2 demonstrates the inhibition of the growth in vitro of Listeria monocytogenes by the Bifidobacterium pseudolongum bacteria of the present invention according to methodology set out in example 2.
- FIG. 3 demonstrates the inhibition of the growth in vitro of Listeria innocua by the Bifidobacterium pseudolongum bacteria of the present invention according to methodology set out in example 2.
- FIG. 4 demonstrates the inhibition of the growth in vitro of Escherichia coli 0157H45 by the Bifidobacterium pseudolongum bacteria of the present invention according to methodology set out in example 2.
- FIG. 5 demonstrates the in vitro acid stability of the Bifidobacterium pseudolongum bacteria of the present invention according to methodology set out in example 3.
- FIG. 6 demonstrates the growth characteristics of the Bifidobacterium pseudolongum bacteria of the present invention in the presence of 0.5%, 1% and 5% porcine bile salts.
- FIG. 7 demonstrates the in vitro ability of the Bifidobacterium pseudolongum bacteria of the present invention to adhere to HT-29 gut epithelial cells.
- SEQ. ID NO. 1 16s-23s intergenic spacer nucleotide sequence from Bifidobacterium pseudolongum AHC7 (NCIMB 41199).
- SEQ. ID NO. 2 Primary sequences for 16s-23s DNA sequence analysis.
- the table below indicates Bifidobacteria pseudolongum strains that are examples of the present invention.
- the bacterial strains are deposited with the National Collections of Industrial Food and Marine Bacteria, Ltd. (NCIMB, Ltd.), Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen AB21 9YA, Scotland, UK, under deposit number NCIMB 41199, on Sep. 4, 2003.
- compositions referred to herein are weight percentages and all ratios are weight ratios.
- CFU colony-forming unit
- mutants thereof includes derived bacterial strains having at least 93% homology, preferably at least 96% homology, more preferably 98% homology to the 16s-23s intergenic spacer polynucleotide sequence of a referenced strain, but otherwise comprising DNA mutations in other DNA sequences in the bacterial genome.
- DNA mutations includes natural or induced mutations comprising at least single base alterations including deletions, insertions, transversions, and other DNA modifications known to those skilled in the art, including genetic modification introduced into a parent nucleotide or amino acid sequence whilst maintaining at least 50% homology to the parent sequence.
- the sequence comprising the DNA mutation or mutations has at least 60%, more preferably at least 75%, more preferably still 85% homology with the parental sequence.
- sequence “homology” can be determined using standard techniques known to those skilled in the art. For example, homology may be determined using the on-line homology algorithm “BLAST” program, publicly available at http://www.ncbi.nlm.nih.gov/BLAST/.
- genetic modification includes the introduction of exogenous and/or endogenous DNA sequences into the genome of an organism either by insertion into the genome of said organism or by vectors including plasmid DNA or bacteriophage as known by one skilled in the art, said DNA sequence being at least two deoxyribonucleic acid bases in length.
- “companion animal” means a domestic animal.
- “companion animal” means a domestic canine, feline, rabbit, ferret, horse, cow, or the like. More preferably, “companion animal” means a domestic canine or feline.
- the first aspect of the present invention comprises a strain of Bifidobacterium pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having probiotic activity in animals.
- Probiotics are micro-organisms, either viable or dead, processed compositions of micro-organisms, their constituents such as proteins or carbohydrates, or purified fractions of bacterial ferments that beneficially affect a host.
- the general use of probiotic bacteria is in the form of viable cells. However, it can be extended to non-viable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This may include thermally killed micro-organisms, or micro-organisms killed by exposure to altered pH or subjected to pressure.
- probiotics is further intended to include the metabolites generated by the micro-organisms of the present invention during fermentation, if they are not separately indicated. These metabolites may be released to the medium of fermentation, or they may be stored within the micro-organism.
- probiotic also includes bacteria, bacterial homogenates, bacterial proteins, bacterial extracts, bacterial ferment supernatants, and mixtures thereof, which perform beneficial functions to the host animal when given at a therapeutic dose.
- strains of Bifidobacterium pseudolongum obtainable by isolation directly from resected and washed GI tract of mammals are adherent to the GI tract following feeding of viable bacterial cells, and are also significantly immunomodulatory when fed to animals in viable, non-viable or fractionated form.
- the Bifidobacterium pseudolongum obtainable by isolation from resected and washed GI tract closely associate with the gut mucosal tissues. Without further being bound by theory, this is believed to result in the probiotic Bifidobacterium pseudolongum of the present invention generating alternative host responses that result in its probiotic action.
- probiotic bacteria obtainable by isolation from resected and washed GI tract can modulate the host's immune system via direct interaction with the mucosal epithelium, and the host's immune cells.
- This immunomodulation in conjunction with the traditional mechanism of action associated with probiotic bacteria, i.e. the prevention of pathogen adherence to the gut by occlusion and competition for nutrients, results in the Bifidobacterium pseudolongum of the present invention being highly efficacious as a probiotic organism.
- the Bifidobacterium pseudolongum of the present invention obtainable by isolation from resected and washed canine GI tract, have in vitro anti-microbial activity against a number of pathogenic bacterial strains/species, as measured by zones of inhibition or bacterial growth inhibition assays known to those skilled in the art. Without being bound by theory, it is believed that this in vitro anti-microbial activity is indicative of potential probiotic activity in vivo in animals, preferably companion animals such as canines and felines.
- the lactic acid bacteria of the present invention preferably have in vitro anti-microbial activity against Salmonella typhimurium, Listeria monocytogenes, Listeria innocua or Eschericia coli , more preferably a mixture of these strains, more preferably still, all of these strains.
- the anti-microbial activity of the Bifidobacterium pseudolongum bacteria of the present invention may be the result of a number of different actions by the Bifidobacterium pseudolongum bacteria herein. It has previously been suggested in the art that several strains of bacteria isolated from fecal samples exert their probiotic effect in the GI tract following oral consumption by preventing the attachment of pathogenic organisms to the gut mucosa by occlusion. This requires oral consumption of “live” or viable bacterial cells in order for a colony of bacteria to be established in the gut.
- the Bifidobacterium pseudolongum of the present invention obtainable by isolation from resected and washed canine GI tract, whilst exerting some probiotic effect due to occlusion if given in a viable form, may deliver a substantial probiotic effect in either the viable or non-viable form due to the production during fermentation in vitro of a substance or substances that either inhibit the growth of or kill pathogenic micro-organisms, and/or alter the host animal's immune competence.
- This form of probiotic activity is desirable, as the bacteria of the present invention can be given as either viable or non-viable cultures or purified fermentation products and still deliver a beneficial therapeutic effect to the host animal.
- the Bifidobacterium pseudolongum bacteria of the present invention are able to maintain viability following transit through the GI tract. This is desirable in order for live cultures of the bacteria to be taken orally, and for colonisation to occur in the intestines and bowel following transit through the oesophagus and stomach. Colonisation of the intestine and bowel by the lactic acid bacteria of the present invention is desirable for long-term probiotic benefits to be delivered to the host. Oral dosing of non-viable cells or purified isolates thereof induces temporary benefits, but as the bacteria are not viable, they are not able to grow, and continuously deliver a probiotic effect in situ. As a result this may require the host to be dosed regularly in order to maintain the health benefits. In contrast, viable cells that are able to survive gastric transit in the viable form, and subsequently colonise by adhering to and proliferating on the gut mucosa are able to deliver probiotic effects continuously in situ.
- the lactic acid bacteria of the present invention maintain viability after suspension in a media having a pH of 2.5 for 1 hour.
- “maintain viability” means that at least 25% of the bacteria initially suspended in the test media are viable using the plate count method known to those skilled in the art.
- “maintain viability” means that at least 50% of the bacteria initially suspended are viable. It is desirable for the lactic acid bacteria of the present invention to maintain viability following exposure to low pH as this mimics the exposure to gastric juices in the stomach and upper intestine in vivo following oral consumption in animals.
- the lactic acid bacteria of the present invention have a growth of at least 33% when in the presence of at least 0.5% porcine bile salts. Growth, as used herein is described in further detail in example 3. More preferably, the bacteria of the present invention have a growth of at least 33% when in the presence of at least 1% porcine bile salts. Without being bound by theory it is believed that the lactic acid bacteria of the present invention, capable of growth in the presence of at least 0.5% porcine bile salts, are able to survive the conditions present in the intestine. This is thought to be a result of the addition of porcine bile to the culture medium mimicking the conditions of the intestine.
- the Bifidobacterium pseudolongum bacteria of the present invention have significant adhesion to gut epithelial cells in vitro.
- “significant adhesion” means at least 4% of the total number of lactic acid bacteria co-incubated with the epithelial cells in vitro adhere to the epithelial cells. More preferably, at least 6% of bacterial cells co-incubated adhere to epithelial cells in vitro.
- gut epithelial cell adherence in vitro is indicative of the lactic acid bacteria's ability to colonise the GI tract of an animal in vivo.
- the 16s-23s intergenic polynucleotide sequence is known to those skilled in the art as the sequence of DNA in the bacterial genome that can be used in order to identify different species and strains of bacteria. This intergenic polynucleotide sequence can be determined by the method detailed below in example 4.
- the strain of Bifidobacterium pseudolongum has a 16s-23s intergenic polynucleotide sequence that has at least 93%, preferably at least 96%, more preferably at least 99% homology with the polynucleotide sequence according to SEQ. ID NO. 1. More preferably, the strain of lactic acid bacteria according to the present invention has a 16s-23s polynucleotide sequence according to SEQ. ID NO. 1. More preferably still, the strain of lactic acid bacteria according to the present invention is Bifidobacterium pseudolongum strain NCIMB 41199 (AHC7), or a mutant thereof.
- AHC7 Bifidobacterium pseudolongum strain NCIMB 41199
- the strain of lactic acid bacteria of the genus Bifidobacterium pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract can be used to deliver probiotic benefit following oral consumption in animals, preferably companion animals or humans. This probiotic benefit generally maintains and improves the overall health of the animal.
- Non-limiting elements of animal health and physiology that benefit, either in therapeutically relieving the symptoms of, or disease prevention by prophylaxis include inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly those of the gastrointestinal and immune systems), diarrhoeal disease, antibiotic associated diarrhea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, amyloidosis, rheumatoid arthritis, arthritis, joint mobility, diabetes mellitus, insulin resistance, bacterial infections, viral infections, fungal infections, periodontal disease, urogenital disease, surgical associated trauma, surgical-induced metastatic disease, sepsis, weight loss, weight gain, excessive adipose tissue accumulation, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier infection, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system, hepatic disease, ischa
- inflammatory disorders including autoimmune disease and inflammation may be detected and monitored using in vivo immune function tests such as lymphocyte blastogenesis, natural killer cell activity, antibody response to vaccines, delayed-type hypersensitivity, and mixtures thereof.
- in vivo immune function tests such as lymphocyte blastogenesis, natural killer cell activity, antibody response to vaccines, delayed-type hypersensitivity, and mixtures thereof.
- ameliorating the effects of age may be determined using dual x-ray absorptometry or CT scan for measuring body composition, including body fat mass, fat-free mass and bone mineral content.
- this method may be used to determine anatomy changes such as weight loss or bone density in subjects following infection.
- the Bifidobacteria of the present invention may also be used in a method for reducing stress levels in companion animals.
- Concentrations of blood stress hormones including epinephrine, norepinephrine, dopamine, cortisol and C-reactive protein may be measured to determine stress levels and their reduction or maintenance. These hormones are recognized biomarkers of stress and can be readily measured using techniques known to those skilled in the art.
- maintenance or improvement of the health of the skin and/or coat system of companion animals, including atopic disease of the skin may be measured using skin and coat assessments conducted by two trained individuals. Examples of criteria examined during such assessments include:
- the treatment or prevention of gastrointestinal infection, including diarrhea, in companion animals may be measured using stool scores.
- Stools scores may be recorded daily according to the following guidelines and control and test groups compared before and after feeding with the bacteria according to the present invention.
- This stool is hard and does not stick to surfaces. Stool will roll when pushed. No indentations are made when stool is picked up. Stool is often defecated in groups of individual stools instead of one complete unit. The stool maintains original shape after collection.
- This stool is firm, well shaped, and cylindrical. This stool does not break apart easily when picked up. This stool may leave residue on surfaces and gloves. This stool is often defecated as one unit. The stool maintains original shape after collection.
- This stool is soft, however there are definite shapes. This stool will break apart easily and will definitely leave residue on surfaces and gloves. The stool often loses original shape after collection. This stool is often present with another score but can comprise whole stool sample.
- This stool is soft and will have no cylindrical shape.
- the shape often associated with a “2” is a “cow patty” shape.
- This stool will lose the original shape when collected and will definitely leave residue on surfaces and gloves.
- This stool score is often present with another score but can comprise the whole stool sample. This stool sample may spread over an area of several inches.
- This stool score will always resemble liquid and there may or may not be particulate matter present. This stool will often be defecated in groups of piles instead of one complete unit. Mucous is often present with this stool sample. This stool sample is very difficult to collect and residue is always left on surfaces and gloves. This stool sample may spread over an area of several inches.
- the treatment of gastrointestinal infection in companion animals may comprise improving microbial ecology of companion animals.
- Improving the microbial ecology of companion animals preferably comprises reducing the levels of pathogenic bacteria in the feces of companion animals.
- the levels of pathogenic bacteria present in the feces of companion animals may be enumerated using the standard plate count method known to those skilled in the art.
- the pathogenic bacteria are selected from the group consisting of Clostridia, Escherichia, Salmonella, bacteriodes and mixtures thereof.
- suitable strains of pathogenic bacteria include C. perfringens, C. difficile, Eschericia coli, Salmonella typhimurium and mixtures thereof.
- the method of use of the bacteria of the present invention may also include the treatment, either prophylactic or therapeutic of the urinary tract of mammals, preferably companion animals.
- urinary tract treatment include treatment or prevention of urinary tract infections, treatment or prevention of kidney disease, including kidney stones, treatment or prevention of bladder infections and the like.
- the Bifidobacteria of the present invention are useful in preventing these ailments as a result of their ability to degrade oxalic acid, as demonstrated in vitro.
- Oxalic acid is a by-product of urinary metabolism that can form insoluble precipitates that result in kidney, bladder and other urinary tract infections.
- the bacteria of the present invention may treat and prevent infections and other ailments of the urinary tract.
- Oxalic acid degradation may be measured in vitro using the Oxalic acid test kit cat #755699 commercially available from Boehringer Mannheim/R-Biopharm.
- the Bifidobacterium pseudolongum of the present invention may be used in a method for improving or maintaining the health of companion animals comprising improving fiber digestion. Improving fiber digestion is desirable as it promotes the growth of said probiotic bacteria, as well as beneficial endogenous microflora, which aid in the suppression of some potentially pathogenic bacteria. In addition, a decrease in the amount of toxic metabolites and detrimental enzymes that result from colonic fermentation has been documented in humans (Tomomatsu, H. “Health effects of oligosaccharides”, (1994) Food Technol, 48, 61-65). Fiber digestion may be determined using the method described in Vickers et al.
- the method of use of the Bifidobacterium pseudolongum bacteria of the present invention typically involves oral consumption by the animal. Oral consumption may take place as part of the normal dietary intake, or as a supplement thereto. The oral consumption typically occurs at least once a month, preferably at least once a week, more preferably at least once per day.
- the Bifidobacterium pseudolongum bacteria of the present invention may be given to the companion animal in a therapeutically effective amount to maintain or improve the health of the animal, preferably a companion animal.
- the term “therapeutically effective amount” with reference to the lactic acid bacteria means that amount of the bacteria sufficient to provide the desired effect or benefit to a host animal in need of treatment, yet low enough to avoid adverse effects such as toxicity, irritation, or allergic response, commensurate with a reasonable benefit/risk ratio when used in the manner of the present invention.
- the specific “therapeutically effective amount” will vary with such factors as the particular condition being treated, the physical condition of the user, the duration of the treatment, the nature of concurrent therapy (if any), the specific dosage form to be used, the carrier employed, the solubility of the dose form, and the particular dosing regimen.
- the lactic acid bacteria are given to the companion animal at a dose of from 1.0E+04 to 1.0E+14 CFU per day, more preferably from 1.0E+06 to 1.0E+12 CFU per day.
- the composition preferably may contain at least 0.001% of from 1.0E+04 to 1.0E+12 CFU/g of the Bifidobacterium pseudolongum obtainable by isolation from resected and washed canine GI tract.
- the Bifidobacterium pseudolongum bacteria can be given to the animal in either viable form, or as killed cells, or distillates, isolates or other fractions of the fermentation products of the lactic acid bacteria of the present invention, or any mixture thereof.
- the Bifidobacterium pseudolongum bacteria are used to prepare a composition intended to maintain or improve the health of an animal.
- the composition may be part of the normal dietary intake, or a supplement.
- the composition may be in the form of a dried animal food such as biscuits or kibbles, a processed grain feed, a wet animal food, yogurts, gravies, chews, treats and the like.
- compositions may comprise further components.
- Other components are beneficial for inclusion in the compositions used herein, but are optional for purposes of the invention.
- food compositions are preferably nutritionally balanced.
- the food compositions may comprise, on a dry matter basis, from about 20% to about 50% crude protein, preferably from about 22% to about 40% crude protein, by weight of the food composition.
- the crude protein material may comprise any material having a protein content of at least about 15% by weight, non-limiting examples of which include vegetable proteins such as soybean, cotton seed, and peanut, animal proteins such as casein, albumin, and meat tissue.
- meat tissue useful herein include fresh meat, and dried or rendered meals such as fish meal, poultry meal, meat meal, bone meal and the like.
- suitable crude protein sources include wheat gluten or corn gluten, and proteins extracted from microbial sources such as yeast.
- the food compositions may comprise, on a dry matter basis, from about 5% to about 35% fat, preferably from about 10% to about 30% fat, by weight of the food composition.
- food compositions comprising the lactic acid bacteria of the present invention may also comprise from about 4% to about 25% total dietary fiber.
- the compositions may also comprise a multiple starch source as described in WO99/51108.
- compositions of the present invention may further comprise a source of carbohydrate.
- Grains or cereals such as rice, corn, milo, sorghum, barley, alfalfa, wheat, and the like are illustrative sources.
- the compositions may also contain other materials such as dried whey and other dairy by products.
- compositions comprising the bacteria of the present invention may also comprise a prebiotic.
- prebiotic includes substances or compounds that are fermented by the intestinal flora of the pet and hence promote the growth or development of lactic acid bacteria in the gastrointestinal tract of the pet at the expense of pathogenic bacteria. The result of this fermentation is a release of fatty acids, in particular short-chain fatty acids in the colon. This has the effect of reducing the pH value in the colon.
- suitable prebiotics include oligosaccharides, such as inulin and its hydrolysis products commonly known as fructooligosaccharides, galacto-oligosaccarides, xylo-oligosaccharides or oligo derivatives of starch.
- the prebiotics may be provided in any suitable form.
- the prebiotic may be provided in the form of plant material which contains the fiber. Suitable plant materials include asparagus, artichokes, onions, wheat or chicory, or residues of these plant materials.
- the prebiotic fiber may be provided as an inulin extract, for example extracts from chicory are suitable. Suitable inulin extracts may be obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark “Raftiline”.
- the inulin may be provided in the form of Raftiline (g) ST which is a fine white powder which contains about 90 to about 94% by weight of inulin, up to about 4% by weight of glucose and fructose, and about 4 to 9% by weight of sucrose.
- the fiber may be in the form of a fructooligosaccharide such as obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark “Raftilose”.
- the inulin may be provided in the form of Raftilose (g) P95.
- the fructooligosaccharides may be obtained by hydrolyzing inulin, by enzymatic methods, or by using micro-organisms.
- a suitable process is extrusion cooking, although baking and other suitable processes may be used.
- the dried pet food is usually provided in the form of a kibble.
- the prebiotic may be admixed with the other ingredients of the dried pet food prior to processing.
- a suitable process is described in European patent application No 0850569. If a probiotic micro-organism is used, the organism is best coated onto or filled into the dried pet food.
- a suitable process is described in European patent publication Number EP 0 862 863.
- Typical wet food compositions may comprise from about 5% to about 15% protein, from about 1% to about 10% fat, and from about 1% to about 7% fiber.
- Non-limiting ingredients that may be used in wet food compositions include chicken, turkey, beef, whitefish, chicken broth, turkey broth, beef broth, chicken liver, brewers rice, corn grits, fish meal, egg, beet pulp, chloride, flax meal, lamb, beef by-products, chicken by-products and mixtures thereof.
- supplement compositions such as biscuits, chews, and other treats may comprise, on a dry matter basis, from about 20% to about 60% protein, or from about 22% to about 40% protein, by weight of the supplement composition.
- the supplement compositions may comprise, on a dry matter basis, from about 5% to about 35% fat, or from about 10% to about 30% fat, by weight of the supplement composition.
- Food and supplement compositions intended for use by canines or felines are commonly known in the art.
- the pet foods may contain other active agents such as long chain fatty acids and zinc.
- Suitable long chain fatty acids include alpha-linoleic acid, gamma linolenic acid, linoleic acid, eicosapentanoic acid, and docosahexanoic acid.
- Fish oils are a suitable source of eicosapentanoic acids and docosahexanoic acid.
- Borage oil, blackcurrent seed oil and evening primrose oil are suitable sources of gamma linolenic acid.
- Safflower oils, sunflower oils, corn oils and soy bean oils are suitable sources of linoleic acid. These oils may also be used in the coating substrates referred to above.
- Zinc may be provided in various suitable forms, for example as zinc sulfate or zinc oxide. Further, many ingredients commonly used in pet foods are sources of fatty acids and zinc. It has been observed that the combination of chicory, as a source of prebiotic, with a linoleic-acid rich oil, such as soy bean oil, provides unexpected benefits, suggestive of a synergistic effect.
- the composition preferably comprises at least 10% of a broth, or stock, non-limiting examples of which include vegetable beef, chicken or ham stock.
- Typical gravy compositions may comprise from about 0.5% to about 5% crude protein, from about 2% to about 5% crude fat, and from about 1% to about 5% fiber.
- compositions suitable binding agents are required to maintain the pill in a solid, pressed form.
- suitable binding agents include the natural gums such as xanthan gum, pectins, lecithins, alginates and others known to those skilled in the art.
- the composition is in the form of a capsule, the composition is preferably encapsulated using technologies known to those skilled in the art.
- suitable encapsulation materials include polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), alginates, and gelatin.
- Yoghurt-based compositions may comprise from about 1% to about 5% protein, from about 10% to about 20% carbohydrate, from about 1% to about 5% fiber, from about 1% to about 5% fat and from about 50% to about 90% liquid carrier such as milk.
- Canine intestinal samples were obtained from healthy dogs presenting at the local veterinarians for owner initiated and approved euthanasia. All animals were healthy and disease-free. The colon, mid-colon, caecum and ileum of each dog were dissected in order to expose the mucosa.
- Suitable isolates were tested for Gram reaction and catalase activity. Identification of gram positive, catalase negative rods was performed using API testing (API 50CHL, BioMerieux). Harvested cells were washed twice with 0.05M phosphate buffer (pH 6.5) and cysteine-HCl (500 mg/l) followed by sonication. Centrifugation removed cellular debris. Supernatants were incubated with NaF (6 mg/ml) and Na iodoacetate (10 mg/ml) for 30 minutes at 37° C. The reaction was stopped by incubation with hydroxylamine HCl (pH6.5) for 10 minutes at room temperature.
- lactic acid bacterial strains were isolated from resected and washed canine GI tract, of which six were found to be of the genus Bifidobacterium , and one of the strain B. pseudolongum.
- the isolated Bifidobacterium pseudolongum bacterial strains were incubated anaerobically in TPY broth. 2 ⁇ l of each culture were spotted onto TPY agar plates and incubated anaerobically overnight. Salmonella typhimurium, Listeria monocytogenes, Listeria innocua and Eschericia coli 0157H45 were pre-grown overnight and 100 ⁇ l inoculated into molten agar (1% v/v). This indicator culture was poured onto the surface of the inoculated MRS or TPY plates. Following overnight incubation, zones of inhibition around the probiotic colony were measured. All experiments were performed in duplicate on three separate occasions. In addition, incorporating the buffer 2% betaglycerophosphate into the agar enabled assessment of the contribution of acid production to the observed pathogen inhibition in vitro.
- FIGS. 1, 2, 3 and 4 clearly demonstrate that the Bifidobacterium pseudolongum bacteria strains of the present invention obtainable by isolation from resected and washed canine GI tract have anti-microbial activity in vitro, indicative of potential probiotic activity.
- Bacterial cells were harvested from overnight cultures, washed twice in phosphate buffer (pH 6.5) and resuspended in TPY broth adjusted with 1M HCl to pH 2.5. The cells were incubated anaerobically at 37° C. and their survival measured at intervals of 0, 30, 60, 120, 240 and 360 minutes using the plate count method known to those skilled in the art.
- FIG. 5 clearly demonstrates that nine strains were not pH 2.5 resistant over 1 hour, and the 49 strains were resistant to pH 2.5 over 1 hour. Table 2 summarises this data per strain.
- the bacterial strains were streaked onto TPY agar supplemented with porcine bile (Sigma) at 0.5%, 1% and 5% (w/v). Plates were incubated at 37° C. under anaerobic conditions and the growth recorded after 24 hours. Growth was compared with control plates by an experienced observer, and the growth of colonies described as:
- the growth descriptors are given numerical values of 0, 1, 2 or 3 ( ⁇ ; +; ++, +++ respectively), and then expressed as a percentage, where 3 represents 100%.
- FIG. 6 demonstrates that the Bifidobacteria of the present invention clearly demonstrate a resistance to bile salts, being able to grow and form colonies at a level of at least 33% when exposed to 0.5% bile salts.
- the human epithelial cell line, HT-29 was used to assess the adhesion properties of selected strains.
- Epithelial cells were routinely cultured as a monolayer in 75 cm 2 tissue culture flasks at 37° C. in a humidified atmosphere containing 5% CO 2 in Dulbecco's Minimal Essential Media (DMEM) containing 10% foetal calf serum (FCS), pen/strep, glutamine and fungizone.
- DMEM Dulbecco's Minimal Essential Media
- FCS foetal calf serum
- glutamine glutamine
- fungizone fungizone
- the epithelial monolayers were washed with antibiotic-free medium containing 10% FCS. Bacterial suspensions plus/in antibiotic-free DMEM were added to each well and the cells incubated for 90 minutes at 37° C. Following incubation, the monolayers were washed three times with PBS. The epithelial cells were lysed in deionised H 2 O and the number of adherent bacteria enumerated using the plate count method known to those skilled in the art. Adhesion was expressed as a percentage of the number of bacteria initially plated.
- the Bifidobacterium pseudolongum strain deposited with the NCIMB under deposition number NCIMB 41199 adhere to HT-29 gut epithelial cells at levels of at least 4%.
- Bifidobacterium pseudolongum colonies were picked from an Agar plate and resuspended in 1 ⁇ PCR buffer, heated at 96° C. for 5 minutes, frozen at ⁇ 70° C. for 5-10 minutes, thawed and an aliquot was added to a PCR eppendorf tube.
- PCR was performed using the intergenic spacer (IGS) primers, IGS L: 5′-GCTGGATCACCTCCTTTC-3′ and IGS R: 5′-CTGGTGCCAAGGCATCCA-3′.
- the cycling conditions were 96° C. for 1 min (1 cycle), 94° C. for 30 sec, 53° C. for 30 sec, 72° C. for 30 sec (28 cycles).
- the PCR reaction contained 5 ⁇ l of DNA, PCR buffer (Bioline, UK), 0.2 mM dNTPs (Roche, UK), 0.4 ⁇ M IGS L and R primer (150 ng/50 ⁇ l) (MWG Biotech, Germany) and Bioline Taq polymerase (0.6 units).
- the PCR reactions were performed on a Hybaid thermocycler.
- the PCR products (8 ⁇ l) were ran alongside a molecular weight marker ( ⁇ X 174 Hae III, Promega) on a 2% agarose EtBr stained gel in TAE, to determine their IGS profile.
- the intergenic spacer (IGS) DNA was sequenced for the 2 canine Bifidobacterium pseudolongum strains using methods known to those skilled in the art.
- Examples 1 to 4 are examples of dried kibble compositions comprising the probiotic Bifidobacterium pseudolongum of the present invention.
- Examples 5 to 7 are examples of wet pet food compositions comprising the probiotic Bifidobacterium pseudolongum of the present invention.
- Examples 8 to 10 are examples of yogurt supplement compositions comprising the probiotic Bifidobacterium pseudolongum of the present invention.
Abstract
Description
16s-23s | ||
Strain | Deposit Number | Sequence |
Bifidobacterium pseudolongum AHC7 | NCIMB 41199 | SEQ. ID NO. 1 |
-
- 1. Lymphocyte blastogenesis: This assay measures the proliferative response in vitro of lymphocytes isolated from fresh whole blood of test and control animals to various mitogens and is a measure of overall T- and B-cell function. Briefly, peripheral blood mononucleocytes (PBMC) are isolated from whole blood by Ficoll-Hypaque density centrifugation methods known to those skilled in the art. The isolated PBMCs are washed twice in RPMI 1640 cell media supplemented with HEPES, L-glutamine and penicillin/streptomycin. The washed cells are resuspended in RPMI 1640, counted, and the cell density adjusted appropriately. The 2×105 cells are exposed to a range of concentrations (0.1 g/ml to 100 g/ml) of various mitogens, some examples of which include pokeweed mitogen (Gibco), phytohaemagglutinin (Gibco) and conconavalin A (Sigma) in triplicate for 72 hours at 37° C. and 5% CO2 with 10% foetal bovine serum (Sigma). At 54 hours the cells are pulsed with 1 Ci 3H-thymidine, and the cells harvested and scintillation counts read on a TopCount NXT at 72 hours.
- 2. Natural killer cell activity: As described in U.S. Pat. No. 6,310,090, this assay measures the in vitro effector activity of natural killer cells isolated from fresh whole blood of test and control animals. Natural killer cells are a component of the innate immune function of a mammal. Canine thyroid adenocarcinoma cells were used as target cells in assessing NK cell cytotoxic activity. This cell line was previously shown to be susceptible to killing by canine NK cell. Target cells were cultured in a T75 flask with 20 mL minimum essential medium (MEM; Sigma Chem. Co., St. Louis, Mo.) supplemented with 10% fetal calf serum (FCS), 100 U/mL of penicillin and 100 g/mL of streptomycin. When confluent, target cells were trypsinized, washed 3 times and resuspended to 5×105 cells/mL in complete medium (RPMI-1640+10% FCS+100 U/mL of penicillin+100 g/mL of streptomycin).
Triplicate 100. L aliquots of the target cells were pipetted into 96-well U-bottom plates (Costar, Cambridge, Mass.) and incubated for 8 hours to allow cell adherence. Lymphocytes (effector cells; 100. L) isolated by Ficoll-Hypaque separation (as described above) were then added to the target cells to provide an effector/target cell (E:T) ratio of 10:1. After 10 hours of incubation at 37° C., 20. 1 of a substrate containing 5. g of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added. The mixture was incubated for 4 hours at 37° C. after which the unmetabolized MTT was removed by aspiration. The formazan crystals were dissolved by adding 200 L of 95% ethanol. Optical density was measured at 570 nm using a microplate reader. The percentage of NK cell-specific lysis was calculated as follows:
Specific Cytotoxicity (%)=100×{1−[(OD of target cells and effector cells−OD of effector cells)/(OD of target cells)]} - 3. Antibody response to vaccines: The test subjects are given an array (up to 5) of vaccines after at least 12 weeks of probiotic or control feeding. The vaccines may be a mixture of novel and redundant vaccines. Non-limiting examples of vaccine arrays that may be used include mixtures of vaccines prepared by Fort Dodge Animal Health. Non-limiting examples of vaccines suitable for use herein include Canine distemper, adenovirus, coronavirus, parainfluenza, and parvovirus. The test subject's vaccine history will determine the vaccines to be used. The specific antibodies to the vaccines given are measured in blood for 3 weeks and the length and strength of response in control and probiotic feeding groups compared.
- 4. Delayed-type hypersensitivity: An in vivo, non-invasive method of assessing immune system status. This test comprises an intradermal injection of the polyclonal mitogen Phytohemmaglutinin (PHA) in combination with sheep red blood cells a multivalent vaccine, histamine (100 μL of 0.0275 g/L Histamine Phosphate; Greer, Lenoir, N.C.), or PBS (100 μL of Phosphate Buffered Saline, 8.5 g/L; Sigma). The immune response to the antigen is recorded as skinfold thickness using calipers at time intervals of 0, 24, 48 and 72 hours post-injection. An increase in skinfold thickness is indicative of a greater hypersensitivity response that should be decreased by treatment with the bacteria of the present invention.
-
- a) Shedding index: A shedding index is assigned to each test subject by collecting hair produced during a standardized brushing session. The hair is retained and weighed, and control and test subjects compared.
- b) Subjective skin/coat evaluations: Trained panelists subjectively evaluate skin and coat condition by assessing shedding, dander, shine, uniformity, softness and density.
- c) Skin functional assessment: The barrier function of the skin may be assessed by wiping the skin surface with an acetone-soaked gauze. This technique effectively disrupts the skin barrier by removing single cell layers and associated lipid fractions of the stratum corneum. Barrier disruption is quantified by measuring the increase in transepidermal water loss (TEWL) and the degree of redness of the insulted site using methods known to those skilled in the art. Redness (erythema) scores are obtained using the previously described camera and lighting system. TEWL readings and redness scores are obtained immediately before and after disruption, and at five and 24-hour endpoints to assess the protective and healing properties of skin.
TABLE 2 | |||
Strain designation | Starting Conc. | Conc. After 1 hour | Viability (%) |
AHC A | 1.50E+08 | 1.20E+08 | 80 |
AHC B | 4.00E+07 | 5.50E+07 | 137 |
AHC C | 1.10E+08 | 1.50E+08 | 136 |
AHC F | 6.00E+08 | 6.00E+08 | 100 |
| 2.50E+07 | 4.50E+07 | 180 |
Bile Resistance
Percentage on a weight Basis |
Ingredient | Ex. 1 | Ex. 2 | Ex. 3 | Ex. 4 |
Cereal grains | To 100 | To 100 | To 100 | To 100 |
Poultry by-product meal | 43.5 | 40 | 45 | 35 |
Poultry fat | 1.28 | 1.02 | 1.16 | 1.35 |
Egg product | 2.4 | 2.1 | 2.5 | 2.2 |
Chicken liver meal | 1.0 | 1.0 | 1.0 | 1.0 |
Brewer's dried yeast | 1.0 | 1.0 | 1.0 | 1.0 |
Monosodium phosphate | 1.0 | 1.0 | 1.0 | 1.0 |
Calcium carbonate | 0.8 | 0.8 | 0.8 | 0.8 |
Potassium chloride | 0.6 | 0.6 | 0.6 | 0.6 |
Vitamins | 0.4 | 0.4 | 0.4 | 0.4 |
Choline chloride | 0.3 | 0.3 | 0.3 | 0.3 |
Minerals | 0.3 | 0.3 | 0.3 | 0.3 |
DL-Methionine | 0.1 | 0.1 | 0.1 | 0.1 |
Sodium Chloride | 0.03 | 0.03 | 0.03 | 0.03 |
Probiotic (1 × 1010 cfu/g | 0.1 | 0.5 | 1 | 0.4 |
NCIMB 41199 in sunflower | ||||
oil) | ||||
Percentage on a weight Basis |
Ingredient | Ex. 5 | Ex. 6 | Ex. 7 | |
Water | To 38 | To 47 | To 50 | |
Poultry Liver | To 25 | To 20 | To 15 | |
Poultry Products | 25 | 20 | 20 | |
Brewers Rice | 5 | 7 | 10 | |
Egg Product | 3 | 2.5 | 1.5 | |
Poultry Fat | 2.9 | 3.0 | 3.2 | |
Chicken Stock | 0.6 | 0.7 | 0.9 | |
Taurine | 0.1 | 0.1 | 0.1 | |
Vitamins | 0.05 | 0.1 | 0.1 | |
Minerals | 0.05 | 0.1 | 0.1 | |
Probiotic (1 × 1010 cfu/g | 4 | 5 | 6 | |
NCIMB 41199) | ||||
Percentage on a weight Basis |
Ingredient | Ex. 8 | Ex. 9 | Ex. 10 | |
Milk | 82.75 | 81.9 | 82.7 | |
|
12 | 12 | 10 | |
Modified Starch | 1.0 | 0.8 | 0.8 | |
Prebiotic | 0.25 | 0.3 | 0.5 | |
Probiotic (1 × 1010 cfu/g | 4 | 5 | 6 | |
NCIMB 41199) | ||||
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/292,171 US9580680B2 (en) | 2003-12-19 | 2008-11-13 | Canine probiotic bifidobacterium pseudolongum |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53109903P | 2003-12-19 | 2003-12-19 | |
US11/013,117 US20050158294A1 (en) | 2003-12-19 | 2004-12-15 | Canine probiotic Bifidobacteria pseudolongum |
US12/292,171 US9580680B2 (en) | 2003-12-19 | 2008-11-13 | Canine probiotic bifidobacterium pseudolongum |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/013,117 Continuation US20050158294A1 (en) | 2003-12-19 | 2004-12-15 | Canine probiotic Bifidobacteria pseudolongum |
Publications (2)
Publication Number | Publication Date |
---|---|
US20090136455A1 US20090136455A1 (en) | 2009-05-28 |
US9580680B2 true US9580680B2 (en) | 2017-02-28 |
Family
ID=34738622
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/013,117 Abandoned US20050158294A1 (en) | 2003-12-19 | 2004-12-15 | Canine probiotic Bifidobacteria pseudolongum |
US12/148,305 Active 2028-06-16 US8900568B2 (en) | 2003-12-19 | 2008-04-18 | Method of treating diarrhea in a canine |
US12/292,171 Active 2027-10-24 US9580680B2 (en) | 2003-12-19 | 2008-11-13 | Canine probiotic bifidobacterium pseudolongum |
US12/271,090 Active 2025-05-22 US7998473B2 (en) | 2003-12-19 | 2008-11-14 | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/013,117 Abandoned US20050158294A1 (en) | 2003-12-19 | 2004-12-15 | Canine probiotic Bifidobacteria pseudolongum |
US12/148,305 Active 2028-06-16 US8900568B2 (en) | 2003-12-19 | 2008-04-18 | Method of treating diarrhea in a canine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/271,090 Active 2025-05-22 US7998473B2 (en) | 2003-12-19 | 2008-11-14 | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
Country Status (9)
Country | Link |
---|---|
US (4) | US20050158294A1 (en) |
EP (1) | EP1718266B1 (en) |
JP (2) | JP4602351B2 (en) |
AR (1) | AR047065A1 (en) |
AU (1) | AU2004308396B2 (en) |
BR (1) | BRPI0417826B1 (en) |
CA (1) | CA2550309C (en) |
ES (1) | ES2523984T3 (en) |
WO (1) | WO2005062879A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11357803B2 (en) | 2017-09-22 | 2022-06-14 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
US11766050B2 (en) * | 2018-06-26 | 2023-09-26 | Country Food, Llc | Yogurt for dogs |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
CA2607949C (en) * | 2005-05-31 | 2012-09-25 | Thomas William-Maxwell Boileau | Feline probiotic bifidobacteria |
EP2261323A1 (en) * | 2005-05-31 | 2010-12-15 | The Iams Company | Feline probiotic lactobacilli |
US7682619B2 (en) * | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
PL2124966T3 (en) | 2007-02-01 | 2016-01-29 | Iams Europe B V | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
JP2008195635A (en) * | 2007-02-09 | 2008-08-28 | Crossfield Bio Inc | Lactic acid bacteria preparation for horse |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US20110189149A1 (en) * | 2008-06-20 | 2011-08-04 | Remy Burcelin | New Uses of Lactic Acid Bacteria and Bifidobacteria |
US9232813B2 (en) * | 2008-07-07 | 2016-01-12 | The Iams Company | Probiotic supplement, process for making, and packaging |
EP2334196B1 (en) * | 2008-09-11 | 2012-08-29 | The IAMS Company | Animal feed kibble with protein-based core and related methods |
EP3120709A1 (en) | 2009-05-28 | 2017-01-25 | IAMS Europe B.V. | Pet food in the form of a coated kibble |
US9210945B2 (en) | 2009-07-31 | 2015-12-15 | The Iams Company | Animal food having low water activity |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US20110027417A1 (en) * | 2009-07-31 | 2011-02-03 | Patrick Joseph Corrigan | Process for Dusting Animal Food |
US8691303B2 (en) | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
CN102711512A (en) | 2010-01-22 | 2012-10-03 | 爱默思公司 | Process for making a pet food in the form of a coated kibble |
WO2012027519A2 (en) | 2010-08-27 | 2012-03-01 | The Iams Company | Methods of measuring activities of daily living |
US20120115798A1 (en) | 2010-11-04 | 2012-05-10 | Stefan Patrick Massimino | Method for improving the immunity of a companion animal |
AU2012205598B2 (en) | 2011-01-14 | 2015-04-09 | Mars, Incorporated | Compositions and methods relating to carotenoids |
US20120282373A1 (en) | 2011-05-02 | 2012-11-08 | Ashok Premchand Luhadiya | Compositions Comprising a Glucose Anti-Metabolite and Selenium |
US20120283197A1 (en) | 2011-05-02 | 2012-11-08 | Ashok Premchand Luhadiya | Compositions Comprising a Glucose Anti-Metabolite, BHA, and/or BHT |
US20130295227A1 (en) | 2012-05-01 | 2013-11-07 | Robbert H. ter Haar | Composition Comprising a Sensitive Ingredient |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
WO2014121301A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
WO2014121304A1 (en) * | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
US20140349002A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Ingestible Compositions Containing Criollo Avocado Component |
WO2015077794A1 (en) | 2013-11-25 | 2015-05-28 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
EP3082431A4 (en) | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
CN105002109B (en) * | 2014-04-23 | 2018-09-14 | 法玛科技顾问股份有限公司 | Lactic acid bacteria, the composition comprising the lactic acid bacteria with and application thereof |
EP3258792A1 (en) | 2015-02-16 | 2017-12-27 | Mars, Incorporated | Interlocking kibble |
EP3288394A4 (en) | 2015-04-28 | 2019-01-23 | Mars, Incorporated | Process of preparing a sterilized wet pet food product |
CN111212655A (en) | 2017-08-14 | 2020-05-29 | 赛里斯治疗公司 | Compositions and methods for treating cholestatic diseases |
KR102270024B1 (en) * | 2019-07-19 | 2021-06-30 | 유한회사 비피코리아 | Solid lactic acid bacteria for companion animal and manufacturing method thereof |
CN115305210A (en) * | 2021-05-06 | 2022-11-08 | 江苏恒丰强生物技术有限公司 | Method for culturing chicken-derived bifidobacterium pseudolongum and application thereof |
CN114854639B (en) * | 2022-05-24 | 2023-08-08 | 江南大学 | Bifidobacterium pseudolongum capable of high-yield inosine and relieving ulcerative colitis and application thereof |
Citations (393)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US571521A (en) | 1896-11-17 | Package for powders | ||
US1086936A (en) | 1913-05-15 | 1914-02-10 | Malcolm Pounder | Dental massage implement. |
US1503094A (en) | 1923-09-15 | 1924-07-29 | Cramerton Mills Inc | Warp condenser |
US2473773A (en) | 1945-11-16 | 1949-06-21 | Eleanor Kushmaul | Toothbrush |
US2540979A (en) | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
US2641548A (en) | 1950-04-06 | 1953-06-09 | Helen W Heinrich | Method of preserving avocados |
US3320130A (en) | 1962-07-19 | 1967-05-16 | Eurorga | Medicament for colitis, gastroenteritis and enterocolitis |
US3398001A (en) | 1963-04-26 | 1968-08-20 | Air Reduction | Process of preparing and packaging frozen avocados |
US3429426A (en) | 1966-06-28 | 1969-02-25 | Hoefliger & Karg | Package |
US3431338A (en) | 1963-09-10 | 1969-03-04 | Hoffmann La Roche | Coated dosage form adapted to oral emetine or dehydroemetine therapy |
GB1190387A (en) | 1966-05-24 | 1970-05-06 | Green Cross Corp | Enteric Coated Medicaments |
US3677898A (en) | 1969-01-31 | 1972-07-18 | Ajinomoto Kk | Acid protease and method of preparing the same |
US3897572A (en) | 1973-05-16 | 1975-07-29 | Star Kist Foods | Formed meat product |
US3898132A (en) | 1972-08-24 | 1975-08-05 | Int Feed Improvement Ass Inc | Method of preparing stowable, dormant bacteria |
US3931885A (en) | 1973-04-30 | 1976-01-13 | Nahill Edmond P | Medicine dispensing system |
US3957974A (en) | 1974-11-05 | 1976-05-18 | Seikenkai | Method for deodorization of excrements |
US3989822A (en) | 1974-02-14 | 1976-11-02 | Purdue Research Foundation | Weight control compound |
GB1503094A (en) | 1975-04-09 | 1978-03-08 | Nisshin Flour Milling Co | Method for the prophylaxis and treatment of diarrhoea in dogs |
US4248857A (en) | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
GB1595054A (en) | 1977-11-14 | 1981-08-05 | Metal Box Co Ltd | Capsules containing micro-organisms |
US4295567A (en) | 1978-11-10 | 1981-10-20 | Beecham Group Limited | Medicament container |
US4314995A (en) | 1976-02-23 | 1982-02-09 | Seikenkai | Pharmaceutical lactobacillus preparations |
US4332790A (en) | 1978-12-05 | 1982-06-01 | Societe D'assistance Technique Pour Produits Nestle S.A. | Microcapsule containing a microorganism and a process for its production |
US4338346A (en) | 1978-12-21 | 1982-07-06 | The Procter & Gamble Company | Non-nutritive sweetener |
US4399163A (en) | 1980-11-05 | 1983-08-16 | Pfizer Inc. | Branched amides of L-aspartyl-D-amino acid dipeptides |
US4403623A (en) | 1981-11-16 | 1983-09-13 | Colgate-Palmolive Company | Combined toothbrush and gum massage device |
US4411925A (en) | 1980-01-21 | 1983-10-25 | Pfizer Inc. | Branched amides of L-aspartyl-d-amino acid dipeptides |
US4423029A (en) | 1981-06-25 | 1983-12-27 | The Procter & Gamble Company | (S)-3-Amino-4-[(S,S)-1-(1-hydroxyethyl)alkyl amino]-4-oxo-butyric acid compounds suitable as non-nutritive sweetners |
US4434231A (en) | 1979-04-05 | 1984-02-28 | Rhone-Poulenc Industries | Means for embedding microorganisms in a polymer matrix |
JPS59213368A (en) | 1983-05-17 | 1984-12-03 | Hanamaruki Kk | Fruit food and its preparation |
US4518696A (en) | 1983-01-11 | 1985-05-21 | Chr. Hansen's Laboratory, Inc. | Stabilized liquid bacterial suspension for oral administration to animals |
JPS6024153Y2 (en) | 1982-07-20 | 1985-07-18 | 山陽菓機工業有限会社 | Oil application equipment in food manufacturing process |
US4592748A (en) | 1984-05-18 | 1986-06-03 | Vortex Research Corp. | Yoghurt based douche kit and assembly therefor |
US4647453A (en) | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
EP0212747A2 (en) | 1985-08-16 | 1987-03-04 | The Procter & Gamble Company | Drug particles having constant release and immediate release |
EP0212746A2 (en) | 1985-08-16 | 1987-03-04 | The Procter & Gamble Company | Drug particles having constant release |
JPS6297221U (en) | 1985-12-09 | 1987-06-20 | ||
JPS62201823U (en) | 1986-06-16 | 1987-12-23 | ||
US4736849A (en) | 1983-12-19 | 1988-04-12 | Leonard Walter G | Calendar-oriented pill dispenser |
EP0168112A3 (en) | 1984-07-13 | 1988-07-27 | The Procter & Gamble Company | Alpha-l-aspartyl-d-phenylglycine esters and amides useful as high intensity sweeteners |
US4764389A (en) | 1986-04-24 | 1988-08-16 | Labarge Universal Ripener, Inc. | Method of accelerating fruit respiration |
US4767623A (en) | 1984-11-08 | 1988-08-30 | Chemical Dynamics Sweden Ab | Method of binding microflora and preparations therefor |
US4781939A (en) | 1986-10-28 | 1988-11-01 | Nestec, S.A. | Layered meat emulsion product and method of producing same |
WO1988008452A1 (en) | 1987-05-01 | 1988-11-03 | Probiologics International, Inc. | Antibiotic reuterin |
DE3715070A1 (en) | 1987-05-06 | 1988-11-17 | Kneipp Werke Kneipp Mittel Zen | Process for the preparation of extracts of plants, in particular of juices of plants |
FR2615203A1 (en) | 1987-05-12 | 1988-11-18 | Agronomique Inst Nat Rech | INOCULUM IN WHICH THE MICROORGANISMS ARE PACKED IN THE FORM OF BIODEGRADABLE PELLETS, ITS PREPARATION PROCESS AND ITS APPLICATIONS |
US4786507A (en) | 1982-06-07 | 1988-11-22 | Boehringer Ingelheim Kg | Long shelf life tablet containing hydrolysis prone active ingredient |
US4797289A (en) | 1987-03-09 | 1989-01-10 | Reddy Malireddy S | Enhancement of lactobacillus acidophilus growth and viability in yogurt and other cultured dairy products |
EP0298605A1 (en) | 1987-06-10 | 1989-01-11 | Unilever Plc | Process for producing a stable bacterial composition and process for breadmaking using this composition |
US4806368A (en) | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US4808626A (en) | 1986-09-23 | 1989-02-28 | Monell Chemical Senses Center | Use of 2,5-anhydro-D-mannitol as a food intake modifier |
US4814193A (en) | 1988-04-06 | 1989-03-21 | General Foods Corporation | Reduction of microbial population on surface of food materials |
US4816259A (en) | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
WO1989005849A1 (en) | 1987-12-23 | 1989-06-29 | Chr. Hansen's Laboratorium A/S | Lactic acid bacteria for use in fermented milk products and veterinary compositions |
US4859377A (en) | 1987-07-10 | 1989-08-22 | The United States Of America, As Represented By The Secretary Of Agriculture | Starch encapsulation of entomopathogens |
JPH01278781A (en) | 1988-05-02 | 1989-11-09 | Nec Corp | Nonvolatile semiconductor memory device |
US4889238A (en) | 1989-04-03 | 1989-12-26 | The Procter & Gamble Company | Medicament package for increasing compliance with complex therapeutic regimens |
EP0353581A2 (en) | 1988-08-05 | 1990-02-07 | Dr. A. Tosi Farmaceutici S.R.L. | Pharmaceutical compositions comprising selected lactobacillus strains |
WO1990001335A1 (en) | 1988-08-02 | 1990-02-22 | Borody Thomas J | Treatment of gastro-intestinal disorders |
EP0366621A1 (en) | 1988-10-20 | 1990-05-02 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Orally pharmaceutical preparations with colon selective delivery |
US4935247A (en) | 1987-05-08 | 1990-06-19 | Orion-Yhtyma Oy | Composition for the oral administration of pharmaceuticals |
US4937077A (en) | 1987-09-21 | 1990-06-26 | Eastman Kodak Company | Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose |
EP0391416A1 (en) | 1989-04-06 | 1990-10-10 | Chugai Seiyaku Kabushiki Kaisha | Process for preparing a therapeutic agent for rotavirus infection |
EP0399819A2 (en) | 1989-05-24 | 1990-11-28 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilised spore-forming viable microorganisms preparation, its production and pellet thereof |
US5032399A (en) | 1985-04-17 | 1991-07-16 | Sherwood L. Gorbach | L. acidophilus strains |
JPH0376561U (en) | 1989-11-24 | 1991-07-31 | ||
GB2241421A (en) | 1990-02-28 | 1991-09-04 | Sitia Yomo Spa | Milky mousse; preparation process; dessert |
WO1991017672A1 (en) | 1990-05-18 | 1991-11-28 | Hannu Salovaara | Food product containing dietary fiber and method of making said product |
DE4018392A1 (en) | 1990-06-08 | 1991-12-12 | Kaysan Rolf Dipl Kaufm | Recovery of plant hydrolysates for bio:cosmetics and pharmaceuticals - by comminuting the plant prods. then adding aq. cellulolytic and pectinolytic enzyme soln. |
GB2245492A (en) | 1990-07-04 | 1992-01-08 | Zambon Spa | Programmed release oral solid pharmaceutical dosage form |
EP0181170B1 (en) | 1984-11-05 | 1992-03-04 | Kabushiki Kaisya Advance | Hypocholesterolemically active products |
US5096717A (en) | 1989-09-07 | 1992-03-17 | Ciba-Geigy Corporation | Double-coated granules of disodium pamidronate |
FR2668081A1 (en) | 1990-10-19 | 1992-04-24 | Lvmh Rech | METHOD AND APPARATUS FOR MANUFACTURING SOLID PARTICLES FROM A SOLIDIFIABLE MATERIAL IN THE PRESENCE OF A SOLIDIFYING AGENT IN GOOD YIELDS. |
CA1300538C (en) | 1986-08-01 | 1992-05-12 | Robert Charley | Maintenance of the viability of microorganisms for use in microbial inoculants |
US5132137A (en) | 1989-10-04 | 1992-07-21 | Effem Gmbh | Process for the production of a lumpy meat emulsion product |
GB2252228A (en) | 1991-01-29 | 1992-08-05 | Sitia Yomo Spa | Milky mousse and its use |
US5160745A (en) | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
WO1993002558A1 (en) | 1991-08-01 | 1993-02-18 | Biogaia Biologics Ab | Method and formulation for reducing microbial populations |
FR2663198B1 (en) | 1990-06-14 | 1993-09-17 | Xeda International | USE OF ANTIOXIDANT COMPOUNDS FOR INCREASING THE RESISTANCE OF FRUITS AND VEGETABLES AGAINST FUNGAL INFECTIONS. |
CA2093287A1 (en) | 1992-04-03 | 1993-10-04 | Heinrich Eggert | Blister pack |
US5286495A (en) | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
WO1994004180A2 (en) | 1992-08-20 | 1994-03-03 | Schering Corporation | Novel uses of il-4 and/or il-10, and antibodies against the same |
US5292657A (en) | 1990-12-31 | 1994-03-08 | Pioneer Hi-Bred International, Inc. | Process for preparing rotary disc fatty acid microspheres of microorganisms |
US5322686A (en) | 1989-12-22 | 1994-06-21 | Grahn Eva E | Pharmaceutical preparation for controlling pathogenic intestinal bacteria |
EP0439315B1 (en) | 1990-01-22 | 1994-08-24 | McNEIL-PPC, INC. | Dual subcoated simulated capsule-like medicament |
US5344824A (en) | 1990-02-02 | 1994-09-06 | Matsutani Chemical Industries Co., Ltd. | Method for reducing insulin secretion |
WO1994021284A1 (en) | 1993-03-15 | 1994-09-29 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
EP0627173A1 (en) | 1993-05-31 | 1994-12-07 | GIULIANI S.p.A. | Preparation for dietetic use or as a food supplement, with targeted release in the colon |
US5389389A (en) | 1988-05-13 | 1995-02-14 | Basic American Foods | Compositions and methods for inhibiting browning of processed produce |
WO1995007090A1 (en) | 1993-09-06 | 1995-03-16 | Zeneca Limited | Probiotics |
WO1995003809A3 (en) | 1993-07-30 | 1995-03-16 | Isis Innovation | Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours |
US5413960A (en) | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
EP0659769A2 (en) | 1993-12-20 | 1995-06-28 | Matsutani Chemical Industry Co., Ltd. | Agent for promoting the proliferation of bifidobacterium |
US5451400A (en) | 1993-03-16 | 1995-09-19 | The United States Of America As Represented By The Secretary Of Agriculture | Nucosal competitive exclusion flora |
US5474932A (en) | 1991-07-25 | 1995-12-12 | Probi Ab | Intestine colonizing strains of lactobacilli |
WO1995034292A2 (en) | 1994-06-14 | 1995-12-21 | Recordati S.A. Chemical And Pharmaceutical Company | Stabilized biologically active compounds contained in coated microgranules which can be suspended in alimentary fluids |
WO1996001612A1 (en) | 1994-07-11 | 1996-01-25 | Therapicon S.R.L. | A novel drug delivery system |
US5501857A (en) | 1992-07-24 | 1996-03-26 | Midwestern Bio-Ag Products & Services, Inc. | Oral nutritional and dietary composition |
US5501868A (en) | 1993-09-21 | 1996-03-26 | Colgate Palmolive Company | Extruded dog treat food product having improved resistance to breakage |
US5516684A (en) | 1994-03-11 | 1996-05-14 | The Calpis Food Industry Co., Ltd. | Biologically pure culture of Lactobacillus acidophilus FERM-P-14204 or FERM-P-14205 |
US5518733A (en) | 1991-06-27 | 1996-05-21 | Bioeurope | Cosmetic compositions containing oligosaccharides |
US5531988A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
EP0508701B1 (en) | 1991-04-08 | 1996-07-10 | Quest International B.V. | Probiotic |
US5538743A (en) | 1993-10-22 | 1996-07-23 | Onken Gmbh | Complete animal food for cats and dogs |
US5540945A (en) | 1989-05-11 | 1996-07-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
US5569634A (en) | 1992-12-21 | 1996-10-29 | W. R. Grace & Co.-Conn. | Process upset-resistant inorganic supports for bioremediation |
US5578302A (en) | 1992-07-06 | 1996-11-26 | Nestec S.A. | Treatment of stomach ulcers |
WO1996038159A1 (en) | 1995-06-02 | 1996-12-05 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5582643A (en) | 1994-02-25 | 1996-12-10 | Freund Industrial Co., Ltd. | Centrifugal tumbling granulating-coating apparatus |
US5603930A (en) | 1992-07-06 | 1997-02-18 | Nestec S.A. | Lactobacillus johnsonii CNCM I-1225 |
WO1997009448A1 (en) | 1995-09-07 | 1997-03-13 | Oulutech Oy | Method for determining lactic acid bacterial species |
WO1997016198A1 (en) | 1995-11-02 | 1997-05-09 | Chr. Hansen Biosystems A/S | Probiotically acting formulation |
WO1997020577A1 (en) | 1995-12-06 | 1997-06-12 | Pharma Pacific Pty. Ltd. | Improved therapeutic formulation and method |
US5645830A (en) | 1991-11-15 | 1997-07-08 | Research Corporation Technologies, Inc. | Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections |
RU2086248C1 (en) | 1996-04-02 | 1997-08-10 | Всероссийский государственный научно-исследовательский институт контроля, стандартизации и сертификации ветеринарных препаратов | Probiotic preparation for animals |
GB2311027A (en) | 1996-03-15 | 1997-09-17 | Johnson & Johnson Medical | Coated bioabsorbable beads for wound treatment |
US5726161A (en) | 1994-01-14 | 1998-03-10 | Fuisz Technologies Ltd. | Porous particle aggregate and method therefor |
US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
WO1998019968A1 (en) | 1995-10-06 | 1998-05-14 | Kerr-Mcgee Chemical Corporation | METHOD OF PREPARING Li1+xMn2-xO4 FOR USE AS SECONDARY BATTERY ELECTRODE |
WO1998023727A1 (en) | 1996-11-29 | 1998-06-04 | Bio K + International Inc. | Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof |
US5766520A (en) | 1996-07-15 | 1998-06-16 | Universal Preservation Technologies, Inc. | Preservation by foam formation |
EP0850569A1 (en) | 1996-12-24 | 1998-07-01 | Societe Des Produits Nestle S.A. | Gelatinized cereal product containing oligosaccharide |
WO1998027967A1 (en) | 1996-12-20 | 1998-07-02 | Dumex-Alpharma A/S | Release-controlled coated tablets |
US5785990A (en) | 1995-07-10 | 1998-07-28 | Merrick's, Inc. | Feed fortifier and enhancer for preruminant calves and method of using same |
WO1998035014A2 (en) | 1997-02-11 | 1998-08-13 | Enterprise Ireland Trading As Bioresearch Ireland | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
US5824779A (en) | 1996-04-26 | 1998-10-20 | Wisconsin Alumni Research Foundation | Phytase-protein-pigmenting concentrate derived from green plant juice |
WO1998047374A1 (en) | 1997-04-18 | 1998-10-29 | Ganeden Biotech, Inc. | Topical use of probiotic bacillus spores to prevent or control microbial infections |
WO1998054982A1 (en) | 1997-06-03 | 1998-12-10 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with sids |
US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
RU2123343C1 (en) | 1997-06-26 | 1998-12-20 | Алин Борис Иннокентьевич | Method of preparing capsules containing bacteria bacterium bifidum (dry bifidumbacterin in capsules) |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
US5858356A (en) | 1995-12-21 | 1999-01-12 | Abbott Laboratories | Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals |
US5871802A (en) | 1997-12-16 | 1999-02-16 | Moorman Manufacturing Co. | Animal feed pelleting process and animal feed pellets produced therefrom |
US5871794A (en) | 1996-08-07 | 1999-02-16 | Brito; Jorge Issac | Stabilized guacamole and method for making same |
WO1999009839A1 (en) | 1997-08-22 | 1999-03-04 | Cultor Corporation | A composition and a product containing the same |
WO1999011245A1 (en) | 1997-08-29 | 1999-03-11 | Pharmacia & Upjohn Company | A pharmaceutical composition having two coating layers |
US5894029A (en) | 1994-03-21 | 1999-04-13 | Purebred Pet Products, Inc. | Method of making pet snack food |
WO1999020745A1 (en) | 1997-10-17 | 1999-04-29 | Il Yang Pharm. Co., Ltd. | Enteric coated microgranules for stabilizing lactic acid bacteria |
US5910447A (en) | 1996-08-13 | 1999-06-08 | Litmus Concepts, Inc. | pH and amine test to diagnosis of vaginal infections |
WO1999030576A1 (en) | 1997-12-17 | 1999-06-24 | The Nutrasweet Company | Beverage compositions comprising sweetener with extremely high potency |
US5939117A (en) | 1997-08-11 | 1999-08-17 | Mantrose-Haeuser Co., Inc. | Methods for preserving fresh fruit and product thereof |
WO1999048372A1 (en) | 1998-03-23 | 1999-09-30 | General Mills, Inc. | Encapsulation of components into edible products |
US5962043A (en) | 1996-02-29 | 1999-10-05 | Seal Rock Technologies Incorporated | Weight reduction method for dogs and other pets |
WO1999051108A1 (en) | 1998-04-06 | 1999-10-14 | The Iams Company | Composition for improving glucose and insulin metabolism in companion animals |
WO1999052511A1 (en) | 1998-03-27 | 1999-10-21 | Valtion Teknillinen Tutkimuskeskus | Tarch capsules containing microorganisms and/or polypeptides or proteins and a process for producing them |
US5976579A (en) | 1997-07-03 | 1999-11-02 | Mclean; Linsey | Nutritional supplement for the prevention and treatment of excessive intestinal permeability |
DE19819475A1 (en) | 1998-04-30 | 1999-11-04 | Basf Ag | Dry microorganism cultures and methods for their production |
EP0956858A1 (en) | 1998-04-30 | 1999-11-17 | Renata Maria Anna Cavaliere Vesely | Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections |
EP0609056B1 (en) | 1993-01-27 | 1999-12-15 | Kyowa Hakko Kogyo Co., Ltd. | Prescription diet composition for pet animals |
US6007808A (en) | 1995-06-23 | 1999-12-28 | Dibra S.P.A. | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
US6010725A (en) | 1996-07-09 | 2000-01-04 | Nestec S.A. | Spray-drying process |
WO2000006127A1 (en) | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Centerfill delivery system for nutraceuticals |
US6042857A (en) | 1997-08-18 | 2000-03-28 | Seal Rock Technologies Incorporated | Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value |
WO2000027364A1 (en) | 1998-11-11 | 2000-05-18 | Pharmacia Ab | New controlled release bead, a method of producing the same and multiple unit formulation comprising it |
CA2256256A1 (en) | 1997-06-20 | 2000-06-17 | Ascor Chimici S.R.L. | Composition with controlled release of biologically active substances for zootechnical use |
US6077530A (en) | 1997-07-28 | 2000-06-20 | Weinstein; Robert | Analgesic dosage units for coordinated administration |
EP1010372A2 (en) | 1998-12-15 | 2000-06-21 | Novartis Nutrition AG | Bakery products comprising live lyophilised lactic bacteria |
US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
US6083520A (en) | 1994-05-19 | 2000-07-04 | Ewos Aktiebolag | Bioactive feed |
DE19860375A1 (en) | 1998-12-28 | 2000-07-06 | Aventis Res & Tech Gmbh & Co | Alpha amylase-resistant starch for the production of food and pharmaceuticals |
JP2000191519A (en) | 1998-12-25 | 2000-07-11 | Nippon Kayaku Co Ltd | Rapid release granule wherein unpleasant functional property of medicinally active ingredient is masked |
WO2000042168A2 (en) | 1999-01-15 | 2000-07-20 | Enterprise Ireland (Trading As Bioresearch Ireland) | Bifidobacterium in the treatment of inflammatory disease |
US6117477A (en) | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
WO2000057712A1 (en) | 1999-03-26 | 2000-10-05 | The Pillsbury Company | Food products with biocontrol preservation |
US6133323A (en) | 1997-04-09 | 2000-10-17 | The Iams Company | Process for enhancing immune response in animals using β-carotene as a dietary supplement |
US6156355A (en) | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
US6190591B1 (en) | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
WO2001012164A1 (en) | 1999-08-12 | 2001-02-22 | Merck Patent Gmbh | Oral form of administration containing probiotic micro-organisms |
US6214336B1 (en) | 1997-08-05 | 2001-04-10 | Probi Ab | Use of lactobacillus for reduction of the fibrinogen level in blood |
US6254886B1 (en) | 1997-12-19 | 2001-07-03 | Merck Patent Gmbh | Multilayer tablet |
US20010018048A1 (en) | 1995-10-20 | 2001-08-30 | Robert Jan Leer | Novel adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors |
US20010018071A1 (en) | 1995-03-24 | 2001-08-30 | Cochran George Randall | Oral 2-methyl-thieno-benzodiazepine formulation |
EP0862863B1 (en) | 1997-01-09 | 2001-10-17 | Societe Des Produits Nestle S.A. | Cereal product containing probiotics |
US6309666B1 (en) | 1995-07-20 | 2001-10-30 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
US6310090B1 (en) | 1999-05-27 | 2001-10-30 | The Iams Company | Process and product for enhancing immune response in companion animals using a combination of antioxidants |
JP2001309753A (en) | 2000-04-28 | 2001-11-06 | Natl Fedelation Of Agricult Coop Assoc | Dog food for prophylaxis and therapy of infectious disease peculiar to dog |
WO2001090311A1 (en) | 2000-05-25 | 2001-11-29 | Societe Des Produits Nestle S.A. | Novel probiotics for pet food applications |
US20020022019A1 (en) | 2000-07-17 | 2002-02-21 | Svend Laulund | Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments |
US6355242B1 (en) | 1997-05-23 | 2002-03-12 | Ixion Biotechnology, Inc. | Materials and methods for treating or preventing oxalate-related disease |
US6358555B1 (en) | 1999-03-31 | 2002-03-19 | Hideyuki Takahashi | Process for producing frozen avocados |
US20020035071A1 (en) | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
WO2001093011A3 (en) | 2000-05-31 | 2002-04-11 | Motorola Inc | Method and apparatus for iterative training of a classification system |
US6375956B1 (en) | 1999-07-22 | 2002-04-23 | Drugtech Corporation | Strip pack |
US6394803B1 (en) | 1999-12-09 | 2002-05-28 | Ivoclar Ag | Mixing arrangement |
US6406853B1 (en) | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
KR20020050048A (en) | 2000-12-20 | 2002-06-26 | 박흥재 | Identification system for lactobacillus sp dw-1 |
US20020098235A1 (en) | 2000-11-20 | 2002-07-25 | Dittmar Gregory Paul | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US20020119237A1 (en) | 2000-12-22 | 2002-08-29 | Hevey Maurice O. | Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis |
US20020127211A1 (en) | 1997-07-05 | 2002-09-12 | Dominique Brassart | Absorption of minerals by intestinal cells |
US6451341B1 (en) | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
WO2002083879A2 (en) | 2001-04-02 | 2002-10-24 | Alimentary Health Limited | Immunotherapy based on dendritic cells |
US6500463B1 (en) | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
WO2003010298A1 (en) | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | 'probiotic lactobacillus salivarius strains |
WO2003010297A1 (en) | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | Probiotic bifidobacterium strains |
WO2003010299A1 (en) | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | Probiotic lactobacillus casei strains |
US20030049240A1 (en) | 2000-01-18 | 2003-03-13 | Oliver Ballevre | Pet food composition for treating helicobacter species in pets |
US6537544B1 (en) | 1997-10-03 | 2003-03-25 | Probi Ab | Feed product |
US20030060503A1 (en) | 2000-01-25 | 2003-03-27 | Juvenon, Inc. | Nutritional supplements for mature pets |
US6562336B2 (en) | 1999-05-28 | 2003-05-13 | Vsl Pharma Limited | Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
EP1312667A1 (en) | 2000-08-25 | 2003-05-21 | Wakamoto Pharmaceutical Co., Ltd. | Probiotics products containing lactic acid bacterium |
US6572854B1 (en) | 1998-02-20 | 2003-06-03 | Mendes S.R.L. | Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
WO2003045356A1 (en) | 2000-11-20 | 2003-06-05 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings |
US20030104090A1 (en) | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
US6586027B2 (en) | 2001-02-23 | 2003-07-01 | T.F.H. Publications, Inc. | Health chew toy |
US6588180B2 (en) | 2001-02-02 | 2003-07-08 | R. P. Scherer Technologies, Inc. | Constricted neck blister pack and apparatus and method for making the same |
US6592863B2 (en) | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
US6596946B2 (en) | 1997-09-04 | 2003-07-22 | Yazaki Corporation | Molding with integral fixation member |
US20030143293A1 (en) | 2002-01-31 | 2003-07-31 | Sergei Shushunov | Compositions and methods for treating diarrhea |
US20030157166A1 (en) | 2001-03-16 | 2003-08-21 | Chen Chih Ming | Controlled release sulfonylurea formulation |
US20030170355A1 (en) | 2002-01-15 | 2003-09-11 | Glazier Barry D. | Methods and products produced thereby to stabilize multi-layer food products |
US6620440B1 (en) | 1996-06-10 | 2003-09-16 | Viva America Marketing, Inc. | Nutritive composition for cardiovascular health |
WO2003075676A1 (en) | 2002-03-12 | 2003-09-18 | Societe Des Produits Nestle S.A. | Probiotic delivery system |
US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
US20030190314A1 (en) | 2001-01-30 | 2003-10-09 | The Lauridsen Group | Methods and compositions of treatment for modulating the immune system of animals |
US20030194423A1 (en) | 2002-04-15 | 2003-10-16 | Mars, Inc. | Composition for enhancing nutritional content of food |
DE10217970A1 (en) | 2002-04-22 | 2003-11-13 | Henkel Kgaa | Blister pack has first wall section originating and widening from base area opening into second wall section widening to lesser extent than first one |
US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
US6681935B1 (en) | 2002-04-02 | 2004-01-27 | Graham L. Lewis | Method of providing a therapeutic regimen and prefabricated container therefor |
US20040047896A1 (en) | 2001-03-09 | 2004-03-11 | Armand Malnoe | Composition for improving age-related physiological deficits and increasing longevity |
KR20040024774A (en) | 2002-09-16 | 2004-03-22 | 이성표 | a compositions which is composed of a nature medicines suitable for a different physical condition by a blood type |
US6733795B2 (en) | 2002-07-30 | 2004-05-11 | Laboratoires Expanscience | Method for producing an avocado leaf extract rich in furanic lipids |
US6737089B2 (en) | 1999-08-27 | 2004-05-18 | Morinda, Inc. | Morinda citrifolia (Noni) enhanced animal food product |
US6746672B2 (en) | 2000-06-19 | 2004-06-08 | Regents Of The University Of Minnesota | Isolated bifidobacteria that produce siderophores which inhibit growth of lactococcus lactis |
JP2004173675A (en) | 2002-10-02 | 2004-06-24 | Takayuki Hirano | Bacterium-encapsulated product having chemical-resistant property and method for producing the same |
US6767573B1 (en) | 1999-03-10 | 2004-07-27 | Nestec S.A. | Fried pet treats |
US20040161422A1 (en) | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US20040167229A1 (en) | 2002-11-15 | 2004-08-26 | Rebecca Bakker-Arkema | Method of lowering CRP and reducing systemic inflammation |
WO2004074496A1 (en) | 2003-02-18 | 2004-09-02 | Mars Uk Limited | Food product and process for their preparation by enzymatic galactosyltransfer with lactobacillus alpha-galactosidase |
US20040175389A1 (en) | 2003-01-14 | 2004-09-09 | Porubcan Randolph Stanley | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
US6797266B2 (en) | 2000-12-18 | 2004-09-28 | Probiohealth | Probiotic composition containing Lactobacillus casei strain ATCC PTA-3945 |
US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
US20040234579A1 (en) | 2003-05-22 | 2004-11-25 | Mark D. Finke, Inc. | Dietary supplements and methods of preparing and administering dietary supplements |
WO2004100670A1 (en) | 2003-03-25 | 2004-11-25 | General Mills, Inc. | Method of treating avocados and method of preparing guacamole therefrom |
US20040253357A1 (en) | 2003-05-26 | 2004-12-16 | De Zarate Dominique Ortiz | Hard dragee-coating process |
US6835397B2 (en) | 2002-12-23 | 2004-12-28 | Balchem Corporation | Controlled release encapsulated bioactive substances |
US6835376B1 (en) | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
US20040265279A1 (en) | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
US20050013849A1 (en) | 2001-07-17 | 2005-01-20 | Bernard Lemaure | Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
US20050074519A1 (en) | 2003-10-01 | 2005-04-07 | Sensient Flavors Inc. | Method for the production of natural botanical extracts |
US20050079244A1 (en) | 2001-11-12 | 2005-04-14 | Giffard Catriona Julie | Foodstuff |
US20050084479A1 (en) | 2001-12-11 | 2005-04-21 | Irene Corthesy-Theulay | Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
US20050106131A1 (en) | 2002-02-21 | 2005-05-19 | Lionel Breton | Photoprotective orally administrable composition for skin |
US6896914B2 (en) | 2001-10-26 | 2005-05-24 | David I. Chapnick | Method for normalizing insulin levels |
US20050112259A1 (en) | 2003-11-26 | 2005-05-26 | Fernando Qvyjt | Pet food composition having enhanced palatability |
US6905679B1 (en) | 1999-10-26 | 2005-06-14 | Nestec S.A. | Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis |
US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US20050158293A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
US20050164978A1 (en) | 2001-10-26 | 2005-07-28 | Chapnick David I. | Method for normalizing insulin levels |
WO2005070232A1 (en) | 2004-01-27 | 2005-08-04 | Mars Incorporated | Food product and process for producing it |
US20050175598A1 (en) | 2003-12-19 | 2005-08-11 | The Procter & Gamble Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050180961A1 (en) | 2002-05-24 | 2005-08-18 | Sophie Pecquet | Probiotics and oral tolerance |
US6932990B2 (en) | 2000-08-01 | 2005-08-23 | Oryza Oil & Fat Chemical Co., Ltd. | Carbohydrate absorption inhibitor and method for manufacturing the same |
US20050208163A1 (en) | 2002-07-31 | 2005-09-22 | Brovelli Ernesto A | Compositions containing avocado leaf extract for lowering cholesterol levels |
WO2005092116A1 (en) | 2004-03-24 | 2005-10-06 | Mars Incorporated | Foodstuff comprising a probiotic and prebiotic |
US20050249837A1 (en) | 2004-05-10 | 2005-11-10 | The Procter & Gamble Company | Processes for preparing plant matter extracts and pet food compositions |
US20050249841A1 (en) | 2001-09-12 | 2005-11-10 | The Procter & Gamble Company | Pet food compositions |
US20050266438A1 (en) | 2004-03-16 | 2005-12-01 | The Regents Of The University Of California | Genetic networks regulated by attenuated GH/IGF1 signaling and caloric restriction |
US6974594B2 (en) | 2001-01-25 | 2005-12-13 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
US20050281910A1 (en) | 1999-09-22 | 2005-12-22 | Eduardo Schiffrin | Method for increasing pet activity |
US6979675B2 (en) | 2003-01-10 | 2005-12-27 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
US20060002909A1 (en) | 2004-06-14 | 2006-01-05 | Kabushiki Kaisha Yonezawa Biru Shisutemu Sabisu | Microorganism separated from Kefir grains, a microorganism culture obtained by culturing said microorganism or microorganisms including it, and a product using such microorganisms or microorganism cultures |
US20060008511A1 (en) | 2004-07-08 | 2006-01-12 | Jhy-Jhu Lin | Probiotic products for pet applications |
US6991819B2 (en) | 2000-06-13 | 2006-01-31 | Mars, Inc. | Food product containing instable additives |
JP2006505515A (en) | 2002-07-30 | 2006-02-16 | ラボラトワール エクスパンシアンス | Process for producing avocado leaf extract rich in furan lipids |
JP2006055145A (en) | 2004-08-19 | 2006-03-02 | Kosshi:Kk | Pet food and method for offering the same |
US7008648B2 (en) | 2001-11-16 | 2006-03-07 | Novartis Nutrition Ag | Plant derived or derivable material with appetite suppressing activity |
US20060070895A1 (en) | 2004-08-16 | 2006-04-06 | Faisal Khawaja | Drug administration kit |
US7029669B1 (en) | 1999-03-11 | 2006-04-18 | Nestec S. A. | Lactic acid bacteria strains capable of preventing diarrhoea |
US7052688B2 (en) | 1999-06-21 | 2006-05-30 | Vsl Pharmaceuticals, Inc. | Method for prevention and/or treatment of infections and inflammatory conditions using a combination of lactic acid bacteria |
US20060116330A1 (en) | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US20060147962A1 (en) | 2003-06-16 | 2006-07-06 | Mars, Inc. | Genotype test |
US7081478B2 (en) | 2001-06-29 | 2006-07-25 | Chrysantis, Inc. | Mixed zeaxanthin ester concentrate and uses thereof |
US20060165670A1 (en) | 2003-04-08 | 2006-07-27 | Michael Beer | Synbiotic combination |
US7115297B2 (en) | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
US20060228448A1 (en) | 2005-04-11 | 2006-10-12 | The Iams Company | Pet food compositions comprising two components |
US20060228459A1 (en) | 2005-04-11 | 2006-10-12 | The Iams Company | Compositions comprising a cocoa butter component and an animal-derived fat component |
US20060263416A1 (en) | 2005-05-20 | 2006-11-23 | The Lams Company | Coated pet food products |
USRE39436E1 (en) | 1999-12-23 | 2006-12-19 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
US20070009577A1 (en) | 2005-07-05 | 2007-01-11 | Mankovitz Roy J | Probiotic compositions and methods |
US7179460B2 (en) | 2002-12-05 | 2007-02-20 | Danisco A/S | Bacterial composition and its use |
EP1547466B1 (en) | 2003-12-23 | 2007-04-04 | Rohm And Haas Company | A method to reverse ethylene inhibitor responses in plants |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
US20070082107A1 (en) | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for reducing food intake and controlling weight |
US20070098744A1 (en) | 2005-10-06 | 2007-05-03 | Nestec S.A. | Probiotic enterococci for improved immunity |
JP2007117083A (en) | 2005-09-30 | 2007-05-17 | Global Technology:Kk | Immunoactivity modulator for animal and animal feed containing the same |
US20070116853A1 (en) | 2003-10-09 | 2007-05-24 | Nestec S.A. | Coated fat-based confectionery products |
US20070122531A1 (en) | 2005-09-01 | 2007-05-31 | Wellmark International | Methods for Selecting a Pet-Appropriate Product |
US20070123460A1 (en) | 2004-04-20 | 2007-05-31 | The University Of Chicago | Probiotic compounds from Lactobacillus GG and uses therefor |
US20070129428A1 (en) | 2003-12-18 | 2007-06-07 | Myriam Richelle | Composition for improving skin, hair and coat health containing flavanones |
US7235276B2 (en) | 2003-09-24 | 2007-06-26 | General Mills Ip Holdings Ii, Llc | High protein puffed food product and method of preparation |
US7235395B2 (en) | 2001-03-02 | 2007-06-26 | Nestec S.A. | Lactic acid bacteria as agents for treating and preventing allergy |
US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
EP1806056A1 (en) | 2006-01-05 | 2007-07-11 | IPC Process-Center GmbH & Co. | Particles including sensitive component |
US20070160589A1 (en) | 2006-01-11 | 2007-07-12 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
US20070166295A1 (en) | 2006-01-13 | 2007-07-19 | Vet Solutions L.P. | Anti-Diarrhea Preparations for Small Domestic Animals |
US20070178078A1 (en) | 2005-12-29 | 2007-08-02 | Christina Khoo | Method for Modifying Gut Flora in Animals |
US20070190171A1 (en) | 2005-12-02 | 2007-08-16 | Yamka Ryan M | Methods for Altering Stool Quality and/or Stool Frequency |
US20070218164A1 (en) | 2005-04-11 | 2007-09-20 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
US20070231371A1 (en) | 2006-02-01 | 2007-10-04 | Nestec, S. A. | Nutritional system and methods for increasing longevity |
US20070231414A1 (en) | 2006-03-29 | 2007-10-04 | Kaneka Corporation | Composition having bone resorption inhibition-related effect and method for inhibiting bone resorption |
WO2007126990A2 (en) | 2006-03-29 | 2007-11-08 | Nestec S.A. | Dietary supplements containing probiotics |
US20070269515A1 (en) | 2003-12-24 | 2007-11-22 | Henriksen Kristian L | Probiotic Tablet Formulations |
US20070269553A1 (en) | 2005-02-10 | 2007-11-22 | Anh Le | Heated food product with coating of encapsulated flavors |
WO2007060539A3 (en) | 2005-11-28 | 2007-12-06 | Jorrocks Pty Ltd | Methods for preparation of animal feeds |
US20070280964A1 (en) | 2005-10-06 | 2007-12-06 | Ruth Knorr | Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and preventing or treating conjunctivitis |
WO2007137808A1 (en) | 2006-05-29 | 2007-12-06 | University College Dublin, National University Of Ireland, Dublin | Compositions comprising oligosaccharides for treating prion disease |
US20070286935A1 (en) | 2004-10-07 | 2007-12-13 | Nestec S.A. | Bioactive Compositions, Natural Methods of Producing Them and Computational Methods for Designing Natural Production Processes |
US20080044481A1 (en) | 2004-05-27 | 2008-02-21 | Mordechai Harel | Microparticles for Oral Delivery |
US20080050354A1 (en) | 2004-10-22 | 2008-02-28 | Compagnie Gervais Danone | Protecting bioactive food ingredients using microorganisms having reduced metabolizing capacity |
US20080050355A1 (en) | 2004-10-22 | 2008-02-28 | Compagnie Gervais Danone | Protection of bioactive food ingredients by means of encapsulation |
US20080053490A1 (en) | 2006-09-01 | 2008-03-06 | Bausch & Lomb Incorporated | Method for hydrating a contact lens |
EP1637041B1 (en) | 2004-09-21 | 2008-04-30 | Nestec S.A. | Improving longevity of elderly cats |
US20080107699A1 (en) | 2006-10-25 | 2008-05-08 | Mark Spigelman | Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor |
US20080145341A1 (en) | 2003-11-07 | 2008-06-19 | Graham John Myatt | Stabilised Compositions Comprising Probiotics |
US7427398B2 (en) | 2002-06-06 | 2008-09-23 | Mars, Inc. | Mammalian animal composition |
US20080241226A1 (en) | 2007-03-27 | 2008-10-02 | Abeln Susan L | Methods and Kits For Administering Probiotics |
US20080260866A1 (en) | 2004-05-10 | 2008-10-23 | Stefan Patrick Massimino | Method for decreasing inflammation and stress in a mammal |
US20080260696A1 (en) | 2007-02-01 | 2008-10-23 | Stefan Patrick Massimino | Method for decreasing inflammation and oxidative stress in mammals |
US20080280274A1 (en) | 2005-06-01 | 2008-11-13 | Kim Gene Friesen | Methods For Enhancing Palatability of Compositions for Animal Consumption |
US20080279786A1 (en) | 2004-12-17 | 2008-11-13 | Cash Alan B | Method for Extending Lifespan Delaying the Onset of Age-Related Disease |
US20080305210A1 (en) | 2004-07-01 | 2008-12-11 | General Mills, Inc. | Cultures Encapsulated With Compound Fat Breakfast Cereals Coated With Compound Fat and Methods of Preparation |
US20080311226A1 (en) | 2005-11-04 | 2008-12-18 | Hill's Pet Nutrition, Inc. | Methods and Compositions For Improving Stool Quality |
US20080317905A1 (en) | 2005-05-20 | 2008-12-25 | Ryan Michael Yamka | Methods for Promoting Health or Wellness in Adult Animals |
US7498162B2 (en) | 2000-09-25 | 2009-03-03 | Nestec S.A. | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
US7544497B2 (en) | 2003-07-01 | 2009-06-09 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
US7547527B2 (en) | 2000-10-06 | 2009-06-16 | Markus Baur | Use of probiotic lactic acid bacteria for balancing the skin's immune system |
US7550285B2 (en) | 2001-02-06 | 2009-06-23 | Nestec S.A. | Endotoxin binding lactic acid bacteria and bifidobacteria |
US20090252834A1 (en) | 2004-05-10 | 2009-10-08 | Michael Griffin Hayek | Compositions comprising glucose anti-metabolites |
US7604809B2 (en) | 2000-05-25 | 2009-10-20 | Compagnie Gervais Danone | Reinforcing systemic immune responses with lactobacillus casei |
US20090263542A1 (en) | 2005-05-13 | 2009-10-22 | Charlie Hungwei Lin | Dry Food Compositions Having Enhanced Palatability |
US20090274796A1 (en) | 2005-05-11 | 2009-11-05 | Ryan Yamka | Methods for Enhancing Palatability of Compositions for Animal Consumption |
US20090324761A1 (en) | 2005-10-19 | 2009-12-31 | Hill's Pet Nutrition, Inc. | Methods And Compositions for Improving Gastrointestinal Health |
US20100003369A1 (en) | 2008-07-07 | 2010-01-07 | Ter Haar Robert H | Probiotic supplement, process for making, and packaging |
US7647098B2 (en) | 2005-10-31 | 2010-01-12 | New York University | System and method for prediction of cognitive decline |
US7674808B2 (en) | 2006-05-31 | 2010-03-09 | Glaxo Group Limited | Heterocyclic compounds |
US7687085B2 (en) | 2000-01-18 | 2010-03-30 | Nagaoka Perfumery Co., Ltd | Anti-obestic composition |
US7687077B2 (en) | 2003-11-26 | 2010-03-30 | Hill's Pet Nutrition, Inc. | Method to reduce stool odor of companion animals |
US7700141B2 (en) | 2005-09-20 | 2010-04-20 | Mars Incorporated | Composition |
US7700315B2 (en) | 2001-01-30 | 2010-04-20 | Nestec S.A. | Serpin in bifidobacteria |
US20100158070A1 (en) | 2008-12-18 | 2010-06-24 | Roche Diagnostics Operations, Inc. | Method for Monitoring the Thermal Coupling of a Measuring Cell |
EP1806057B1 (en) | 2006-01-05 | 2010-07-14 | IPC Process-Center GmbH & Co. | Micro pellets for the preparation of animal feed pellets |
US20100203225A1 (en) | 2008-07-07 | 2010-08-12 | George Scott Kerr | Supplement, Process for Making, and Packaging |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US7795227B2 (en) | 2004-06-17 | 2010-09-14 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
US20100233320A1 (en) | 2008-09-11 | 2010-09-16 | Gregory Dean Sunvold | Animal Feed Kibble with Protein-Based Core and Related Methods |
US7816547B2 (en) | 2005-11-18 | 2010-10-19 | Laboratoires Expanscience | Process for producing refined avocado oil rich in triglycerides, and oil obtainable by said process |
US7833554B2 (en) | 2004-04-30 | 2010-11-16 | Laboratoires Expanscience | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency |
US7838057B2 (en) | 2002-03-25 | 2010-11-23 | Mars Incorporated | Protein-containing food product and method of preparing same |
US7842329B2 (en) | 2001-09-18 | 2010-11-30 | Nestec S.A. | Pet food product and method of manufacture |
RU2407401C2 (en) | 2007-02-13 | 2010-12-27 | Общество С Ограниченной Ответственностью "Марс" | Dog feeding method |
US7897579B2 (en) | 2004-04-30 | 2011-03-01 | Laboratoires Expanscience | Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases |
US7935334B2 (en) | 2005-07-07 | 2011-05-03 | Imagilin Technologies, LLC | Probiotics as alternative medicines against infectious diseases |
US20110117068A1 (en) | 2006-08-18 | 2011-05-19 | Organobalance Gmbh | Probiotic microorganisms for the reduction of manure odor |
US7951493B2 (en) | 2005-09-30 | 2011-05-31 | Hill's Pet Nutrition, Inc. | Methods for extending the shelf-life of food compositions containing polyunsaturated fatty acids |
US7960605B2 (en) | 2006-03-17 | 2011-06-14 | BioMaker Pharmaceuticals, Inc. | Methods for testing for caloric restriction (CR) mimetics |
US8030279B2 (en) | 2003-03-21 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Tamandarin analogs and fragments thereof and methods of making and using |
US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
US8057840B2 (en) | 2006-01-25 | 2011-11-15 | Tate & Lyle Ingredients Americas Llc | Food products comprising a slowly digestible or digestion resistant carbohydrate composition |
US8092608B2 (en) | 2001-03-22 | 2012-01-10 | Nestec S.A. | Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
US8101170B2 (en) | 2005-06-14 | 2012-01-24 | Erber Aktiengesellschaft | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof |
US8142810B2 (en) | 2002-05-30 | 2012-03-27 | The Procter & Gamble Company | Dietary method for modulating glucose metabolism and associated conditions and increasing longevity |
US20120115798A1 (en) | 2010-11-04 | 2012-05-10 | Stefan Patrick Massimino | Method for improving the immunity of a companion animal |
CA2569249C (en) | 2004-05-10 | 2012-08-14 | The Iams Company | Processes for preparing plant matter extracts and pet food compositions |
US8263146B2 (en) | 2001-02-19 | 2012-09-11 | Nestec S.A. | Consumable product containing probiotics |
US20120283197A1 (en) | 2011-05-02 | 2012-11-08 | Ashok Premchand Luhadiya | Compositions Comprising a Glucose Anti-Metabolite, BHA, and/or BHT |
US20120282373A1 (en) | 2011-05-02 | 2012-11-08 | Ashok Premchand Luhadiya | Compositions Comprising a Glucose Anti-Metabolite and Selenium |
US8329190B2 (en) | 2001-05-23 | 2012-12-11 | Societe Des Produits Nestle S.A. | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria |
US8394370B2 (en) | 2003-06-23 | 2013-03-12 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
US8486389B2 (en) | 1997-05-23 | 2013-07-16 | Oxthera, Inc. | Compositions and methods for treating or preventing oxalate-related disease |
US20130183255A1 (en) | 2010-12-22 | 2013-07-18 | Laboratoires Expanscience | Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same |
US8524304B2 (en) | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith |
US8540980B2 (en) | 2001-09-28 | 2013-09-24 | Tntgamble, Inc. | Delivery system for biological component |
US8557764B2 (en) | 2007-01-26 | 2013-10-15 | The Regents Of The University Of Colorado, A Body Corporate | Methods of modulating immune function |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US8637495B2 (en) | 2004-07-01 | 2014-01-28 | Nestec S.A. | Osteoarthritis diet formulations |
US8691303B2 (en) | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
US8722112B2 (en) | 2005-07-14 | 2014-05-13 | Hill's Pet Nutrition, Inc. | Method for prolonging the life of animals |
US8802179B2 (en) | 2001-04-17 | 2014-08-12 | Guy W. Miller | Non-digestible sugar-coated products and process |
US8808770B2 (en) | 2004-07-30 | 2014-08-19 | Nutramax Laboratories, Inc. | Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals |
US20140274920A1 (en) | 1997-07-08 | 2014-09-18 | The Iams Company | Methods of treating or preventing overweight and obsesity in mammals by administering a composition comprising mannoheptulose |
US8865197B2 (en) | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
US20140349002A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Ingestible Compositions Containing Criollo Avocado Component |
US20140348975A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Mimicking the Metabolic Effect of Caloric Restrictions by Administration of Glucose Anti-Metabolites to Enhance Positive Response in a Mammal |
US20140348986A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Avocado Processing |
US8916145B2 (en) | 2006-02-15 | 2014-12-23 | Nestec S.A. | Use of Bifidobacterium longum for the prevention and treatment of inflammation |
US8962007B2 (en) | 2002-04-05 | 2015-02-24 | Nestec S.A. | Method of improving absorption of vitamin E by a pet animal |
US20150132420A1 (en) | 2013-11-11 | 2015-05-14 | The Iams Company | Processes for preparing a carbohydrate extract comprising mannoheptulose and compositions comprising same |
US9089576B2 (en) | 2004-04-30 | 2015-07-28 | Laboratoires Expanscience | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin |
US20150208679A1 (en) | 2012-07-25 | 2015-07-30 | Agrofresh, Inc. | Methods of handling avocados and system |
US9119843B2 (en) | 2009-12-04 | 2015-09-01 | Caliper Life Sciences, Inc. | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4338163A (en) * | 1980-12-03 | 1982-07-06 | Eltra Corporation | Curing of tetrabasic lead pasted battery electrodes |
NL8203297A (en) | 1982-08-24 | 1984-03-16 | Philips Nv | RESISTANCE BODY. |
JPS62201823A (en) | 1986-02-28 | 1987-09-05 | Freunt Ind Co Ltd | Material containing beneficial enterobacterium and production thereof |
US4767939A (en) * | 1987-06-09 | 1988-08-30 | Calley David G | Wind driven electric current producer |
AU2809899A (en) | 1997-03-18 | 1999-07-22 | Mendel Institute For Nutraceutical Research Inc, The | Dosing beverage with a bacteria formulation |
US6310909B1 (en) * | 1998-12-23 | 2001-10-30 | Broadcom Corporation | DSL rate adaptation |
GB0326403D0 (en) * | 2003-11-13 | 2003-12-17 | Vandagraph Ltd | Adaptor means |
-
2004
- 2004-12-15 US US11/013,117 patent/US20050158294A1/en not_active Abandoned
- 2004-12-17 JP JP2006545601A patent/JP4602351B2/en active Active
- 2004-12-17 CA CA2550309A patent/CA2550309C/en active Active
- 2004-12-17 WO PCT/US2004/043072 patent/WO2005062879A2/en not_active Application Discontinuation
- 2004-12-17 BR BRPI0417826-2A patent/BRPI0417826B1/en active IP Right Grant
- 2004-12-17 EP EP04815186.4A patent/EP1718266B1/en not_active Not-in-force
- 2004-12-17 AU AU2004308396A patent/AU2004308396B2/en active Active
- 2004-12-17 ES ES04815186.4T patent/ES2523984T3/en active Active
- 2004-12-20 AR ARP040104778A patent/AR047065A1/en active IP Right Grant
-
2008
- 2008-04-18 US US12/148,305 patent/US8900568B2/en active Active
- 2008-11-13 US US12/292,171 patent/US9580680B2/en active Active
- 2008-11-14 US US12/271,090 patent/US7998473B2/en active Active
-
2010
- 2010-04-15 JP JP2010094308A patent/JP5683832B2/en active Active
Patent Citations (433)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US571521A (en) | 1896-11-17 | Package for powders | ||
US1086936A (en) | 1913-05-15 | 1914-02-10 | Malcolm Pounder | Dental massage implement. |
US1503094A (en) | 1923-09-15 | 1924-07-29 | Cramerton Mills Inc | Warp condenser |
US2473773A (en) | 1945-11-16 | 1949-06-21 | Eleanor Kushmaul | Toothbrush |
US2540979A (en) | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
US2641548A (en) | 1950-04-06 | 1953-06-09 | Helen W Heinrich | Method of preserving avocados |
US3320130A (en) | 1962-07-19 | 1967-05-16 | Eurorga | Medicament for colitis, gastroenteritis and enterocolitis |
US3398001A (en) | 1963-04-26 | 1968-08-20 | Air Reduction | Process of preparing and packaging frozen avocados |
US3431338A (en) | 1963-09-10 | 1969-03-04 | Hoffmann La Roche | Coated dosage form adapted to oral emetine or dehydroemetine therapy |
GB1190387A (en) | 1966-05-24 | 1970-05-06 | Green Cross Corp | Enteric Coated Medicaments |
US3429426A (en) | 1966-06-28 | 1969-02-25 | Hoefliger & Karg | Package |
US3677898A (en) | 1969-01-31 | 1972-07-18 | Ajinomoto Kk | Acid protease and method of preparing the same |
US3898132A (en) | 1972-08-24 | 1975-08-05 | Int Feed Improvement Ass Inc | Method of preparing stowable, dormant bacteria |
US3931885A (en) | 1973-04-30 | 1976-01-13 | Nahill Edmond P | Medicine dispensing system |
US3897572A (en) | 1973-05-16 | 1975-07-29 | Star Kist Foods | Formed meat product |
US3989822A (en) | 1974-02-14 | 1976-11-02 | Purdue Research Foundation | Weight control compound |
US3957974A (en) | 1974-11-05 | 1976-05-18 | Seikenkai | Method for deodorization of excrements |
GB1503094A (en) | 1975-04-09 | 1978-03-08 | Nisshin Flour Milling Co | Method for the prophylaxis and treatment of diarrhoea in dogs |
US4314995A (en) | 1976-02-23 | 1982-02-09 | Seikenkai | Pharmaceutical lactobacillus preparations |
GB1595054A (en) | 1977-11-14 | 1981-08-05 | Metal Box Co Ltd | Capsules containing micro-organisms |
US4295567A (en) | 1978-11-10 | 1981-10-20 | Beecham Group Limited | Medicament container |
US4295567B1 (en) | 1978-11-10 | 1997-09-09 | Beecham Grp Ltd | Medicament container |
US4332790A (en) | 1978-12-05 | 1982-06-01 | Societe D'assistance Technique Pour Produits Nestle S.A. | Microcapsule containing a microorganism and a process for its production |
US4338346A (en) | 1978-12-21 | 1982-07-06 | The Procter & Gamble Company | Non-nutritive sweetener |
US4434231A (en) | 1979-04-05 | 1984-02-28 | Rhone-Poulenc Industries | Means for embedding microorganisms in a polymer matrix |
US4248857A (en) | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4411925A (en) | 1980-01-21 | 1983-10-25 | Pfizer Inc. | Branched amides of L-aspartyl-d-amino acid dipeptides |
US4399163A (en) | 1980-11-05 | 1983-08-16 | Pfizer Inc. | Branched amides of L-aspartyl-D-amino acid dipeptides |
US4423029A (en) | 1981-06-25 | 1983-12-27 | The Procter & Gamble Company | (S)-3-Amino-4-[(S,S)-1-(1-hydroxyethyl)alkyl amino]-4-oxo-butyric acid compounds suitable as non-nutritive sweetners |
US4403623A (en) | 1981-11-16 | 1983-09-13 | Colgate-Palmolive Company | Combined toothbrush and gum massage device |
US4786507A (en) | 1982-06-07 | 1988-11-22 | Boehringer Ingelheim Kg | Long shelf life tablet containing hydrolysis prone active ingredient |
JPS6024153Y2 (en) | 1982-07-20 | 1985-07-18 | 山陽菓機工業有限会社 | Oil application equipment in food manufacturing process |
US4518696A (en) | 1983-01-11 | 1985-05-21 | Chr. Hansen's Laboratory, Inc. | Stabilized liquid bacterial suspension for oral administration to animals |
JPS59213368A (en) | 1983-05-17 | 1984-12-03 | Hanamaruki Kk | Fruit food and its preparation |
US4736849A (en) | 1983-12-19 | 1988-04-12 | Leonard Walter G | Calendar-oriented pill dispenser |
US4592748A (en) | 1984-05-18 | 1986-06-03 | Vortex Research Corp. | Yoghurt based douche kit and assembly therefor |
EP0168112A3 (en) | 1984-07-13 | 1988-07-27 | The Procter & Gamble Company | Alpha-l-aspartyl-d-phenylglycine esters and amides useful as high intensity sweeteners |
US4647453A (en) | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
EP0181170B1 (en) | 1984-11-05 | 1992-03-04 | Kabushiki Kaisya Advance | Hypocholesterolemically active products |
US4767623A (en) | 1984-11-08 | 1988-08-30 | Chemical Dynamics Sweden Ab | Method of binding microflora and preparations therefor |
US5032399A (en) | 1985-04-17 | 1991-07-16 | Sherwood L. Gorbach | L. acidophilus strains |
EP0212746A2 (en) | 1985-08-16 | 1987-03-04 | The Procter & Gamble Company | Drug particles having constant release |
EP0212747A2 (en) | 1985-08-16 | 1987-03-04 | The Procter & Gamble Company | Drug particles having constant release and immediate release |
JPS6297221U (en) | 1985-12-09 | 1987-06-20 | ||
US4764389A (en) | 1986-04-24 | 1988-08-16 | Labarge Universal Ripener, Inc. | Method of accelerating fruit respiration |
US5160745A (en) | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
JPS62201823U (en) | 1986-06-16 | 1987-12-23 | ||
CA1300538C (en) | 1986-08-01 | 1992-05-12 | Robert Charley | Maintenance of the viability of microorganisms for use in microbial inoculants |
US4808626A (en) | 1986-09-23 | 1989-02-28 | Monell Chemical Senses Center | Use of 2,5-anhydro-D-mannitol as a food intake modifier |
US4781939A (en) | 1986-10-28 | 1988-11-01 | Nestec, S.A. | Layered meat emulsion product and method of producing same |
US4816259A (en) | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
US4797289A (en) | 1987-03-09 | 1989-01-10 | Reddy Malireddy S | Enhancement of lactobacillus acidophilus growth and viability in yogurt and other cultured dairy products |
WO1988008452A1 (en) | 1987-05-01 | 1988-11-03 | Probiologics International, Inc. | Antibiotic reuterin |
US5413960A (en) | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
DE3715070A1 (en) | 1987-05-06 | 1988-11-17 | Kneipp Werke Kneipp Mittel Zen | Process for the preparation of extracts of plants, in particular of juices of plants |
US4935247A (en) | 1987-05-08 | 1990-06-19 | Orion-Yhtyma Oy | Composition for the oral administration of pharmaceuticals |
FR2615203A1 (en) | 1987-05-12 | 1988-11-18 | Agronomique Inst Nat Rech | INOCULUM IN WHICH THE MICROORGANISMS ARE PACKED IN THE FORM OF BIODEGRADABLE PELLETS, ITS PREPARATION PROCESS AND ITS APPLICATIONS |
FR2615203B1 (en) | 1987-05-12 | 1989-08-18 | Agronomique Inst Nat Rech | INOCULUM IN WHICH MICROORGANISMS ARE PACKAGED IN THE FORM OF BIODEGRADABLE GRANULES, ITS PREPARATION METHOD AND ITS APPLICATIONS |
EP0298605A1 (en) | 1987-06-10 | 1989-01-11 | Unilever Plc | Process for producing a stable bacterial composition and process for breadmaking using this composition |
EP0298605B1 (en) | 1987-06-10 | 1993-08-18 | Unilever Plc | Process for producing a stable bacterial composition and process for breadmaking using this composition |
US4859377A (en) | 1987-07-10 | 1989-08-22 | The United States Of America, As Represented By The Secretary Of Agriculture | Starch encapsulation of entomopathogens |
US4806368A (en) | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US4937077A (en) | 1987-09-21 | 1990-06-26 | Eastman Kodak Company | Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose |
WO1989005849A1 (en) | 1987-12-23 | 1989-06-29 | Chr. Hansen's Laboratorium A/S | Lactic acid bacteria for use in fermented milk products and veterinary compositions |
US4814193A (en) | 1988-04-06 | 1989-03-21 | General Foods Corporation | Reduction of microbial population on surface of food materials |
JPH01278781A (en) | 1988-05-02 | 1989-11-09 | Nec Corp | Nonvolatile semiconductor memory device |
US5389389A (en) | 1988-05-13 | 1995-02-14 | Basic American Foods | Compositions and methods for inhibiting browning of processed produce |
WO1990001335A1 (en) | 1988-08-02 | 1990-02-22 | Borody Thomas J | Treatment of gastro-intestinal disorders |
EP0353581A2 (en) | 1988-08-05 | 1990-02-07 | Dr. A. Tosi Farmaceutici S.R.L. | Pharmaceutical compositions comprising selected lactobacillus strains |
US5171580A (en) | 1988-10-20 | 1992-12-15 | Boehringer Ingelheim Italia S.P.A. | Orally-pharmaceutical preparations with colon selective delivery |
EP0366621A1 (en) | 1988-10-20 | 1990-05-02 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Orally pharmaceutical preparations with colon selective delivery |
US4889238A (en) | 1989-04-03 | 1989-12-26 | The Procter & Gamble Company | Medicament package for increasing compliance with complex therapeutic regimens |
EP0391416A1 (en) | 1989-04-06 | 1990-10-10 | Chugai Seiyaku Kabushiki Kaisha | Process for preparing a therapeutic agent for rotavirus infection |
US5540945A (en) | 1989-05-11 | 1996-07-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
EP0399819A2 (en) | 1989-05-24 | 1990-11-28 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilised spore-forming viable microorganisms preparation, its production and pellet thereof |
EP0399819B1 (en) | 1989-05-24 | 1995-05-10 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilised spore-forming viable microorganisms preparation, its production and pellet thereof |
US5096717A (en) | 1989-09-07 | 1992-03-17 | Ciba-Geigy Corporation | Double-coated granules of disodium pamidronate |
US5132137A (en) | 1989-10-04 | 1992-07-21 | Effem Gmbh | Process for the production of a lumpy meat emulsion product |
JPH0376561U (en) | 1989-11-24 | 1991-07-31 | ||
US5322686A (en) | 1989-12-22 | 1994-06-21 | Grahn Eva E | Pharmaceutical preparation for controlling pathogenic intestinal bacteria |
EP0439315B1 (en) | 1990-01-22 | 1994-08-24 | McNEIL-PPC, INC. | Dual subcoated simulated capsule-like medicament |
US5344824A (en) | 1990-02-02 | 1994-09-06 | Matsutani Chemical Industries Co., Ltd. | Method for reducing insulin secretion |
US6451341B1 (en) | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
GB2241421A (en) | 1990-02-28 | 1991-09-04 | Sitia Yomo Spa | Milky mousse; preparation process; dessert |
WO1991017672A1 (en) | 1990-05-18 | 1991-11-28 | Hannu Salovaara | Food product containing dietary fiber and method of making said product |
DE4018392A1 (en) | 1990-06-08 | 1991-12-12 | Kaysan Rolf Dipl Kaufm | Recovery of plant hydrolysates for bio:cosmetics and pharmaceuticals - by comminuting the plant prods. then adding aq. cellulolytic and pectinolytic enzyme soln. |
FR2663198B1 (en) | 1990-06-14 | 1993-09-17 | Xeda International | USE OF ANTIOXIDANT COMPOUNDS FOR INCREASING THE RESISTANCE OF FRUITS AND VEGETABLES AGAINST FUNGAL INFECTIONS. |
US5629017A (en) | 1990-07-04 | 1997-05-13 | Zambon Group S.P.A. | Programmed release oral solid pharmaceutical dosage form |
GB2245492A (en) | 1990-07-04 | 1992-01-08 | Zambon Spa | Programmed release oral solid pharmaceutical dosage form |
FR2668081A1 (en) | 1990-10-19 | 1992-04-24 | Lvmh Rech | METHOD AND APPARATUS FOR MANUFACTURING SOLID PARTICLES FROM A SOLIDIFIABLE MATERIAL IN THE PRESENCE OF A SOLIDIFYING AGENT IN GOOD YIELDS. |
US5292657A (en) | 1990-12-31 | 1994-03-08 | Pioneer Hi-Bred International, Inc. | Process for preparing rotary disc fatty acid microspheres of microorganisms |
GB2252228A (en) | 1991-01-29 | 1992-08-05 | Sitia Yomo Spa | Milky mousse and its use |
EP0508701B1 (en) | 1991-04-08 | 1996-07-10 | Quest International B.V. | Probiotic |
US5518733A (en) | 1991-06-27 | 1996-05-21 | Bioeurope | Cosmetic compositions containing oligosaccharides |
US5474932A (en) | 1991-07-25 | 1995-12-12 | Probi Ab | Intestine colonizing strains of lactobacilli |
WO1993002558A1 (en) | 1991-08-01 | 1993-02-18 | Biogaia Biologics Ab | Method and formulation for reducing microbial populations |
US5645830A (en) | 1991-11-15 | 1997-07-08 | Research Corporation Technologies, Inc. | Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections |
CA2093287A1 (en) | 1992-04-03 | 1993-10-04 | Heinrich Eggert | Blister pack |
EP0563934A1 (en) | 1992-04-03 | 1993-10-06 | Dr. Karl Thomae GmbH | Blisterstrip out of polymeric film with double or multiple-dose. |
US6033888A (en) | 1992-05-11 | 2000-03-07 | University Of Florida | Process for microencapsulating cells |
US5286495A (en) | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
US5603930A (en) | 1992-07-06 | 1997-02-18 | Nestec S.A. | Lactobacillus johnsonii CNCM I-1225 |
US5578302A (en) | 1992-07-06 | 1996-11-26 | Nestec S.A. | Treatment of stomach ulcers |
US5501857A (en) | 1992-07-24 | 1996-03-26 | Midwestern Bio-Ag Products & Services, Inc. | Oral nutritional and dietary composition |
WO1994004180A2 (en) | 1992-08-20 | 1994-03-03 | Schering Corporation | Novel uses of il-4 and/or il-10, and antibodies against the same |
WO1994004180A3 (en) | 1992-08-20 | 1994-06-09 | Schering Corp | Novel uses of il-4 and/or il-10, and antibodies against the same |
US5569634A (en) | 1992-12-21 | 1996-10-29 | W. R. Grace & Co.-Conn. | Process upset-resistant inorganic supports for bioremediation |
EP0609056B1 (en) | 1993-01-27 | 1999-12-15 | Kyowa Hakko Kogyo Co., Ltd. | Prescription diet composition for pet animals |
WO1994021284A1 (en) | 1993-03-15 | 1994-09-29 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
US5451400A (en) | 1993-03-16 | 1995-09-19 | The United States Of America As Represented By The Secretary Of Agriculture | Nucosal competitive exclusion flora |
EP0627173A1 (en) | 1993-05-31 | 1994-12-07 | GIULIANI S.p.A. | Preparation for dietetic use or as a food supplement, with targeted release in the colon |
WO1995003809A3 (en) | 1993-07-30 | 1995-03-16 | Isis Innovation | Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours |
WO1995007090A1 (en) | 1993-09-06 | 1995-03-16 | Zeneca Limited | Probiotics |
US5501868A (en) | 1993-09-21 | 1996-03-26 | Colgate Palmolive Company | Extruded dog treat food product having improved resistance to breakage |
US5538743A (en) | 1993-10-22 | 1996-07-23 | Onken Gmbh | Complete animal food for cats and dogs |
EP0659769A2 (en) | 1993-12-20 | 1995-06-28 | Matsutani Chemical Industry Co., Ltd. | Agent for promoting the proliferation of bifidobacterium |
EP0659769B1 (en) | 1993-12-20 | 1998-07-15 | Matsutani Chemical Industry Co., Ltd. | Agent for promoting the proliferation of Bifidobacterium |
US5726161A (en) | 1994-01-14 | 1998-03-10 | Fuisz Technologies Ltd. | Porous particle aggregate and method therefor |
US5582643A (en) | 1994-02-25 | 1996-12-10 | Freund Industrial Co., Ltd. | Centrifugal tumbling granulating-coating apparatus |
US5516684A (en) | 1994-03-11 | 1996-05-14 | The Calpis Food Industry Co., Ltd. | Biologically pure culture of Lactobacillus acidophilus FERM-P-14204 or FERM-P-14205 |
US5894029A (en) | 1994-03-21 | 1999-04-13 | Purebred Pet Products, Inc. | Method of making pet snack food |
US6083520A (en) | 1994-05-19 | 2000-07-04 | Ewos Aktiebolag | Bioactive feed |
WO1995034292A2 (en) | 1994-06-14 | 1995-12-21 | Recordati S.A. Chemical And Pharmaceutical Company | Stabilized biologically active compounds contained in coated microgranules which can be suspended in alimentary fluids |
WO1996001612A1 (en) | 1994-07-11 | 1996-01-25 | Therapicon S.R.L. | A novel drug delivery system |
US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
US5531988A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
US20010018071A1 (en) | 1995-03-24 | 2001-08-30 | Cochran George Randall | Oral 2-methyl-thieno-benzodiazepine formulation |
WO1996038159A1 (en) | 1995-06-02 | 1996-12-05 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US6007808A (en) | 1995-06-23 | 1999-12-28 | Dibra S.P.A. | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
US5785990A (en) | 1995-07-10 | 1998-07-28 | Merrick's, Inc. | Feed fortifier and enhancer for preruminant calves and method of using same |
US6309666B1 (en) | 1995-07-20 | 2001-10-30 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
WO1997009448A1 (en) | 1995-09-07 | 1997-03-13 | Oulutech Oy | Method for determining lactic acid bacterial species |
WO1998019968A1 (en) | 1995-10-06 | 1998-05-14 | Kerr-Mcgee Chemical Corporation | METHOD OF PREPARING Li1+xMn2-xO4 FOR USE AS SECONDARY BATTERY ELECTRODE |
US20010018048A1 (en) | 1995-10-20 | 2001-08-30 | Robert Jan Leer | Novel adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
WO1997016198A1 (en) | 1995-11-02 | 1997-05-09 | Chr. Hansen Biosystems A/S | Probiotically acting formulation |
WO1997020577A1 (en) | 1995-12-06 | 1997-06-12 | Pharma Pacific Pty. Ltd. | Improved therapeutic formulation and method |
US5858356A (en) | 1995-12-21 | 1999-01-12 | Abbott Laboratories | Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals |
US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
US5962043A (en) | 1996-02-29 | 1999-10-05 | Seal Rock Technologies Incorporated | Weight reduction method for dogs and other pets |
GB2311027A (en) | 1996-03-15 | 1997-09-17 | Johnson & Johnson Medical | Coated bioabsorbable beads for wound treatment |
RU2086248C1 (en) | 1996-04-02 | 1997-08-10 | Всероссийский государственный научно-исследовательский институт контроля, стандартизации и сертификации ветеринарных препаратов | Probiotic preparation for animals |
US5824779A (en) | 1996-04-26 | 1998-10-20 | Wisconsin Alumni Research Foundation | Phytase-protein-pigmenting concentrate derived from green plant juice |
US6620440B1 (en) | 1996-06-10 | 2003-09-16 | Viva America Marketing, Inc. | Nutritive composition for cardiovascular health |
US6010725A (en) | 1996-07-09 | 2000-01-04 | Nestec S.A. | Spray-drying process |
US5766520A (en) | 1996-07-15 | 1998-06-16 | Universal Preservation Technologies, Inc. | Preservation by foam formation |
US5871794A (en) | 1996-08-07 | 1999-02-16 | Brito; Jorge Issac | Stabilized guacamole and method for making same |
US5910447A (en) | 1996-08-13 | 1999-06-08 | Litmus Concepts, Inc. | pH and amine test to diagnosis of vaginal infections |
US6190591B1 (en) | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
WO1998023727A1 (en) | 1996-11-29 | 1998-06-04 | Bio K + International Inc. | Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof |
WO1998027967A1 (en) | 1996-12-20 | 1998-07-02 | Dumex-Alpharma A/S | Release-controlled coated tablets |
EP0850569B1 (en) | 1996-12-24 | 2000-07-12 | Societe Des Produits Nestle S.A. | Gelatinized cereal product containing oligosaccharide |
EP0850569A1 (en) | 1996-12-24 | 1998-07-01 | Societe Des Produits Nestle S.A. | Gelatinized cereal product containing oligosaccharide |
EP0862863B1 (en) | 1997-01-09 | 2001-10-17 | Societe Des Produits Nestle S.A. | Cereal product containing probiotics |
WO1998035014A3 (en) | 1997-02-11 | 1998-11-19 | Forbairt Trading As Bioresearc | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
WO1998035014A2 (en) | 1997-02-11 | 1998-08-13 | Enterprise Ireland Trading As Bioresearch Ireland | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
US6133323A (en) | 1997-04-09 | 2000-10-17 | The Iams Company | Process for enhancing immune response in animals using β-carotene as a dietary supplement |
WO1998047374A1 (en) | 1997-04-18 | 1998-10-29 | Ganeden Biotech, Inc. | Topical use of probiotic bacillus spores to prevent or control microbial infections |
US6355242B1 (en) | 1997-05-23 | 2002-03-12 | Ixion Biotechnology, Inc. | Materials and methods for treating or preventing oxalate-related disease |
US8486389B2 (en) | 1997-05-23 | 2013-07-16 | Oxthera, Inc. | Compositions and methods for treating or preventing oxalate-related disease |
WO1998054982A1 (en) | 1997-06-03 | 1998-12-10 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with sids |
CA2256256A1 (en) | 1997-06-20 | 2000-06-17 | Ascor Chimici S.R.L. | Composition with controlled release of biologically active substances for zootechnical use |
RU2123343C1 (en) | 1997-06-26 | 1998-12-20 | Алин Борис Иннокентьевич | Method of preparing capsules containing bacteria bacterium bifidum (dry bifidumbacterin in capsules) |
US5976579A (en) | 1997-07-03 | 1999-11-02 | Mclean; Linsey | Nutritional supplement for the prevention and treatment of excessive intestinal permeability |
US20020127211A1 (en) | 1997-07-05 | 2002-09-12 | Dominique Brassart | Absorption of minerals by intestinal cells |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20020035071A1 (en) | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US20140274920A1 (en) | 1997-07-08 | 2014-09-18 | The Iams Company | Methods of treating or preventing overweight and obsesity in mammals by administering a composition comprising mannoheptulose |
US20080214479A1 (en) | 1997-07-08 | 2008-09-04 | The Lams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US20060116330A1 (en) | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US20060100162A1 (en) | 1997-07-08 | 2006-05-11 | The Lams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US6077530A (en) | 1997-07-28 | 2000-06-20 | Weinstein; Robert | Analgesic dosage units for coordinated administration |
US6214336B1 (en) | 1997-08-05 | 2001-04-10 | Probi Ab | Use of lactobacillus for reduction of the fibrinogen level in blood |
US5939117A (en) | 1997-08-11 | 1999-08-17 | Mantrose-Haeuser Co., Inc. | Methods for preserving fresh fruit and product thereof |
US6063414A (en) | 1997-08-18 | 2000-05-16 | Seal Rock Technologies Incorporated | Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value |
US6042857A (en) | 1997-08-18 | 2000-03-28 | Seal Rock Technologies Incorporated | Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value |
WO1999009839A1 (en) | 1997-08-22 | 1999-03-04 | Cultor Corporation | A composition and a product containing the same |
WO1999011245A1 (en) | 1997-08-29 | 1999-03-11 | Pharmacia & Upjohn Company | A pharmaceutical composition having two coating layers |
US6596946B2 (en) | 1997-09-04 | 2003-07-22 | Yazaki Corporation | Molding with integral fixation member |
US6537544B1 (en) | 1997-10-03 | 2003-03-25 | Probi Ab | Feed product |
WO1999020745A1 (en) | 1997-10-17 | 1999-04-29 | Il Yang Pharm. Co., Ltd. | Enteric coated microgranules for stabilizing lactic acid bacteria |
US5871802A (en) | 1997-12-16 | 1999-02-16 | Moorman Manufacturing Co. | Animal feed pelleting process and animal feed pellets produced therefrom |
WO1999030576A1 (en) | 1997-12-17 | 1999-06-24 | The Nutrasweet Company | Beverage compositions comprising sweetener with extremely high potency |
US6254886B1 (en) | 1997-12-19 | 2001-07-03 | Merck Patent Gmbh | Multilayer tablet |
US6572854B1 (en) | 1998-02-20 | 2003-06-03 | Mendes S.R.L. | Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
US6827957B2 (en) | 1998-03-18 | 2004-12-07 | Mars Incorporated | Multicomponent per food or animal food |
US6117477A (en) | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
WO1999048372A1 (en) | 1998-03-23 | 1999-09-30 | General Mills, Inc. | Encapsulation of components into edible products |
US6723358B1 (en) | 1998-03-23 | 2004-04-20 | General Mills, Inc. | Encapsulation of components into edible products |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
WO1999052511A1 (en) | 1998-03-27 | 1999-10-21 | Valtion Teknillinen Tutkimuskeskus | Tarch capsules containing microorganisms and/or polypeptides or proteins and a process for producing them |
WO1999051108A1 (en) | 1998-04-06 | 1999-10-14 | The Iams Company | Composition for improving glucose and insulin metabolism in companion animals |
EP0956858B1 (en) | 1998-04-30 | 2001-10-31 | Renata Maria Anna Cavaliere Vesely | Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections |
DE19819475A1 (en) | 1998-04-30 | 1999-11-04 | Basf Ag | Dry microorganism cultures and methods for their production |
EP0956858A1 (en) | 1998-04-30 | 1999-11-17 | Renata Maria Anna Cavaliere Vesely | Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections |
WO2000006127A1 (en) | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Centerfill delivery system for nutraceuticals |
US6156355A (en) | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
WO2000027364A1 (en) | 1998-11-11 | 2000-05-18 | Pharmacia Ab | New controlled release bead, a method of producing the same and multiple unit formulation comprising it |
US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
EP1010372A2 (en) | 1998-12-15 | 2000-06-21 | Novartis Nutrition AG | Bakery products comprising live lyophilised lactic bacteria |
JP2000191519A (en) | 1998-12-25 | 2000-07-11 | Nippon Kayaku Co Ltd | Rapid release granule wherein unpleasant functional property of medicinally active ingredient is masked |
DE19860375A1 (en) | 1998-12-28 | 2000-07-06 | Aventis Res & Tech Gmbh & Co | Alpha amylase-resistant starch for the production of food and pharmaceuticals |
US20100112003A1 (en) | 1999-01-15 | 2010-05-06 | University College Cork-National University Of Ireland, Cork & Enterprise Ireland | Bifidobacterium in the treatment of inflammatory disease |
US20030170217A1 (en) | 1999-01-15 | 2003-09-11 | Enterprise Ireland (Trading As Bioresearch Ireland And National University Of Ireland, Cork. | Bifidobacterium in the treatment of inflammatory disease |
WO2000042168A2 (en) | 1999-01-15 | 2000-07-20 | Enterprise Ireland (Trading As Bioresearch Ireland) | Bifidobacterium in the treatment of inflammatory disease |
WO2000041707A2 (en) | 1999-01-15 | 2000-07-20 | Enterprise Ireland (Trading As Bioresearch Ireland) | USE OF $i(LACTOBACILLUS SALIVARIUS) |
US6767573B1 (en) | 1999-03-10 | 2004-07-27 | Nestec S.A. | Fried pet treats |
US6835376B1 (en) | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
US7029669B1 (en) | 1999-03-11 | 2006-04-18 | Nestec S. A. | Lactic acid bacteria strains capable of preventing diarrhoea |
WO2000057712A1 (en) | 1999-03-26 | 2000-10-05 | The Pillsbury Company | Food products with biocontrol preservation |
US6358555B1 (en) | 1999-03-31 | 2002-03-19 | Hideyuki Takahashi | Process for producing frozen avocados |
US20040161422A1 (en) | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US6310090B1 (en) | 1999-05-27 | 2001-10-30 | The Iams Company | Process and product for enhancing immune response in companion animals using a combination of antioxidants |
US6562336B2 (en) | 1999-05-28 | 2003-05-13 | Vsl Pharma Limited | Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
US7052688B2 (en) | 1999-06-21 | 2006-05-30 | Vsl Pharmaceuticals, Inc. | Method for prevention and/or treatment of infections and inflammatory conditions using a combination of lactic acid bacteria |
US6375956B1 (en) | 1999-07-22 | 2002-04-23 | Drugtech Corporation | Strip pack |
WO2001012164A1 (en) | 1999-08-12 | 2001-02-22 | Merck Patent Gmbh | Oral form of administration containing probiotic micro-organisms |
US6737089B2 (en) | 1999-08-27 | 2004-05-18 | Morinda, Inc. | Morinda citrifolia (Noni) enhanced animal food product |
US20050281910A1 (en) | 1999-09-22 | 2005-12-22 | Eduardo Schiffrin | Method for increasing pet activity |
US6500463B1 (en) | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
US6905679B1 (en) | 1999-10-26 | 2005-06-14 | Nestec S.A. | Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis |
US6394803B1 (en) | 1999-12-09 | 2002-05-28 | Ivoclar Ag | Mixing arrangement |
US6406853B1 (en) | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
USRE39436E1 (en) | 1999-12-23 | 2006-12-19 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
US7687085B2 (en) | 2000-01-18 | 2010-03-30 | Nagaoka Perfumery Co., Ltd | Anti-obestic composition |
US20030049240A1 (en) | 2000-01-18 | 2003-03-13 | Oliver Ballevre | Pet food composition for treating helicobacter species in pets |
US7910144B2 (en) | 2000-01-18 | 2011-03-22 | Nestec S.A. | Pet food composition for treating helicobacter species in pets |
US20030060503A1 (en) | 2000-01-25 | 2003-03-27 | Juvenon, Inc. | Nutritional supplements for mature pets |
US7115297B2 (en) | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
JP2001309753A (en) | 2000-04-28 | 2001-11-06 | Natl Fedelation Of Agricult Coop Assoc | Dog food for prophylaxis and therapy of infectious disease peculiar to dog |
US20030104090A1 (en) | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
US7771982B2 (en) | 2000-05-25 | 2010-08-10 | Nestec S.A. | Probiotics for pet food applications |
US20030190309A1 (en) | 2000-05-25 | 2003-10-09 | Ralf Zink | Novel probiotics for pet food applications |
US7604809B2 (en) | 2000-05-25 | 2009-10-20 | Compagnie Gervais Danone | Reinforcing systemic immune responses with lactobacillus casei |
US20050106133A1 (en) | 2000-05-25 | 2005-05-19 | Ralf Zink | Novel probiotic strains for pets |
US8771675B2 (en) | 2000-05-25 | 2014-07-08 | Nestec S.A. | Probiotic strains for pets |
WO2001090311A1 (en) | 2000-05-25 | 2001-11-29 | Societe Des Produits Nestle S.A. | Novel probiotics for pet food applications |
WO2001093011A3 (en) | 2000-05-31 | 2002-04-11 | Motorola Inc | Method and apparatus for iterative training of a classification system |
US6991819B2 (en) | 2000-06-13 | 2006-01-31 | Mars, Inc. | Food product containing instable additives |
US6746672B2 (en) | 2000-06-19 | 2004-06-08 | Regents Of The University Of Minnesota | Isolated bifidobacteria that produce siderophores which inhibit growth of lactococcus lactis |
US20020022019A1 (en) | 2000-07-17 | 2002-02-21 | Svend Laulund | Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments |
US6932990B2 (en) | 2000-08-01 | 2005-08-23 | Oryza Oil & Fat Chemical Co., Ltd. | Carbohydrate absorption inhibitor and method for manufacturing the same |
US6592863B2 (en) | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
EP1312667A1 (en) | 2000-08-25 | 2003-05-21 | Wakamoto Pharmaceutical Co., Ltd. | Probiotics products containing lactic acid bacterium |
US7498162B2 (en) | 2000-09-25 | 2009-03-03 | Nestec S.A. | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
US7547527B2 (en) | 2000-10-06 | 2009-06-16 | Markus Baur | Use of probiotic lactic acid bacteria for balancing the skin's immune system |
WO2003045356A1 (en) | 2000-11-20 | 2003-06-05 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings |
US6893662B2 (en) | 2000-11-20 | 2005-05-17 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US20020098235A1 (en) | 2000-11-20 | 2002-07-25 | Dittmar Gregory Paul | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
US6797266B2 (en) | 2000-12-18 | 2004-09-28 | Probiohealth | Probiotic composition containing Lactobacillus casei strain ATCC PTA-3945 |
KR20020050048A (en) | 2000-12-20 | 2002-06-26 | 박흥재 | Identification system for lactobacillus sp dw-1 |
US20020119237A1 (en) | 2000-12-22 | 2002-08-29 | Hevey Maurice O. | Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis |
US6974594B2 (en) | 2001-01-25 | 2005-12-13 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
US20030190314A1 (en) | 2001-01-30 | 2003-10-09 | The Lauridsen Group | Methods and compositions of treatment for modulating the immune system of animals |
US7700315B2 (en) | 2001-01-30 | 2010-04-20 | Nestec S.A. | Serpin in bifidobacteria |
US6588180B2 (en) | 2001-02-02 | 2003-07-08 | R. P. Scherer Technologies, Inc. | Constricted neck blister pack and apparatus and method for making the same |
US7550285B2 (en) | 2001-02-06 | 2009-06-23 | Nestec S.A. | Endotoxin binding lactic acid bacteria and bifidobacteria |
US8263146B2 (en) | 2001-02-19 | 2012-09-11 | Nestec S.A. | Consumable product containing probiotics |
US6586027B2 (en) | 2001-02-23 | 2003-07-01 | T.F.H. Publications, Inc. | Health chew toy |
US7235395B2 (en) | 2001-03-02 | 2007-06-26 | Nestec S.A. | Lactic acid bacteria as agents for treating and preventing allergy |
US20040047896A1 (en) | 2001-03-09 | 2004-03-11 | Armand Malnoe | Composition for improving age-related physiological deficits and increasing longevity |
US20050100617A1 (en) | 2001-03-09 | 2005-05-12 | Armand Malnoe | Method for improving age-related physiological deficits and increasing longevity |
US20030157166A1 (en) | 2001-03-16 | 2003-08-21 | Chen Chih Ming | Controlled release sulfonylurea formulation |
US8092608B2 (en) | 2001-03-22 | 2012-01-10 | Nestec S.A. | Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
WO2002083879A2 (en) | 2001-04-02 | 2002-10-24 | Alimentary Health Limited | Immunotherapy based on dendritic cells |
US8802179B2 (en) | 2001-04-17 | 2014-08-12 | Guy W. Miller | Non-digestible sugar-coated products and process |
US8329190B2 (en) | 2001-05-23 | 2012-12-11 | Societe Des Produits Nestle S.A. | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria |
US7081478B2 (en) | 2001-06-29 | 2006-07-25 | Chrysantis, Inc. | Mixed zeaxanthin ester concentrate and uses thereof |
US20050013849A1 (en) | 2001-07-17 | 2005-01-20 | Bernard Lemaure | Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
WO2003010299A1 (en) | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | Probiotic lactobacillus casei strains |
WO2003010297A1 (en) | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | Probiotic bifidobacterium strains |
WO2003010298A1 (en) | 2001-07-26 | 2003-02-06 | Alimentary Health Limited | 'probiotic lactobacillus salivarius strains |
US8663729B2 (en) | 2001-09-12 | 2014-03-04 | The Iams Company | Pet food compositions |
US8728559B2 (en) | 2001-09-12 | 2014-05-20 | The Iams Company | Pet food compositions |
US7666459B2 (en) | 2001-09-12 | 2010-02-23 | The Procter & Gamble Company | Pet food compositions |
US20050249841A1 (en) | 2001-09-12 | 2005-11-10 | The Procter & Gamble Company | Pet food compositions |
US7842329B2 (en) | 2001-09-18 | 2010-11-30 | Nestec S.A. | Pet food product and method of manufacture |
US8540980B2 (en) | 2001-09-28 | 2013-09-24 | Tntgamble, Inc. | Delivery system for biological component |
US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
US6896914B2 (en) | 2001-10-26 | 2005-05-24 | David I. Chapnick | Method for normalizing insulin levels |
US20050164978A1 (en) | 2001-10-26 | 2005-07-28 | Chapnick David I. | Method for normalizing insulin levels |
US20050079244A1 (en) | 2001-11-12 | 2005-04-14 | Giffard Catriona Julie | Foodstuff |
US7008648B2 (en) | 2001-11-16 | 2006-03-07 | Novartis Nutrition Ag | Plant derived or derivable material with appetite suppressing activity |
US20050084479A1 (en) | 2001-12-11 | 2005-04-21 | Irene Corthesy-Theulay | Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
US20030170355A1 (en) | 2002-01-15 | 2003-09-11 | Glazier Barry D. | Methods and products produced thereby to stabilize multi-layer food products |
US20030143293A1 (en) | 2002-01-31 | 2003-07-31 | Sergei Shushunov | Compositions and methods for treating diarrhea |
US20060099196A1 (en) | 2002-02-21 | 2006-05-11 | Lionel Breton | Photoprotective orally administrable composition for skin |
US20050106131A1 (en) | 2002-02-21 | 2005-05-19 | Lionel Breton | Photoprotective orally administrable composition for skin |
US20050153018A1 (en) | 2002-03-12 | 2005-07-14 | Nestec S.A. | Probiotic delivery system |
WO2003075676A1 (en) | 2002-03-12 | 2003-09-18 | Societe Des Produits Nestle S.A. | Probiotic delivery system |
US7838057B2 (en) | 2002-03-25 | 2010-11-23 | Mars Incorporated | Protein-containing food product and method of preparing same |
US6681935B1 (en) | 2002-04-02 | 2004-01-27 | Graham L. Lewis | Method of providing a therapeutic regimen and prefabricated container therefor |
US8962007B2 (en) | 2002-04-05 | 2015-02-24 | Nestec S.A. | Method of improving absorption of vitamin E by a pet animal |
US20030194423A1 (en) | 2002-04-15 | 2003-10-16 | Mars, Inc. | Composition for enhancing nutritional content of food |
DE10217970A1 (en) | 2002-04-22 | 2003-11-13 | Henkel Kgaa | Blister pack has first wall section originating and widening from base area opening into second wall section widening to lesser extent than first one |
US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
US20050180961A1 (en) | 2002-05-24 | 2005-08-18 | Sophie Pecquet | Probiotics and oral tolerance |
US8142810B2 (en) | 2002-05-30 | 2012-03-27 | The Procter & Gamble Company | Dietary method for modulating glucose metabolism and associated conditions and increasing longevity |
US7427398B2 (en) | 2002-06-06 | 2008-09-23 | Mars, Inc. | Mammalian animal composition |
JP2006505515A (en) | 2002-07-30 | 2006-02-16 | ラボラトワール エクスパンシアンス | Process for producing avocado leaf extract rich in furan lipids |
US6733795B2 (en) | 2002-07-30 | 2004-05-11 | Laboratoires Expanscience | Method for producing an avocado leaf extract rich in furanic lipids |
US20050208163A1 (en) | 2002-07-31 | 2005-09-22 | Brovelli Ernesto A | Compositions containing avocado leaf extract for lowering cholesterol levels |
KR20040024774A (en) | 2002-09-16 | 2004-03-22 | 이성표 | a compositions which is composed of a nature medicines suitable for a different physical condition by a blood type |
JP2004173675A (en) | 2002-10-02 | 2004-06-24 | Takayuki Hirano | Bacterium-encapsulated product having chemical-resistant property and method for producing the same |
US20040167229A1 (en) | 2002-11-15 | 2004-08-26 | Rebecca Bakker-Arkema | Method of lowering CRP and reducing systemic inflammation |
US7179460B2 (en) | 2002-12-05 | 2007-02-20 | Danisco A/S | Bacterial composition and its use |
US6835397B2 (en) | 2002-12-23 | 2004-12-28 | Balchem Corporation | Controlled release encapsulated bioactive substances |
US6979675B2 (en) | 2003-01-10 | 2005-12-27 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
US7229818B2 (en) | 2003-01-14 | 2007-06-12 | Randolph Stanley Porubcan | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
US20040175389A1 (en) | 2003-01-14 | 2004-09-09 | Porubcan Randolph Stanley | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
WO2004074496A1 (en) | 2003-02-18 | 2004-09-02 | Mars Uk Limited | Food product and process for their preparation by enzymatic galactosyltransfer with lactobacillus alpha-galactosidase |
US8030279B2 (en) | 2003-03-21 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Tamandarin analogs and fragments thereof and methods of making and using |
WO2004100670A1 (en) | 2003-03-25 | 2004-11-25 | General Mills, Inc. | Method of treating avocados and method of preparing guacamole therefrom |
US20060165670A1 (en) | 2003-04-08 | 2006-07-27 | Michael Beer | Synbiotic combination |
US20040265279A1 (en) | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
US20040234579A1 (en) | 2003-05-22 | 2004-11-25 | Mark D. Finke, Inc. | Dietary supplements and methods of preparing and administering dietary supplements |
US20040253357A1 (en) | 2003-05-26 | 2004-12-16 | De Zarate Dominique Ortiz | Hard dragee-coating process |
US20060147962A1 (en) | 2003-06-16 | 2006-07-06 | Mars, Inc. | Genotype test |
US8394370B2 (en) | 2003-06-23 | 2013-03-12 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
US7544497B2 (en) | 2003-07-01 | 2009-06-09 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
US7235276B2 (en) | 2003-09-24 | 2007-06-26 | General Mills Ip Holdings Ii, Llc | High protein puffed food product and method of preparation |
US20050074519A1 (en) | 2003-10-01 | 2005-04-07 | Sensient Flavors Inc. | Method for the production of natural botanical extracts |
US20070116853A1 (en) | 2003-10-09 | 2007-05-24 | Nestec S.A. | Coated fat-based confectionery products |
US20080145341A1 (en) | 2003-11-07 | 2008-06-19 | Graham John Myatt | Stabilised Compositions Comprising Probiotics |
US20050112259A1 (en) | 2003-11-26 | 2005-05-26 | Fernando Qvyjt | Pet food composition having enhanced palatability |
US7687077B2 (en) | 2003-11-26 | 2010-03-30 | Hill's Pet Nutrition, Inc. | Method to reduce stool odor of companion animals |
US20070129428A1 (en) | 2003-12-18 | 2007-06-07 | Myriam Richelle | Composition for improving skin, hair and coat health containing flavanones |
US8802158B2 (en) | 2003-12-19 | 2014-08-12 | The Iams Company | Methods of use of probiotic Lactobacilli for companion animals |
US20050175598A1 (en) | 2003-12-19 | 2005-08-11 | The Procter & Gamble Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US20050158293A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
US20080292604A1 (en) | 2003-12-19 | 2008-11-27 | Thomas William-Maxwell Boileau | Canine probiotic lactobacilli |
US20090010893A1 (en) | 2003-12-19 | 2009-01-08 | Thomas William-Maxwell Boileau | Canine probiotic Bifidobacteria globosum |
EP1547466B1 (en) | 2003-12-23 | 2007-04-04 | Rohm And Haas Company | A method to reverse ethylene inhibitor responses in plants |
US20070269515A1 (en) | 2003-12-24 | 2007-11-22 | Henriksen Kristian L | Probiotic Tablet Formulations |
WO2005070232A1 (en) | 2004-01-27 | 2005-08-04 | Mars Incorporated | Food product and process for producing it |
US20050266438A1 (en) | 2004-03-16 | 2005-12-01 | The Regents Of The University Of California | Genetic networks regulated by attenuated GH/IGF1 signaling and caloric restriction |
WO2005092116A1 (en) | 2004-03-24 | 2005-10-06 | Mars Incorporated | Foodstuff comprising a probiotic and prebiotic |
US20070123460A1 (en) | 2004-04-20 | 2007-05-31 | The University Of Chicago | Probiotic compounds from Lactobacillus GG and uses therefor |
US7897579B2 (en) | 2004-04-30 | 2011-03-01 | Laboratoires Expanscience | Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases |
US7833554B2 (en) | 2004-04-30 | 2010-11-16 | Laboratoires Expanscience | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency |
US9089576B2 (en) | 2004-04-30 | 2015-07-28 | Laboratoires Expanscience | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin |
US9023810B2 (en) | 2004-04-30 | 2015-05-05 | Laboratories Expanscience | Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases |
US8349377B2 (en) | 2004-04-30 | 2013-01-08 | Laboratoires Expanscience | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency |
US20080260866A1 (en) | 2004-05-10 | 2008-10-23 | Stefan Patrick Massimino | Method for decreasing inflammation and stress in a mammal |
CA2569249C (en) | 2004-05-10 | 2012-08-14 | The Iams Company | Processes for preparing plant matter extracts and pet food compositions |
US20090252834A1 (en) | 2004-05-10 | 2009-10-08 | Michael Griffin Hayek | Compositions comprising glucose anti-metabolites |
US20050249837A1 (en) | 2004-05-10 | 2005-11-10 | The Procter & Gamble Company | Processes for preparing plant matter extracts and pet food compositions |
US20080044481A1 (en) | 2004-05-27 | 2008-02-21 | Mordechai Harel | Microparticles for Oral Delivery |
US20060002909A1 (en) | 2004-06-14 | 2006-01-05 | Kabushiki Kaisha Yonezawa Biru Shisutemu Sabisu | Microorganism separated from Kefir grains, a microorganism culture obtained by culturing said microorganism or microorganisms including it, and a product using such microorganisms or microorganism cultures |
US7795227B2 (en) | 2004-06-17 | 2010-09-14 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
US20080305210A1 (en) | 2004-07-01 | 2008-12-11 | General Mills, Inc. | Cultures Encapsulated With Compound Fat Breakfast Cereals Coated With Compound Fat and Methods of Preparation |
US8637495B2 (en) | 2004-07-01 | 2014-01-28 | Nestec S.A. | Osteoarthritis diet formulations |
US20060008511A1 (en) | 2004-07-08 | 2006-01-12 | Jhy-Jhu Lin | Probiotic products for pet applications |
US8808770B2 (en) | 2004-07-30 | 2014-08-19 | Nutramax Laboratories, Inc. | Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals |
US20060070895A1 (en) | 2004-08-16 | 2006-04-06 | Faisal Khawaja | Drug administration kit |
JP2006055145A (en) | 2004-08-19 | 2006-03-02 | Kosshi:Kk | Pet food and method for offering the same |
EP1637041B1 (en) | 2004-09-21 | 2008-04-30 | Nestec S.A. | Improving longevity of elderly cats |
US20070286935A1 (en) | 2004-10-07 | 2007-12-13 | Nestec S.A. | Bioactive Compositions, Natural Methods of Producing Them and Computational Methods for Designing Natural Production Processes |
US20080050355A1 (en) | 2004-10-22 | 2008-02-28 | Compagnie Gervais Danone | Protection of bioactive food ingredients by means of encapsulation |
US20080050354A1 (en) | 2004-10-22 | 2008-02-28 | Compagnie Gervais Danone | Protecting bioactive food ingredients using microorganisms having reduced metabolizing capacity |
US20080279786A1 (en) | 2004-12-17 | 2008-11-13 | Cash Alan B | Method for Extending Lifespan Delaying the Onset of Age-Related Disease |
US20070269553A1 (en) | 2005-02-10 | 2007-11-22 | Anh Le | Heated food product with coating of encapsulated flavors |
US20060228459A1 (en) | 2005-04-11 | 2006-10-12 | The Iams Company | Compositions comprising a cocoa butter component and an animal-derived fat component |
US20070218164A1 (en) | 2005-04-11 | 2007-09-20 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
US20060228448A1 (en) | 2005-04-11 | 2006-10-12 | The Iams Company | Pet food compositions comprising two components |
US20090274796A1 (en) | 2005-05-11 | 2009-11-05 | Ryan Yamka | Methods for Enhancing Palatability of Compositions for Animal Consumption |
US20090263542A1 (en) | 2005-05-13 | 2009-10-22 | Charlie Hungwei Lin | Dry Food Compositions Having Enhanced Palatability |
US20060263416A1 (en) | 2005-05-20 | 2006-11-23 | The Lams Company | Coated pet food products |
US20080317905A1 (en) | 2005-05-20 | 2008-12-25 | Ryan Michael Yamka | Methods for Promoting Health or Wellness in Adult Animals |
US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
US20080280274A1 (en) | 2005-06-01 | 2008-11-13 | Kim Gene Friesen | Methods For Enhancing Palatability of Compositions for Animal Consumption |
US8101170B2 (en) | 2005-06-14 | 2012-01-24 | Erber Aktiengesellschaft | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof |
US20070009577A1 (en) | 2005-07-05 | 2007-01-11 | Mankovitz Roy J | Probiotic compositions and methods |
US7935334B2 (en) | 2005-07-07 | 2011-05-03 | Imagilin Technologies, LLC | Probiotics as alternative medicines against infectious diseases |
US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US8722112B2 (en) | 2005-07-14 | 2014-05-13 | Hill's Pet Nutrition, Inc. | Method for prolonging the life of animals |
US20070122531A1 (en) | 2005-09-01 | 2007-05-31 | Wellmark International | Methods for Selecting a Pet-Appropriate Product |
US8865197B2 (en) | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
US7700141B2 (en) | 2005-09-20 | 2010-04-20 | Mars Incorporated | Composition |
US7951493B2 (en) | 2005-09-30 | 2011-05-31 | Hill's Pet Nutrition, Inc. | Methods for extending the shelf-life of food compositions containing polyunsaturated fatty acids |
JP2007117083A (en) | 2005-09-30 | 2007-05-17 | Global Technology:Kk | Immunoactivity modulator for animal and animal feed containing the same |
US20070280964A1 (en) | 2005-10-06 | 2007-12-06 | Ruth Knorr | Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and preventing or treating conjunctivitis |
US20070098744A1 (en) | 2005-10-06 | 2007-05-03 | Nestec S.A. | Probiotic enterococci for improved immunity |
US20070082107A1 (en) | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for reducing food intake and controlling weight |
US20090324761A1 (en) | 2005-10-19 | 2009-12-31 | Hill's Pet Nutrition, Inc. | Methods And Compositions for Improving Gastrointestinal Health |
US7647098B2 (en) | 2005-10-31 | 2010-01-12 | New York University | System and method for prediction of cognitive decline |
US20080311226A1 (en) | 2005-11-04 | 2008-12-18 | Hill's Pet Nutrition, Inc. | Methods and Compositions For Improving Stool Quality |
US7816547B2 (en) | 2005-11-18 | 2010-10-19 | Laboratoires Expanscience | Process for producing refined avocado oil rich in triglycerides, and oil obtainable by said process |
US8524304B2 (en) | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith |
WO2007060539A3 (en) | 2005-11-28 | 2007-12-06 | Jorrocks Pty Ltd | Methods for preparation of animal feeds |
US20070190171A1 (en) | 2005-12-02 | 2007-08-16 | Yamka Ryan M | Methods for Altering Stool Quality and/or Stool Frequency |
US20070178078A1 (en) | 2005-12-29 | 2007-08-02 | Christina Khoo | Method for Modifying Gut Flora in Animals |
EP1806056A1 (en) | 2006-01-05 | 2007-07-11 | IPC Process-Center GmbH & Co. | Particles including sensitive component |
EP1806057B1 (en) | 2006-01-05 | 2010-07-14 | IPC Process-Center GmbH & Co. | Micro pellets for the preparation of animal feed pellets |
US20070160589A1 (en) | 2006-01-11 | 2007-07-12 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
US20070166295A1 (en) | 2006-01-13 | 2007-07-19 | Vet Solutions L.P. | Anti-Diarrhea Preparations for Small Domestic Animals |
US8057840B2 (en) | 2006-01-25 | 2011-11-15 | Tate & Lyle Ingredients Americas Llc | Food products comprising a slowly digestible or digestion resistant carbohydrate composition |
US20070231371A1 (en) | 2006-02-01 | 2007-10-04 | Nestec, S. A. | Nutritional system and methods for increasing longevity |
US8916145B2 (en) | 2006-02-15 | 2014-12-23 | Nestec S.A. | Use of Bifidobacterium longum for the prevention and treatment of inflammation |
US7960605B2 (en) | 2006-03-17 | 2011-06-14 | BioMaker Pharmaceuticals, Inc. | Methods for testing for caloric restriction (CR) mimetics |
US20070231414A1 (en) | 2006-03-29 | 2007-10-04 | Kaneka Corporation | Composition having bone resorption inhibition-related effect and method for inhibiting bone resorption |
US20100316769A1 (en) | 2006-03-29 | 2010-12-16 | Gail Czarnecki-Maulden | Dietary supplements containing probiotics |
WO2007126990A2 (en) | 2006-03-29 | 2007-11-08 | Nestec S.A. | Dietary supplements containing probiotics |
WO2007137808A1 (en) | 2006-05-29 | 2007-12-06 | University College Dublin, National University Of Ireland, Dublin | Compositions comprising oligosaccharides for treating prion disease |
US7674808B2 (en) | 2006-05-31 | 2010-03-09 | Glaxo Group Limited | Heterocyclic compounds |
US20110117068A1 (en) | 2006-08-18 | 2011-05-19 | Organobalance Gmbh | Probiotic microorganisms for the reduction of manure odor |
US20080053490A1 (en) | 2006-09-01 | 2008-03-06 | Bausch & Lomb Incorporated | Method for hydrating a contact lens |
US20080107699A1 (en) | 2006-10-25 | 2008-05-08 | Mark Spigelman | Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor |
US8557764B2 (en) | 2007-01-26 | 2013-10-15 | The Regents Of The University Of Colorado, A Body Corporate | Methods of modulating immune function |
US20080260696A1 (en) | 2007-02-01 | 2008-10-23 | Stefan Patrick Massimino | Method for decreasing inflammation and oxidative stress in mammals |
RU2407401C2 (en) | 2007-02-13 | 2010-12-27 | Общество С Ограниченной Ответственностью "Марс" | Dog feeding method |
US20080241226A1 (en) | 2007-03-27 | 2008-10-02 | Abeln Susan L | Methods and Kits For Administering Probiotics |
US20100203225A1 (en) | 2008-07-07 | 2010-08-12 | George Scott Kerr | Supplement, Process for Making, and Packaging |
US20100003369A1 (en) | 2008-07-07 | 2010-01-07 | Ter Haar Robert H | Probiotic supplement, process for making, and packaging |
US20100233320A1 (en) | 2008-09-11 | 2010-09-16 | Gregory Dean Sunvold | Animal Feed Kibble with Protein-Based Core and Related Methods |
US20100158070A1 (en) | 2008-12-18 | 2010-06-24 | Roche Diagnostics Operations, Inc. | Method for Monitoring the Thermal Coupling of a Measuring Cell |
US8691303B2 (en) | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
US9119843B2 (en) | 2009-12-04 | 2015-09-01 | Caliper Life Sciences, Inc. | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
US20120115798A1 (en) | 2010-11-04 | 2012-05-10 | Stefan Patrick Massimino | Method for improving the immunity of a companion animal |
US20130183255A1 (en) | 2010-12-22 | 2013-07-18 | Laboratoires Expanscience | Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same |
US20120282373A1 (en) | 2011-05-02 | 2012-11-08 | Ashok Premchand Luhadiya | Compositions Comprising a Glucose Anti-Metabolite and Selenium |
US20120283197A1 (en) | 2011-05-02 | 2012-11-08 | Ashok Premchand Luhadiya | Compositions Comprising a Glucose Anti-Metabolite, BHA, and/or BHT |
US20150208679A1 (en) | 2012-07-25 | 2015-07-30 | Agrofresh, Inc. | Methods of handling avocados and system |
US20140349002A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Ingestible Compositions Containing Criollo Avocado Component |
US20140348986A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Avocado Processing |
US20140348975A1 (en) | 2013-05-23 | 2014-11-27 | The Iams Company | Mimicking the Metabolic Effect of Caloric Restrictions by Administration of Glucose Anti-Metabolites to Enhance Positive Response in a Mammal |
US20150132420A1 (en) | 2013-11-11 | 2015-05-14 | The Iams Company | Processes for preparing a carbohydrate extract comprising mannoheptulose and compositions comprising same |
Non-Patent Citations (309)
Title |
---|
"A Balanced Diet", Waltham Book of Dog and Cat Nutrition, Ed. ATB, Edney, Chapter by A. Rainbird, pp. 57-74, Pergamon Press, Oxford, 1988. |
"A Balanced Diet", Waltham Book of Dog and Cat Nutrition, Ed. ATB, Edney, Chapter by A. Rainbird, pp. 57-74, Pergamon Press, Oxford. |
"Changing Times", The Kiplinger Magazine, vol. 31, No. 1, Jan. 1977, pp. 39-40. |
"Kidney Stones in Adults (http://kidney.niddk.nih.gov, pp. 1-14)", retrieved Dec. 12, 2005. |
"Lactobacillus animalis genes for 16S-23S intergenic spacer region, 23S ribosomal RNA, strain", Database EMBL: JCM 5670, Jul. 9, 2004, XP002447038. |
"Lactobacillus murinus genes for 16S-23S intergenic spacer regions, 23S ribosomal RNA, strain: JCM 1717", Database EMBL, Jul. 9, 2004, XP002447039. |
"Mice and Rats", (www.petswarehouse.com, pp. 1-5), retrieved Dec. 12, 2005. |
"Nutrient Profiles for Dog Foods", Association of American Feed Control Officials Incorporated, pp. 110-119, 1994. |
"Probiotic Basics", (www.usprobiotics.org.basics/, p. 1-12), retrieved Dec. 12, 2005. |
"Urinary Tract Infections in Adults", (http://kidney.niddk.nih.gov, pp. 1-11), retrieved Dec. 12, 2005. |
Adeyemi, et al., "Analgesic and Anti-Inflammatory Effects of the Aqueous Extract Leaves of Persea America Mill (Lauraceae)", Fitoterapia, IDB Holdings, Milan, IT, vol. 73, No. 5, Aug. 1, 2002, pp. 375-380, XP002318086. |
Alves-Filho, Drying Technology, 2002, vol. 20, No. 8, pp. 1541-1557, abstract. |
Amendment in response to Nonfinal Office Action mailed Aug. 16, 2011 and issued in connection with U.S. Appl. No. 12/716,540 dated Nov. 15, 2011. |
Amendment in response to Nonfinal Office Action mailed Jun. 10, 2011 and issued in connection with U.S. Appl. No. 12/638,101, Dated Sep. 2, 2011. |
Amendment in response to Nonfinal Office Action mailed Jun. 7, 2011 and issued in connection with U.S. Appl. No. 12/716,518 dated Oct. 7, 2011. |
Amendment in response to Nonfinal office Action mailed Jun. 9, 2011 and issued in connection with U.S. Appl. No. 12/716,562, dated Sep. 2, 2011. |
Anand et al."Cytokines and Inflammatory Bowel Disease", Tropical Gastroenterology, 1999; 20(3):97-106. |
Anderson, et al., Nutrition Reviews, vol. 61, No. 5, pp. S17-S26, May 2003. |
Andus et al., "Imbalance of the Interleukin 1 System in Colonic Mucosa-Association With Intestinal Inflammation and Interleukin 1 Receptor Agonist Genotype 2", Gut, vol. 41, 1997, pp. 651-657, p. 654, col. 2-p. 655, col. 1 figure 2D, XP002296947. |
Anonymous, "The Best Ever Guacamole-Again, Whole Foods Market", Jan. 18, 2013, Retrieved from the Internet: URL:http://www.wholefoodsmarket.com/blog/best-ever-guacamole-again, p. 3. |
Apgar et al., Journal Animal Science, Aug. 1993, 71(8): 2173-2179. |
Appelboom, et al., "Symptoms Modifying Effect of Avocoda/Soybean Unsaponfiables (ASU) in Knee Arthritis. A Double Blind, Prospective, Placebo-Controlled Study", Scandinavian Journal of Rheumatology, vol. 30, pp. 242-247 (2001). |
Arai et al., "Cytokines: Coordinates of Immune and Inflammatory Responses", Annu. Rev. Biochen. 90, 59: 783-836. |
Aranda et al., "Analysis of Intestinal Lymphocytes in Mouse Colitis Medicated by Transfer of CD4+, CD45RB high T Cells to SCID Recipients", 1997, The American Association of Immunologists. |
Arany, et al., "The Effect of Carcinogens and Non-Carcinogens on Some Biochemical Features of the Mouse Lung Tissue", Arch. Toxicol., Suppl. 4, 73 (1980). |
Archived pages from HTTP://web.archive.org for http://medtechnologies.com dated Feb. 2003. |
Asahara, et al., "Antimicrobial Activity of Intraurethrally Adminstered Probiotic Lactobacillus casei in a Murine Model of Escherichia coli Urinary Tract Infection", Antimicrobial Agents & Chemotherapy, 2001, 45(6): 1751-1760. |
Ashcroft, et al., "Glucose Metabolism in Mouse Pancreatic Islets", Biochem. J. (1970), 118, pp. 143-154. |
Au, et al., "Avocado Soybean Unsaponifiables (ASU) suppress TNF-a, IL-1b, cox-2, iNOS Gene Expression, and Prostaglandin E2 and Nitric Oxide Production in Articular Chondrocytes and Monocyte/Macrophages", Osteoarthritis and Cartilage, 2007, 15, 18 pages. |
Balkau, et al., "Insulin resistance: an independent risk factor for cardiovascular disease?", Diabetes Obes. Metab., 1 (Suppl. 1), pp. S23-S31, 1999. |
Barge, "Avocados May Help Prevent Oral Cancer, OSU Study Shows", Journal of Dental Hygiene, vol. 82, No. 2, Apr. 2008, 3 pp. |
Barrows, et al., "Diet and Nutrition", Walleye Culture Manual, R. C. Summerfelt, editor, NCRAC Culture Series 101, North Central Regional Aquaculture Center Publications Office, Iowa State University, Ames, First Edition, 1996. |
Begbie, et al., "The Isolation of Some Heptoses, Heptuloses, Octuloses and Nonuloses from Pimula Officinalis JACQ", Carbohydrate Research, 1966, vol. 2, pp. 272-288. |
Benno, et al., Individual and Seasonal Variations in the Composition of Fecal Microflora of Beagle Dogs, Bifidobacteria Microflora, vol. 11, No. 2, pp. 69-76, 1992. |
Biavati et al., Electrophoretic Patterns of proteins in the Genus Bifidobaterium and Proposal of Four New Species. Journal International Journal Systematic Bacteriology vol. 32 pp. 358-373, 1982. |
Blatherwick, et al., "Metabolism of D-Mannoheptulose. Excretion of the Sugar After Eating Avocado", J. Biol. Chem., vol. 133, pp. 643-650 1940. |
Blue Buffalo Life Protection Formula-package.pdf, http/www.bluebuff.com/products/dogs/lp-adult-chick.shtml Information accessed Feb. 3, 2009. |
Board, et al., "High KM Glucose Phosphorylating (Glucokinase) Activities in a Range of Tumor Cell Lines and Inhibition of Rates of Tumor Growth by the Specific Enzyme Inhibitor Mannoheptulose", Cancer Research, vol. 55, pp. 3278-3285, Aug. 1995. |
Bodmeier R, "Capsule With Controlled Active Ingredient Release Comprises Active Ingredient-Containing Filling, Capsule Shell, Swelling Agent and Water-Insoluble Layer", BODM, May 18, 1999. |
Botterweck, et al., "Intake of Butylated Hydroxyanisole and Butylated Hydroxytoluene and Stomach Cancer Risk: Results from Analyses in the Netherlands Cohort Study", Food and Chemical Toxicology, 38 (2000, 599-605. |
Bouhnik et al., "Effects of Bifidobacterium SP Fermented Milk Ingested With or Without Inulin on Colonic Bifidobacteria and Enezymatic activities in Healthy Humans" European Journal of Clinical Nutrition, (1996) 50, 269-273. |
Brai, et al., "Hypoglycemic and Hypocholesterolemic Potential of Persea americana Leaf Extracts", J. Med. Food, 2007, pp. 356-360. |
Brandtzaeg et al., "Immunopathology of Human Inflammatory Bowel Disease", Springer Seminars in Immunopathology, (1997) 18: 555-589. |
Bredif, et al., "Avocado Sugars are Effective Inducer of Cutaneous Defensive Functions", Journal of the American Academy of Dermatology, St. Loius, Mo, vol. 50, No. 2, Feb. 1, 2007, p. AB84, XP005937005. |
Breeders Choice, AvoDERM product brochures http://www.breeders-choice.com/about/brochures.htm, Information accessed Feb. 3, 2009. |
Bridigidi, et al., "Specific Detection of Bifidobacterium Strains in a Pharmaceutical Probiotic Product and in Human Feces by Polymerase Chain Reaction", System Appl. Microbial., 23, 2000, 391-399. |
Brown, et al., "Glucose Phosphorylation is Essential for the Turnover of Neutral Lipid and the Second Stage Assembly of Triacylglycerol-Rich ApoB-Containing Lipoproteins in Primary Hepatocyte Cultures", American Heart Association, Inc., 1999, pp. 321-329. |
Burger, et al., "Cardiomyopathy in Ostriches (Struthio camelus) Due to Avocado (Persea americana Var. Guatemalensis) Intoxication", Journal of the South African Veterinary Association, vol. Jaargang 65, No. 2, Jun. 1994. |
Campieri, et al., "Reduction of Oxaluria after an Oral Course of Lactic Acid bacteria at High Concentration", Kidney International (2001) vol. 60, pp. 1097-1105. |
Carranza, et al., "Lower Quantities of Avocado as Daily Source of Monounsaturated Fats: Effect on Serum and Membrane Lipids, Endothelial Function, Platelet Aggregation and C-Reactive Protein in Patients with Metabolic Syndrome", Database Embase, Elsevier Science Publishers, Amsterdam NL, Nov. 2004, XP002485347. |
Chadwick et al."Activation of the Mucosal Immune System in Irritable Bowel Syndrome", Gastroenterology, (2002) 122:1778-83. |
Chan, et al., "Ultra Structural and Secretory Heterogeneity of fa/fa (Zucker) Rat Islets", Molecular and Cellular Endocrinology, 136, 1998, pp. 119-129. |
Charteris et al., "Antiobiotic Sysceptibility of Potentially Probiotic Bifidobacterium Isolates From the Human Gastrointestinal Tract", Letters in Applied Microbiology, 1998, 26, 333-337. |
Charteris et al., "Development and application of an In Vitro Methodology to Determine the Transit Tolerance of Potentially Probiotic lactobacillus and bifidobacterium Species in the Upper Human Gastrointestinal Tract", Journal of Applied Microbiology, 1998, 84, 759-768-XP 000929203. |
Charteris et al., "Effect of Conjugated Bile Salts on Antibiotic Susceptibility of Bile Salt-Tolerant Lactobacillus and Bifidobacterium Isolates", Journal of Food Protection, vol. 63, No. 10, 2000, pp. 1369-1376. |
Charteris et al., "Selective Detection, Enumeration and Identification of Potentially Probiotic lactobacillus and bifidobacterium Species in Mixed Bacterial Populations", International Journal of Food Microbiology 35, (1997) 1-27. |
Chauviere et al., "Adhension of Human Lactobacillus Acidophilus Strain LB to Human Enterocyte-like Caco-2 Cells", Journal of General Microbiology, (1992), 138, 1689-1696. |
Chen, et al., "Action of 5-Thio-D-Glucose and Its 1-Phosphate with Hexokinase and Phosphoglucomutase", Arch. Biochem. Biophys. 169, pp. 392-396 (1975). |
Chevalier et al., "Detection of bifidobacterium Species by Enzymatic Methods", Journal of Applied Basteriology, 1990, 68, 619-624. |
Chiricolo, et al., "Cell Adhesion Molecules CD11a and CD18 in Blood Monocytes in Old Age and the Consequences for Immunological Dysfunction", Gerontology, 1995, 41(4), pp. 227-234. |
Cicco et al., "Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Cology-Stimulating Factor and Tumor Necrosis Factor-Alpha", 1990 The American Society of Hematology, Blood, vol. 75, No. 10 May 15, 1990: pp. 2049-2052. |
Collins et al., "Selection of Probiotic Strains for Human Applications", In. Dairy Journal 8, (1998) 487-490. |
Collins, et al., "A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity", Microbial Ecology in Health and Disease, vol. 14, No. 2, Jun. 2002, pp. 81-89. |
Conde, et al., "OeMST2 Encodes a Monosaccharide Transporter Expressed throughout Olive Fruit Maturation", Plant Cell Physiol., 48(9), pp. 1299-1308, 2007. |
Cooke, et al., "Role of Estrogens in Adipocyte Development and Function", Exp. Biol. Med., 229:1127-35, 2004. |
Crane, et al., "The Non-Competitive Inhibition of Brain Hexokinase by Glucose-6-Phosphate and Related Compounds", Biol. Chem., 210, pp. 597-696 (1954). |
Cruzen, et al., "Effects of Caloric Restriction on Cardiovascular Aging in Non-Human Primates and Humans", Clin. Geriatr. Med., vol. 25(4), pp. 733-743, Nov. 2009. |
Cullen, et al., "Inhibition of Glucose Metabolism in Pancreatic Cancer Induces Cytotoxicity via Metabolic Oxidative Stress", Gastroenterology, vol. 128, No. 4, sup. 2, Apr. 2005, pp. A483, XP002495963. |
De Pergola, "The Adipose Tissue Metabolism: Role of Testosterone and Dehydroepiandrosterone", Int. J. Obesity, 24: S59-S63, 2000. |
Dent, et al., "Lactobacillus animalis JCM5670", Database JCM Catalogue, Japan Collection of Microorganisms, 1986, XP002447035. |
Donnelly et al., "Differential Regulation of Il-1 Production in Human Monocytes by IFN-y and IL-4" , The Journal of Immunology, vol. 145, 569-575. No. 2 Jul. 15, 1990. |
Dorland's Pocket Medical Dictionary (24th ed.), W.B. Saunders Co. p. 15, 1989. |
Dreau, et al., "Effects of 2-deoxy-D-glucose Adminstration on Immune Parameters in Mice", Immunopharmacology, vol. 39, Jun. 1, 1998, pp. 201-213. |
Eisai KK, "Sustained-Release Solid Prepn. of Zero Order Drug Releasing Profile Comprises Granules Obtainable by Coating Inner Core Containing Xanthine Deriv. Etc. With Film of Hardend Oil", EISA, Dec. 22, 1989. |
Ekor, et al., "Protective Effect of the Methanolic Leaf Extract of Persea americana (avocado) Against Paracetamol-Induced acute Hepatoxicity in Rats", International Journal of Pharmacology, vol. 2, No. 4, Jan. 1, 2006, pp. 416-420 XP001538905. |
EPO Search Report, mailed Jan. 7, 2013, 3 pages. |
Ernst, "Avocado-Soybean Unsaponifiables (ASU) for Osteoarthritis-A systemic Review", Clin. Rheumatol., 2003, 22, pp. 285-288. |
European Search Report Recieved in Connection with EP 04 81 5182, mailed on Jun. 13, 2008. |
Facchini, et al., "Insulin Resistance as a Predictor of Age-Related Diseases", The Journal of Clinical Endocrinology & Metabolism, Aug. 2001, 86(8): 3574-3578. |
Fajans, et al., "Stimulation of Insulin Release in the Dog by a Nonmetabolizable Amino Acid. Comparison with Leucine and Arginine", J. of Clinical Endocrinology and Metabolism, 33(1) 35-41, Jul. 1971. |
Favier et al., Fecal B-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease, Digestive Diseases and Sciences, vol. 42, No. 4 (Apr. 1997), pp. 817-822. |
Fergus Shanahan, "The Intestinal Immune System", Physiology of the Gastrointestinal Tract, Third Edition, 1994. |
Final Office Action issued in connection with U.S. Appl. No. 12/638,101, mailed Dec. 30, 2011. |
Final Office Action issued in connection with U.S. Appl. No. 12/716,518 mailed Jan. 4, 2012. |
Final Office Action issued in connection with U.S. Appl. No. 12/716,540 mailed Jan. 10, 2012. |
Final Office Action issued in connection with U.S. Appl. No. 12/716,562 mailed Dec. 29, 2011. |
Fishbein, et al., "Biological Effects of Dietary Restriction", Springer-Verlag, 1991. |
Fontana, et al., "Long-term Calorie Restriction is Highly Effective in Reducing the Risk for Artherosclerosis in Humans", PNAS, vol. 101(17), pp. 6659-6663 (2004). |
Francesconi, et al., "5-Thio-D-Glucose: Hypothermic Responses in Mice", Am. J. Physiology, 239(3) 1 Sep. 1, 1980, R214-R218. |
Frech, et al., "The Utility of Nutraceuticals in the Treatment of Osteoarthritis", Current Rheumatology Reports, 2007, 9, pp. 25-30. |
Freund Sangyokk, "Capsule Containing Useful Enteric Bacteria-Includes Hydrophobic Layer Non-Fluid at Room Temp Isolating Bacteria From Membrane, to Prevent Moisture Penetration", Derwent Publication Ltd., FREN, Aug. 5, 1986. |
Fujisawa Pharm Co Ltd., "Long-Acting Oral Prepn.-Comprises Rapidly Soluble Innter Layer and Sustained-Release Outer Layer, Both Layers Containing Principal Agent, Which Is Coronary or Peripheral Vasodilator (Jpn)", Fuji, Sep. 20, 1991. |
Gallagher, et al., "The Effects of Traditional Antidiabetic Plants on In Vitro Glucose Diffusion", Nutrition Research, 23 (2003), pp. 413-424. |
Gartrell, et al., "The Effects of Chocolate and Chocolate by-product Consumption on Wild and Domestic Animals", Chocolate in Health and Nutrition, Humana Press, 2013, pp. 135-141. |
Gasche et al., "IL-10 Secretion and Sensitivity in Normal Human Intestine and Inflammatory Bowel Disease", Journal of Clinical Immunology, vol. 20, No. 5, 2000. |
German, et al., "Glucose Sensing in Pancreatic Islet Beta Cells: The Key Role of Glucokinase and the Glycolytic Intermediates", Proc. Nat. Acad. Sci., 90, 1781-1785 (1993). |
Gibson et al., "Dietary Modulation of the Human Gut Microflora Using Prebiotics", Journal of Nutrition,.(1998) 80. Suppl. 2 S209-S212. |
Gielkens, et al., "Effects of Hyperglycemia and Hyperinsulinemia on Satiety in Humans", Metabolism, vol. 47, No. 3, pp. 321-324, 1998. |
Goldrosen, et al., "Impaired Lymphocyte Blastogenic Response in Patients with Colon Adenocarcinoma: Effects of Disease and Age", Journal of Surgical Oncology, 9:229-234, 1977. |
Golkar, et al., "Apigenin Inhibits Pancreatic Canel Cell Proliferation via Down-Regulation of the GLUT-1 Glucose Transporter", Gastroenterology, vol. 130, No. 4, Jul. 22, 2006. |
Gondwe, "Effects of Persea Americana Mill (Lauraceae) Ethanolic Leaf Extract on Blood Glucose and Kidney Function in Streptozotocin-Induced Diabetic Rats and on Kidney Cell Lines of the Proximal (LLC-PK1) and Distal Tubules (MDBK)", Methods Find Exp Clin. Pharmacol., 2008, 30(1), pp. 25-35. |
Grajales-Lagunes, et al., "Stability and Sensory Quality of Spray Dried Avocado Paste", Drying Technology, Vo. 17, No. 1&2, 1999, pp. 317-326. |
Greetham et al., Bacteriology of the labrador dog gut: A cultural and genotype approach, J. Appl. Microbiol. 93: 640-6 (2002). |
Groux et al., "Regulatory T Cells and Inflammatory Bowel Disease", Viewpoint Immunology Today, Oct. 1999. |
Guo, et al., "In Vivo 2-Deoxyglucose Administration Preserves Glucose and Glutamate Trasport and Mitochondrial Function in Cortical Synaptic Terminals after Exposure to Amyloid Beta-Peptide and Iron: Evidence for a Stress Response", Experimental Neurology, vol. 166., No. 1, Jan. 1, 2000, XP008056810, pp. 173-179. |
Hammarstrom, et al., "Mitogenic Leukoagglutinin from Phaseolus vulgaris Binds to a Pentasaccharide Unit in N-acetyllactosamine-type Glycoprotein Glycans", Proc. Natl. Acad. Sci. USA, 79, 1611-1615 (1982). |
Hemme, et al., "Lactobacillus murinus JCM1717", Database JCM Catalogue, Japan Collection of Microorganisms, 1982, XP002447036. |
Henrotin, et al., "Pharmaceutical and Nutraceutical Management of Canine Osteoarthritis: Present and Future Perspectives", The Veterinary Journal, 170 (2005), pp. 113-123. |
Henry J. Binder, M.D., "Genes, Bacteria and T Cells: Ingredients for Inflammatory Bowel Disease", Selected Summaries, Gastroenterology, 1998; 115: 1695-1600, vol. 115, No. 6. |
Hershkovitz, et al., "Ethylene regulation of Avocado Ripening Differs Between Seeded and Seedless Fruit", Postharvest Biology and Technology, vol. 56, No. 2, May 1, 2010, pp. 138-146. |
Hideo Tomomatsu, "Health Effrects of Oligosaccharides", 1994, Food Technol, 48, pp. 61-65. |
Hildesheim et al., "Simultaneous Measurement of Several Cytokines Using Small Volumes of Biospecimens", Cancer Epidemiology, Biomarkers & Prevention, vol. IKI, pp. 1477-1484, Nov. 2002, XP002296946 abstract. |
Hillsvet, "Hill's Presciption Diet, A New Way to Define Pet Obesity", Internet Article, 2010, http://www.hillsvet.com/conference-documents/Weight-Management/Therapeutic?Weight-Reduction-Program/BFI-Backgrounder.pdf. |
Hoffman, et al., "Diabetogenic Action of 5-Thio-D-glucopyranose in Rats", Biochemistry, vol. 7, pp. 4479-4483 (1968). |
Hommes et al., "Anti- and Proinflammatory Cytokines in the Pathogenesis of Tissue Damage in Crohn's Disease", 2000 Lippincott Williams and Wilkins, 1363-1950. |
International Search Report for PCT/US2011/058861, dated Feb. 10, 2012. |
International Search Report for PCT/US2012/035921, dated Jul. 10, 2012. |
International Search Report for PCT/US2012/036035, dated Jul. 11, 2012. |
International Search Report Recieved in Connection with PCT/IB2008/050382, mailed on Oct. 7, 2008. |
International Search Report Recieved in Connection with PCT/US2004/043068, mailed on Sep. 25, 2007. |
Isolauri, et al., "Probiotics: A Role in the Treatment of Intestinal Infection and Inflammation?", Gut, 2002, 50 (Suppl III), pp. iii54-iii59. |
Issekutz, et al., "Effect of Mannoheptulose on Glucose Kinetics in Normal and Glucocorticoid Treated Dogs", Life Sciences, 15(4), pp. 635-643, 1974. |
Iwasaki et al., "Unique Functions of CD11+, CD8alpha+, and Double-Negative Peyer's Patch Dendritic Cells", 2001, The American Association of Immunologists. |
Iwasaki et al., "Unique Functions of CD11+, CD8α+, and Double-Negative Peyer's Patch Dendritic Cells", 2001, The American Association of Immunologists. |
Jay, et al., "Metabolic Stability of 3-O-Methyl-D-Glucose in Brain and Other Tissues" J. Neurochem., 55, pp. 989-1000 (1990). |
Johnson, et al., "Glucose-Dependent Modulation in Insulin Secretion and Intracellular Calcium Ions by GKA5O, a Glucokinase Activator", Diabetes, vol. 56, Jun. 2007, pp. 1694-1702. |
Johnston, "Small Intestinal Bacterial Overgrowth", The Veterinary Clinics of North America, Small Animal Practice, Mar. 1999, vol. 29, No. 2, Mar. 1999, pp. 523-550. |
Kalani, et al., "Effects of Caloric Restriction and Exercise on Age-Related, Chronic Inflammation Assessed by C-Reactive Protein and Interleukin-6", J. Gerontol. A. Bio. Sci. Med. Sci., vol. 61(3), pp. 211-217 (2006). |
Kalant, et al., "Effect of Diet Restriction on Glucose Metabolism and Insulin Responsiveness in Aging Rates", Mechanisms of Aging and Development, 46 (1988) 89-104. |
Kappler-Tanudyaya, et al., "Combination of Biotransformation and Chromatography for the Isolation and Purification of Mannoheptulose", Biotechnology J. 2007, 2, 692-699. |
Katzmarzyk, "The Metabolic Syndrome: An Introduction", Appl. Physiol. Nutr. Metab., 32, pp. 1-3 (2007). |
Kaufman, et al., "Identification and Quantification of Bifidobacterium Species Isolated from Food with Genus-Specific 16S rRNA-Targeted Probes by Colony Hybridization and PCR", Appl. Environ. Miorobiol., Apr. 1997, vol. 63, pp. 1268-1273. |
Kealy, et al., "Effects of Diet Restriction on Life Span and Age-Related Changes in Dogs", JAVMA, vol. 220, No. 9, May 1, 2002. |
Kibenge, et al., "Identification of Biochemical Defects in Pancreatic Islets of fa/fa Rats", Obesity Research, 3(2), pp. 171-178, Mar. 1995. |
Klain, et al., "Mannoheptulose and Fatty Acid Synthesis in the Rat", The Journal of Nutrition, pp. 473-477, 1974. |
Koh, et al., "Effects of Mannoheptulose on Lipid Metabolism of Rats", J. Nutr., vol. 104, pp. 1227-1233, 1974. |
Koizumi, et al., "Influences of Dietary Restriction and Age on Liver Enzyme Activities and Lipid Peroxidation in Mice", American Institute of Nutrition, Jul. 1986. |
Koizumi, et al., "Influences of Dietary Restriction and Age on Liver Enzyme Activities and Lipid Peroxidation in Mice", J. Nutr., 117: 361-367, 1987. |
Kok et al., Applied and Environmental Microbiology, 1996, vol. 62, pp. 3668-3672. |
Kudo et al., An Electron Microscopic Study on Bifidobacterium Pseudolongum SS-24 with Extracellular Material and Naked Bifidobacterium Thermophilum SS-19, AJAS, vol. 2, No. 3, pp. 444-445, 1989. |
Kurata, et al., "Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat", Metabolism, vol. 38, No. 1 Jan. 1989: pp. 46-51. |
Kyoto Yakuhin KK, "Sustains-Release Formulation Which Floats in Stomach-Comprises Core of Fats and Oils, Coated With Drug Containing Layer of e.g. Agar", KYOT, Jul. 10, 1987. |
L. Lakatos, "Immunology of Inflammatory Bowel Diseases", Acta Physiologica Hungarica, vol. 87 (4), pp. 355-372 (2000). |
La Forge, "Absorption and Effect of Ingested Mannoheptulose", Nutrition Reviews, 1969, vol. 27, No. 7, pp. 206-208. |
La Forge, "D-Mannoketoheptose, A New Sugar from the Avocado", J. Biol. Chem. 28:511-22, 1917. |
Lab Prod. Ethiques Ethypharm, "Coated Microgranules Containing a Gastric Protoon Pump Inhibitor With Two Hydrophobic Mateials, Free From Alkali and Any Ionic Surffactant", Derwent Publications Ltd., Ethi, May 21, 1999. |
LabScan XE User's Manual, Manual Version 1.2, A60-1010-862, Jan. 2003, 53 pp. |
Lane, et al., "2-Deoxy-D-Glucose Feeding in Rats Mimics Physiologic Effects of Calorie Restriction", Journal of Anti-Aging Medicine, vol. 1, No. 4, pp. 327-337, 1998. |
Lane, et al., "Calorie Restriction in Nonhuman Primates: Implications for Age-Related Disease Risk", Journal of Anti-Aging Medicine, vol. 1, No. 4, pp. 315-326, 1998. |
Lane, et al., "Calorie Restriction Lowers Body Temperature in Rhesus Monkeys, Consistent with a Postulated Anti-Aging Mechanisms in Rodents", PNAS, vol. 93, pp. 4159-4164, Apr. 1996. |
Langhans, et al., "Changes in Food Intake and Meal Patterns Following Injection of D-Mannoheptulose in Rats", Behavioral and Neural Biology, 38, pp. 269-286 (1983). |
Leblond-Bourget, et al., "16S rRNA and 16S to 23S Internal Transcribed Spacer Sequence Analysis Reveal Inter- and Intraspecific Bifidobacterium Phytogeny", International Journal of Systemic Bacteriology, vol. 6, No. 1, Jan. 1996, pp. 102-111. |
Leclercq-Meyer, et al., "Effects of D-mannoheptulose and its Hexaacetate Ester on Hormonal Secretion From the Perfused Pancreas", International Journal of Molecular Medicine, 2000, vol. 6, pp. 143-152. |
Lee, "Medicinal Plant Composition Suitable for Each Blood Type", WPI/THOMSON, vol. 2004, No. 46, Mar. 22, 2004. |
Libby, "Inflammatory mechanisms: the molecular basis of inflammation and disease", Nutr. Rev., Dec. 2007, 65 (12 Pt. 2): S140-6. |
Liu, et al., "Hass Avocado Carbohydrate Fluctuations. I. Growth and Phenology", J. Amer. Soc. Hort. Sci., 124(6):671-675, 1999. |
Liu, et al., "Hass Avocado Carbohydrate Fluctuations. II. Fruit Growth and Ripening", J. Amer. Soc. Hort. Sci., 124(6):676-681 (1999). |
Liu, et al., "Postulated Physiological Roles of the Seven Carbon Sugars, Mannoheptulose, and perseitol in Avocado", J. Amer. Soc. Hort. Sci., 127(1):108-114, 2002. |
Maklashina, et al., "Is Defective Electron Transport at the Hub of Aging", Aging Cell, vol. 3, 21-27, 2004. |
Mamula, et al., Gastrointestinal Tract Infections-Chapter 11. 2004, pp. 79-89. |
Marteau et al., "Potential of Using Lactic Acid Bacteria for Therapy and Immunomodulation in Man", FEMS Microbiology Reviews 12, (1993) 207-220. |
Masoro, "Overview of Caloric Restriction and Aging", Mech. Aging Dev., vol. 126, pp. 913-922 (2005). |
Masoro, et al., "Dietary Restriction Alters Characteristics of Glucose Fuel Use", Journal of Gerontology, Biological Sciences, 1992, vol. 47, No. 6, B202-B208. |
Massi, et al., NCBI Genbank Accession No. AB102654; NCBI Genbank (1994). |
Mattarelli et al., (1994) Microbiologica vol. 17, pp. 327-331. |
Mattson, et al., "Beneficial Effects of Intermittent Fasting and Caloric Restriction on the Cardiovascular and Cerebrovascular Systems", J. Nutr, Biol. 16, 3:129-137, 2005. |
McCarthy et al., "Double Blind, Placebo Controlled Trial of Two Probiotic Straiins in Interleukin 10 Knockout Mice and Mechanistic Link With Cytokine Balance", Gastroenterology., vol. 122, Nr. 4 Suppl. 1, pp. A-389-A390 DDW Meeting Abstract Nr. T962, XP009036733 the whole document. |
McCay, et al., "The Effect of Retarded Growth upon the Length of Life Span and upon the Ultimate Body Size", J. Nutr., vol. 10, pp. 63-79 (1935). |
McGee et al., "A Synergistic Relationship Between TNF-x, IL-1B, and TGF-B1 on IL-6 Secretion by the IEC-6 Intestinal Epithelial Cell Line", Immunology, 1995 86 6-11. |
McKay et al., "Review article: In Vitro Models in Inflammatory Bowel Disease", Aliment Pharmacol Ther, 1997: 11 (Suppl. 3): 70-80. |
Medaglini et al., "Mucosal and Systemic Immune Responses to a Recombinant Protein Expressed on the Surface of the Oral Commensal Bacterium Streptococcus gordonii after oral colonization", Proc. Natl. Acad. Sci. USA, vol. 92, pp. 6868-6872, Jul. 1995 Medical Sciences. |
Mentula, et al., "Comparison Between Cultured Small-Intestinal and Fecal Microbiotas in Beagle Dogs", Applied and Environmental Microbiology, Aug. 2005, vol. 71, No. 8, p. 4169-4175. |
Mentula, S., et al., Comparison between Cultured Small-Intestinal and Fecal Microbiotas in Beagle Dogs, Applied and Environmental Microbiology (Aug. 2005) vol. 71 (8), pp. 4169-4175, 7 pages. |
Mermelstein, "Novel Dryer Uses Refractance Window Principle", Food Technology, 51(10), p. 96, 1997. |
Meyer, et al., "Long-Term Caloric Restriction Ameliorates the Decline in Diastolic Function in Humans", J. Am. College of Cardiology, vol. 47(2), pp. 398-402 (2006). |
Miller, et al., "2-Deoxy-D-Glucose-Induced Metabolic Stress Enhances Resistance to Listeria monocytogenes Infection in Mice", Physiology & Behavior, vol. 65., No. 3, pp. 535-543, 1998, 1998, 535-543. |
Miller, et al., "The Metabolic Stressor 2-Deoxy-D-Glucose (2-DG) Enhances LPS-Stimulated Cytokine Production in Mice", Brain, Behavior, and Immunity, 1993, vol. 7, pp. 317-325, 1993, 317-325. |
Mitsuoka, et al., "Ecology of the Bifidobacteria.", The American Journal of Clinical Nutrition, Nov. 1977, vol. 30, pp. 1799-1810. |
Mohamed, et al., "Effect of Long-Term Ovariectomy and Estrogen Replacement on the Expression of Estrogen Receptor Gene in Female Rats", Eur. J. Endocrinol., 15, 142:307-14, 2000. |
Monteleone et al., "Manipulation of Cytokines in the Management of Patients With Inflammatory Bowel Disease", Ann Med., Nov. 2000;32(8):552-60. |
Morishita Jintan KK, "Capsule Preparation for Enteral Administration of Unsaturated Fatty Acids (Jpn)", Derwent Publications Ltd., MORI, Oct. 30, 1997. |
Morishita Jintan KK, "Yogurt for Supply Physiologically Important Intestinal Bacteria-Contains Bacteria Contained in Capsule Having Inner Layer Made of Digestible Substance and Outer Layer Dissolving in Intestine", MORI, Mar. 10, 1995. |
Moustafa, et al., "Effects of aging and antioxidants on glucose transport in rat adipocytes", Gerontology, 1995, 41(6):301-7. |
Murphy, et al., "Evaluation and Characterisation of Probiotic Therapy in the CD45RB Transfer Model of Colitis", AGA Abstracts, Gastroenterology, vol. 116, No. 4. |
Naaz, et al., "THe Soy Isoflavone Genistein Decreases Adipose Deposition in Mice", Endocrinology, 144(8):3315-3320, 2003. |
Natures Logic Natural Chicken Dinner Fare FROZEN-package.pdf http://www.natureslogic.com/products/dp-rf-chi.html, Information accessed Feb. 3, 2009. |
Natures Logic Natural Chicken Meal-package.pdf http://www.natureslogic.com/products/dp-dry-chi.html, Information accessed Feb. 3, 2009. |
Naveh, et al., "Defatted Avocado Pulp Reduces Body Weight and Total Hepatic Fat but Increases Plasma Chloesterol in Male Rats fed Diets with Cholesterol", Am. Soc. for Nutritional Sciences, 2002, 2015-2018. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/638,101, mailed Jun. 10, 2011. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,518 mailed Jun. 7, 2011. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,540, mailed Aug. 16, 2011. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,562, mailed Jun. 9, 2011. |
Nordal, et al., "Isolation of Mannoheptulose and Identification of its Phosphate in Avocado Leaves", J. Am. Chem. Soc., 1954, vol. 76, No. 20, pp. 5054-5055. |
Nordal, et al., "Isolation of Mannoheptulose and Identification of its Phosphate in Avocado Leaves", Meddelelser fra Norsk Farmaceutisk Selskap, (1955), 17, 207-213. |
Novogrodsky, et al., "Lymphocyte Transformation Induced by Concanavalin A and its Reversion by methyl-alpha-D-mannopyranoside", Biochim. Biophys. Acta, 1971, 228, 579-583. |
Obaldiston, et al., "Microflora of Alimentary Tract of Cats", American Journal of Veterinary Research, vol. 32, No. 9, Sep. 1971, pp. 1399-1405. |
O'Callaghan et al., "Human Cytokine Production by Mesenteric Lymph Node Cells in Response to Probiotic and Pathogenic Bacteria", Gastroenterology, vol. 122, No. 4 Suppl. 1, p. A-151 DDW Meeting Abstract Nr. S1040, Apr. 2002, XP009036734 the whole document. |
Ogawa, Journal of Japan Mibyou System Association, 2004, vol. 10, No. 1, p. 140-142 (with machine translation), 2004, 140-142. |
Ojewole, et al., "Cardiovascular Effects of Persea Americana Mill (Lauraceae)(avocado) aqueous Leaf Extract in Experimental Animals", Cardiovasc. J. Afr., 2007, 18, pp. 69-76. |
O'Mahony et al., "Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice", Aliment Pharmacol Ther, 2001: 15: 1219-1225. |
O'Mahony, et al., "Probiotic Human Bifidobacteria: Selection of a New Strain and Evaluation in Vitro and In Vivo", Gastroenterology, vol. 118, No. 4, Apr. 2000. |
Panwala et al., "A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdrla, Spontaneously Develop Colitis", The American Association of Immunologists, 1998, The Journal of Immunology, 1998 161: 5733-5744. |
Park, et al., "Species Specific Oligonucleotide probes for the detection and identification of Lactobacillus isolated from mouse feces", Journal of Applied Microbiology, 2005, vol. 99, pp. 51-57, XP002447051. |
Pawelec, et al., "T Cell Immunosenescence In Vitro and In Vivo", Exp. Gerontol, 1999, 34: 419-429. |
Pelicano, et al., "Glycolysis Inhibition for Anticancer Treatment", Oncogene, 2006, 25, pp. 4633-4646. |
Perlmann, et al., "Inhibition of Cytotoxicity of Lymphocytes by Concanavalin A in vitro", Science, 1970, 168:1112-1115. |
Physician's Desk Reference, 1963 Edition, Medical Economics, Inc. Oradell, N.J., 1962, Product Identification Section, SEction Four, p. VIII and XI. |
Poehlman, et al., "Caloric Restriction Mimetics: Physical Activity and Body Composition Changes", Journal of Gerontology, Series A 2001, vol. 56A (Special Issue I):45-54. |
Powrie et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in Scid Mice Reconstituted with CD45Rbhi CD4+ T Cells"/, Immunity, vol. 1, 553-562, Oct. 1994. |
Publication downloaded from http://en.wikipedia.org/wiki/Noni on May 4, 2009, 9 pages. |
Purina, "Advancing Life Through Diet Restriction", The Purina Pet Institute Symposium, 2002. |
Ramsey, et al., "Dietary Restriction and Aging in Rehesus Monkeys: The University of Wisconsin Study", Experimental Gerontology, 35 (2000) 1131-1149. |
Raonimalala, et al., "Action of Soluble Carbohydrates from Avocado Fruit on Utilization of Calcium in the Rat", Ann. Nutr Aliment, 34(4), 734-744, 1980. |
Rastall, "Baceria in the Gut: Friends and Foes and How to Alter the Balance", The Journal of Nutrition, Waltham Intl Science Symposium: Nature, Nurture, and the Case for Nutrition (2004), pp. 2022S-2026S. |
Reid, et al., "Prevention of Urinary Tract Infection in Rats with an Indigenous Lactobacillus Casei Strain", Infection and Immunity, 1985, 49(2), pp. 320-324. |
Rezek, et al., "Glucose Antimetabolites and Hunger", J. Nutr., 106:143-157 (1976). |
Rezek, et al., "Insulin Dependence of Paradoxical Overeating: Effect of Mannoheptulose, Somatostatin, and Cycloheximide", The American Physiological Society, 1979, E205-E211. |
Ridker, et al., "C-Reactive Protein, the Metabolic Syndrome and Risk of Incident Cardiovascular Events: an 8-Year Follow-up of 14,719 Initially Healthy American Women", Circulation, vol. 107, No. 3, pp. 391-397, Jan. 28, 2003. |
Riquelme, et al., "Regulation of Carbohydrate Metabolism by 2,5-Anhydro-D-Mannitol", PNAS, 80, pp. 4301-4305 (1983). |
Robey, et al., "Akt, Hexokinase, mTOR: Targeting Cellular Energy Metabloism for Cancer Therapy", Drug Discovery Today: Disease Mechanisms, vol. 2, No. 2, 2005, pp. 239-246. |
Rodtong, et al., NCBI Genbank Accession No. AF080100, NCBI Genbank (1998). |
Roe, et al., "Further Studies of the Physiological Availability of Heptoses", J. Biol. Chem., 121:37-43, 1937. |
Roe, et al., "The Utilization of D-Mannoheptulose by Adult Rabbits", J. of Biological Chemistry, 112, 443-449, Jan. 1, 1936. |
Rogler et al., "Cytokines in Inflammatory Bowel Disease", World Journal of Surgery, vol. 22, 1998, pp. 382-389, XP002296948 the whole document. |
Roth, et al., "Caloric Restriction in Primates and Relevance to Humans", Ann. NY Acad. Aci., 928: 305-315, 2001. |
Rowland, et al., "Physiological and Behavioral Responses to Glucoprivation in the Golden Hamster", Physiology and Behavior, vol. 30, No. 5, May 1, 1983, pp. 747-747. |
Ruscetti, et al., "Release of Colony-Stimulating Activity from Thymus-Derived Lymphocytes", J Clin Invest. 1975;55(3):520-527. |
Sakata, et al., "Feeding Modulation by Pentose and Hexose Analogues", Am. J. Clin. Nutr., 1992, 55:272-277S. |
Sayegh, et al., "Impact of Hormone Replacement Therapy on the Body Mass and Fat Compositions of Menopausal Women: A Cross-Sectional Study", Menopause, 6:312-315, 1999. |
Scarbrough, et al., "2-Deoxy-D-Glucose and 17-(allylaminio)-17-demethoxygeldanamycin Enhances Toxicity as wella s Increases Parameters Indicative of Oxidative Stress", Free Radical Biology and Medicine, vol. 43, suppl. 1, Nov. 14, 2007, p. S59. |
Scardovi et al., International Journal Systematic Bacteriology, vol. 21 pp. 276-294, 1971. |
Schmitt et al., "The Immunostimulatory Function of IL-12 in T-Helper Cell Development and Its Regulation by TGF-B, IFN-y and IL-4", Chem Immunet Basel Karger, 1997, vol. 68, pp. 70-85. |
Schrek, et al., "Characterizatoin of the B Lymphocyte Response to Pokeweed Mitogen", Annals of Clinical and Laboratory Science, 1982, vol. 12, Issue 6, pp. 455-462. |
Scrimshaw, et al., "Interactions of Nutrition and Infection", Am. J. Med. Sci., 1959, 237: 367-403. |
Scruel, et al., "Interference of D-Mannoheptuloase with D-Glucose phosphorylation, Metabolism, and Functional Effects: Comparison between Liver, Parotid Cells and Pancreatic Islets", Molecular and Cellular Biochemistry, 187, pp. 113-120, 1998. |
Seikagaku jiten (third edition), Tokyo Kagaku Dojin Publishing Co., Inc., 1998, pp. 657-658. |
Sener, et al., "D-Mannoheptulose Uptake and Its Metabolic and Secretory Effects in Human Pancreatic Islets", International Journal of Molecular Medicine, 6:617-620, 2000. |
Sener, et al., "Environmental Modulation of D-Fructose Insulinotropic Action", Acta Diabetol, 1998, 35, pp. 74-76. |
Shaw, et al., "High Performance Liquid Chromatographic Analysis of d-manno-heptulose, perseitol, glucose and Fructose in Avocado Cultivars", J. Agric. Food Chem., 1980, 28, 279-382. |
Shimada, "Significance of 1,5-Anhydro-D-Glucitol in Diabetes Mellitus Management", Sangyo Igaku, 1994, 36(3), pp. 148-449. |
Silva De Ruiz, et al., "Effect of Lactobacilli and Antibiotics on E. coli Urinary Infections in Mice", Biol. Pharm. Bull., 1996, 19(1): 88-93. |
Simon, et al., "Insulin and Proinsulin Secretion and Action", Israel J. Med. Sci., vol. 8, No. 6, Jun. 1972. |
Simon, et al., "Metabolism of Mannoheptulose in the Rat. I. Diabetogenic Action", Arch. Biochem. Biophys., 69, pp. 592-601 (1957). |
Simons, et al., "2-deoxy-D-glucose (2DG) Enhances Cispalatin Cytotoxicity in Human Head and Neck Cancer Cells via Metabolic Oxidative Stress", Free Radical Biology and Medicine, vol. 41, No. 1, Nov. 15, 2006, pp. S112-S113. |
Simpson et al., Journal of Bacteriology, Apr. 2003, vol. 185, pp. 2571-2581. |
Snow Brand Milk Products, "Enteric Capsules-Comprising Core Containing Drug Etc. and Coating of Hardened Oil of M.Pt. Higher Than Body Temp. and Disintegrated by Lipase in Intestine", SNOW, Mar. 31, 1986. |
Sols, et al., "Substrate Specificity of Brain Hexokinase", Biol. Chem. 210, pp. 581-595 (1954). |
Soudeyns et al., "The Moving Target: Mechanisms of HIV Persistence During Primary Infection", Immunology Today, Oct. 1999. |
SS Pharmaceutical KK, Tablets Containing Double-Coated Granules-Obtained by Coating With Insol. Polymer, Enteric Polymer and/or Waxes, Then Further Coating With Water or Acid-Soluble Polymer, SSSE,Aug. 18, 1988. |
Stallmach et al., "Induction and Modulation of Gastrointestinal Inflammation", Trends Immunology Today, Oct. 1998, vol. 19 No. 10 pp. 438-441. |
Strober et al., "Reciprocal IFN-gamma and TGF-Beta Responses Regulate the Occurrence of Mucosal Inflammation", Immunol Today, Feb. 1997;18(2):61-4. |
Sung, et al., "The Sphincter of Oddi is a Boundary for Bacterial Colonization in the Feline Biliary Tract", Microbial Ecology in Health and Disease, 1990, vol. 3, pp. 199-207. |
Sunvold, et al., "Dietary Fiber for Dogs: IV. In Vitro Fermentation of Selected Fiber Sources by Dog Fecal Inoculum and In Vivo Digestion and Metabolism of Fiber-Supplemented Diets", J. Anim. Sci., vol. 73, 1995, 1099-1109. |
Supplemental Amendment in response to Nonfinal Office Action mailed Jun. 10, 201, and issued in connection with U.S. Appl. No. 12/638,101, dated Sep. 29, 2011. |
Sutton, et al., "Considerations for Successful Development and Launch of Personalized Nutrigenomic Foods", Mutation Research, vol. 622, No. 1-2, Aug. 8, 2007, pp. 117-121. |
Takayanagi, J. Nippon Med. Sch., 2003, vol. 70, No. 1, p. 71 (with machine translation), 2003, 71. |
Takeda Chemical Ind KK, "Dry Coated Tablet-Comprises Core Tablets Containing Enzyme Prepn in Enteric Films Within Outer Shell", TAKE, May 10, 1982. |
Takeda Chemical Ind KK, "Dry Coated Tablet-Comprises Core Tablets Containing Enzyme Prepn. in Enteric Films Within Outer Shell", TAKE, Oct. 5, 1982. |
Tesfay, et al., "Anti-Oxidant Levels in Various Tissues During the Maturation of "Hass" Avocado", Journal of Horticultural Science and Biotechnology, (2010) 85(2): 106-112. |
Tomomatsu, "Health Effects of Oligosaccharides", 1994, Food Technology, 48, pp. 61-65. |
Trovatelli et al., Applied and Environmental Microbiology, 1976, vol. 32, pp. 470-473. |
Trovatelli, et al., "Presence of Bifidobacteria in the Rumen of Calves Fed Different Rations", Appl. Environ. Microbiol., 1976, vol. 32(4), pp. 470-473. |
U.S. Appl. No. 11/012,570, filed Dec. 15, 2004, Thomas William-Maxwell Boileau. |
U.S. Appl. No. 11/013,117, filed Apr. 18, 2008, Thomas William-Maxwell Boileau. |
U.S. Appl. No. 12/263,735, filed Nov. 3, 2008, Thomas William-Maxwell Boileau. |
U.S. Appl. No. 12/271,090, filed Nov. 14, 2008, Thomas William-Maxwell Boileau. |
U.S. Appl. No. 12/289,632, filed Oct. 31, 2008, Thomas William-Maxwell Boileau. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 09/950,052, filed Sep. 12, 2001, 158 pgs. |
USPTO Prosecution History (Office actions) for U.S. Appl. No. 11/313,198, filed Dec. 20, 2005, 90 pgs. |
USPTO Prosecution History (Office actions) for U.S. Appl. No. 11/313,199, filed Dec. 20, 2005, 111 pgs. |
USPTO Prosecution History (Office actions) for U.S. Appl. No. 12/012,317, filed Feb. 1, 2008, 262 pgs. |
USPTO Prosecution History (Office actions) for U.S. Appl. No. 12/082,710, filed Apr. 14, 2008, 221 pgs. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 12/168,400, filed Jul. 7, 2008, 297 pgs. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 12/762,539, filed Apr. 19, 2010, 329 pgs. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 12/939,594, filed Nov. 4, 2010, 290 pgs. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 13/098,741, filed May 2, 2011, 109 pgs. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 13/098,756 filed May 2, 2011, 96 pgs. |
USPTO Prosecution History (Office Actions) for U.S. Appl. No. 14/043,142 filed Oct. 1, 2013, 109 pgs. |
USPTO Prosecution History (Office Actions), for U.S. Appl. No. 10/842,300, filed May 10, 2004, 89 pgs. |
USPTO Prosecution History (Office Actions, Notice of Allowance, Issue Fee Notification) for U.S. Appl. No. 12/371,101, filed Feb. 13, 2009, 187 pgs. |
USPTO Prosecution History (Office Actions, Notice of Allowance, Issue Notification) for U.S. Appl. No. 12/638,128, filed Dec. 15, 2009, 178 pgs. |
USPTO Prosecution History (Office Actions, Notice of Allowance, Issue Notification) for U.S. Appl. No. 12/716,533, filed Mar. 3, 2010, 197 pgs. |
USPTO Prosecution History. (Office Actions) for U.S. Appl. No. 12/371,266, filed Feb. 13, 2009, 123 pgs. |
Valente, et al., "Immunologic Function in the Elderly After Injury-The Neutrophil and Innate Immunity", The Journal of Trauma Injury, Infection and Critical Care, vol. 67, No. 5, pp. 968-974, Nov. 2009. |
Van Damme et al., "The Proportion of Th1 Cells, Which Prevail in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome", 2001, Blackwell Science Ltd, Clinical and Experimental Immunology, 125:383-390. |
Van Damme, et al., "The Proportion of Th 1 Cells, Which Prevail in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome", 2001, Blackwell Science Ltd. Clinical and Experimental Immunology, 125, pp. 383-390. |
Vasconcelos, et al., "Antagonistic and Protective Effects Against Salmonella enterica Serovar Typhimurium by Lactobacillus murinus in the Digestive Tract of Gnotobiotic Mice", Brazilian Journal of Microbiology (2003) 34 (Supple. 1): 21-24. |
Vickers et al., "Comparison of Fermentation of Selected Fructooligosaccharides and Other Fiber Substrates by Canine Colonic Microflora", AJVR, vol. 62, No. 4, Apr. 2001. |
Vickers, et al., "Comparison of Fermentation of Selected Fructooligosaccharides and Other Fiber Substrates by canine Colonic Microflora", AJVR, vol. 62, No. 4, Apr. 2001. |
Viktora, et al., "Effect of Ingested Mannoheptulose in Animals and Man", Metabolism, 18(2), 87-102, 1969. |
Vittorio Scardovi, "Irregular Nonsporing Gram-Positive Rods", Genus Bifidobacterium Orla-Jensen, 1924, 472. |
Voet, et al., Biochemistry, John Wiley & Sons, Inc., pp. 1044-1045 (1995). |
Walker-Bone, et al., "Natural Remedies in the Treatment of Osteoarthritis", Drugs and Aging, 2003, 20(7), pp. 517-526. |
Wamelink, et al., "Detection of Transaldolase Deficiency by Quantification of Novel Seven-Carbon Chain Carbohydrate Biomarkers in Urine", J. Inherit. Metab. Dis., (2007), 30, pp. 735-742. |
Wan, et al., "Dietary Supplementation with 2-deoxy-d-Glucose Improves Cardiovascular and Neuroendocrine Stress Adaptation in Rats", Am. J. Physiol. Hear. Cir. Physiol, 287: H1186-H1193, 2004. |
Wein et al., "Analyzing a Bioterror Attack on the Food Supply: The Case of Botolinum Toxin in Milk", 2005 by The National Academy of Sciences of the USA. |
Wein, et al., "Analyzing a Bioterror Attack on the Food Supply: The Case of Botolinum Toxin in Milk", 2005, The National Academy of Sciences of the USA. |
Weindruch, "The Retardation of Aging by Caloric Restriction", Toxicol. Pathol., 1996, 24:742. |
Weindruch, et al., "The Retardation of Aging and Disease by Dietary Restriction", Charles S. Thomas (1988). |
Willott, et al., "Aging and Presbycusis: Effects on 2-Deoxy-D-Glucose Uptake in the Mouse Auditory Brain Stem in Quiet", Exp. Neurol., vol. 99(3), pp. 615-621 (1988). |
Winnock, et al., "Correlation Between GABA Release from Rat Islet beta-cells and their Metabolic State", Am. J. Physiol Endocrinol. Metab., 282: E937-E942, 2002. |
Wood, et al., "Evidence for Insulin Involvement in Arginine- and Glucose-Induced Hypercalciuria in Rat", J. Nutr., 113, pp. 1561-1567, 1983. |
Yaeshima et al., System Appl. Microbiol., vol. 5, No. 3, pp. 380-385. |
Yaeshima, et al., "Bifidobacterium globosum, Subjective Synonym of Bifidobacterium pseudolongum, and Descrption of Bifidobacterium pseudolongum subsp. pseudolongum com nov. and Bifidobacterium psuedolongum subsp. globosum comb. nov.", Systematic and Applied Microbiology, 1992, vol. 15(3), pp. 380-385. |
Yamamoto, et al., "Changes in Behavior and Gene Expression Induced by Caloric Restriction in C57BL/6 Mice", Physiological Genomics, vol. 39, No. 3, Sep. 8, 2009, pp. 227-235. |
Yang, et al., "The Role of Voltage-Gated Calcium Channels in Pancreatic [beta]-Cell Physiology and Pathophysiology", Endocrine Reviews, vol. 27, No. 6, Oct. 1, 2006. |
Yu, "Aging and Oxidative Stress: Modulation by Dietary Restriction", Free Radical Biology and Medicine, vol. 21, No. 5, pp. 651-668, 1996. |
Yu, et al., "Modulation of Aging Processes by Dietary Restriction", CRC Press, Boca Raton (1994). |
Zhang, et al., "Dissimilar Effects of D-Mannoheptulose on the phosphorylation of alpha vs beta-D-glucose by either Hexokinase or Glucokinase", International Journal of Molecular Medicine, 14, pp. 107-112, 2004. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11357803B2 (en) | 2017-09-22 | 2022-06-14 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
US11766050B2 (en) * | 2018-06-26 | 2023-09-26 | Country Food, Llc | Yogurt for dogs |
Also Published As
Publication number | Publication date |
---|---|
AU2004308396A1 (en) | 2005-07-14 |
BRPI0417826A (en) | 2007-04-10 |
EP1718266A2 (en) | 2006-11-08 |
JP2010178753A (en) | 2010-08-19 |
WO2005062879A9 (en) | 2010-01-28 |
WO2005062879A2 (en) | 2005-07-14 |
JP4602351B2 (en) | 2010-12-22 |
JP2007521024A (en) | 2007-08-02 |
BRPI0417826B1 (en) | 2020-11-03 |
EP1718266B1 (en) | 2014-09-03 |
ES2523984T3 (en) | 2014-12-03 |
US7998473B2 (en) | 2011-08-16 |
US20090148410A1 (en) | 2009-06-11 |
US20050158294A1 (en) | 2005-07-21 |
US20090136455A1 (en) | 2009-05-28 |
AR047065A1 (en) | 2006-01-04 |
US8900568B2 (en) | 2014-12-02 |
EP1718266A4 (en) | 2013-01-30 |
CA2550309A1 (en) | 2005-07-14 |
AU2004308396B2 (en) | 2009-07-16 |
CA2550309C (en) | 2014-01-21 |
JP5683832B2 (en) | 2015-03-11 |
US20090092585A1 (en) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9580680B2 (en) | Canine probiotic bifidobacterium pseudolongum | |
US8809035B2 (en) | Canine probiotic Bifidobacterium | |
US7906112B2 (en) | Canine probiotic Lactobacilli | |
US8034601B2 (en) | Feline probiotic bifidobacteria | |
US9427000B2 (en) | Feline probiotic lactobacilli composition and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALIMENTARY HEALTH, LTD., IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOILEAU, THOMAS WILLIAM-MAXWELL;CEDDIA, MICHAEL ANTHONY;COLLINS, JOHN KEVIN;AND OTHERS;SIGNING DATES FROM 20040119 TO 20040308;REEL/FRAME:040709/0781 Owner name: THE IAMS COMPANY, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOILEAU, THOMAS WILLIAM-MAXWELL;CEDDIA, MICHAEL ANTHONY;COLLINS, JOHN KEVIN;AND OTHERS;SIGNING DATES FROM 20040119 TO 20040308;REEL/FRAME:040709/0781 |
|
AS | Assignment |
Owner name: MARS, INCORPORATED, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE IAMS COMPANY;REEL/FRAME:040950/0484 Effective date: 20161205 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |